<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">JMIR Res Protoc</journal-id><journal-id journal-id-type="iso-abbrev">JMIR Res Protoc</journal-id><journal-id journal-id-type="publisher-id">ResProt</journal-id><journal-title-group><journal-title>JMIR Research Protocols</journal-title></journal-title-group><issn pub-type="epub">1929-0748</issn><publisher><publisher-name>JMIR Publications</publisher-name><publisher-loc>Toronto, Canada</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39671573</article-id><article-id pub-id-type="pmc">PMC11681286</article-id><article-id pub-id-type="publisher-id">v13i1e58206</article-id><article-id pub-id-type="doi">10.2196/58206</article-id><article-categories><subj-group subj-group-type="heading"><subject>Protocol</subject></subj-group><subj-group subj-group-type="article-type"><subject>Protocol</subject></subj-group></article-categories><title-group><article-title>Frontal Pole Neuromodulation for Impulsivity and Suicidality in Veterans With Mild Traumatic Brain Injury and Common Co-Occurring Mental Health Conditions: Protocol for a Pilot Randomized Controlled Trial</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>Leung</surname><given-names>Tiffany</given-names></name></contrib><contrib contrib-type="editor"><name><surname>Khajeei</surname><given-names>Dahlia</given-names></name></contrib></contrib-group><contrib-group><contrib id="contrib1" contrib-type="author"><name><surname>Bernanke</surname><given-names>Alyssa</given-names></name><degrees>MD, PhD</degrees><xref rid="aff1" ref-type="aff">1</xref><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0000-9036-717X</contrib-id></contrib><contrib id="contrib2" contrib-type="author"><name><surname>Hasley</surname><given-names>Rebecca</given-names></name><degrees>BS</degrees><xref rid="aff2" ref-type="aff">2</xref><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0000-4373-4221</contrib-id></contrib><contrib id="contrib3" contrib-type="author"><name><surname>Sabetfakhri</surname><given-names>Niki</given-names></name><degrees>BA</degrees><xref rid="aff3" ref-type="aff">3</xref><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5062-5661</contrib-id></contrib><contrib id="contrib4" contrib-type="author"><name><surname>de Wit</surname><given-names>Harriet</given-names></name><degrees>PhD</degrees><xref rid="aff4" ref-type="aff">4</xref><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7211-8994</contrib-id></contrib><contrib id="contrib5" contrib-type="author"><name><surname>Smith</surname><given-names>Bridget M</given-names></name><degrees>PhD</degrees><xref rid="aff5" ref-type="aff">5</xref><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3301-8843</contrib-id></contrib><contrib id="contrib6" contrib-type="author"><name><surname>Wang</surname><given-names>Lei</given-names></name><degrees>PhD</degrees><xref rid="aff6" ref-type="aff">6</xref><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3870-3388</contrib-id></contrib><contrib id="contrib7" contrib-type="author"><name><surname>Brenner</surname><given-names>Lisa A</given-names></name><degrees>PhD</degrees><xref rid="aff7" ref-type="aff">7</xref><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2629-214X</contrib-id></contrib><contrib id="contrib8" contrib-type="author"><name><surname>Hanlon</surname><given-names>Colleen</given-names></name><degrees>PhD</degrees><xref rid="aff8" ref-type="aff">8</xref><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3151-0279</contrib-id></contrib><contrib id="contrib9" contrib-type="author"><name><surname>Philip</surname><given-names>Noah S</given-names></name><degrees>MD</degrees><xref rid="aff9" ref-type="aff">9</xref><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4889-8775</contrib-id></contrib><contrib id="contrib10" contrib-type="author"><name><surname>Ajilore</surname><given-names>Olusola</given-names></name><degrees>MD, PhD</degrees><xref rid="aff3" ref-type="aff">3</xref><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0737-0437</contrib-id></contrib><contrib id="contrib11" contrib-type="author"><name><surname>Herrold</surname><given-names>Amy</given-names></name><degrees>PhD</degrees><xref rid="aff2" ref-type="aff">2</xref><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5675-4053</contrib-id></contrib><contrib id="contrib12" contrib-type="author" corresp="yes"><name><surname>Aaronson</surname><given-names>Alexandra</given-names></name><degrees>MD, MSCI</degrees><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9015-2240</contrib-id><xref rid="aff2" ref-type="aff">2</xref><address><institution>Edward Hines Department of Veteran Affairs</institution><institution>Mental Health Service Line</institution><addr-line>5001 S 5th Ave</addr-line><addr-line>Hines, IL, 60141</addr-line><country>United States</country><phone>1 708 202 8387</phone><email>alexandra.aaronson@va.gov</email></address></contrib></contrib-group><aff id="aff1">
<label>1</label>
<institution>Northwestern University Feinberg School of Medicine</institution>
<addr-line>Chicago, IL</addr-line>
<country>United States</country>
</aff><aff id="aff2">
<label>2</label>
<institution>Edward Hines Department of Veteran Affairs</institution>
<institution>Mental Health Service Line</institution>
<addr-line>Hines, IL</addr-line>
<country>United States</country>
</aff><aff id="aff3">
<label>3</label>
<institution>University of Illinois, Chicago</institution>
<addr-line>Chicago, IL</addr-line>
<country>United States</country>
</aff><aff id="aff4">
<label>4</label>
<institution>University of Chicago</institution>
<addr-line>Chicago, IL</addr-line>
<country>United States</country>
</aff><aff id="aff5">
<label>5</label>
<institution>SCI/D National Program Office</institution>
<institution>Veterans Health Administration</institution>
<addr-line>Washington, DC</addr-line>
<country>United States</country>
</aff><aff id="aff6">
<label>6</label>
<institution>The Ohio State University</institution>
<addr-line>Columbus, OH</addr-line>
<country>United States</country>
</aff><aff id="aff7">
<label>7</label>
<institution>University of Colorado</institution>
<institution>Anschutz Medical Campus</institution>
<addr-line>Aurora, CO</addr-line>
<country>United States</country>
</aff><aff id="aff8">
<label>8</label>
<institution>BrainsWay</institution>
<addr-line>Burlington, MA</addr-line>
<country>United States</country>
</aff><aff id="aff9">
<label>9</label>
<institution>Center for Neurorestoration and Neurotechnology</institution>
<institution>VA Providence Healthcare System</institution>
<addr-line>Providence, RI</addr-line>
<country>United States</country>
</aff><author-notes><corresp>Corresponding Author: Alexandra Aaronson <email>alexandra.aaronson@va.gov</email></corresp></author-notes><pub-date pub-type="collection"><year>2024</year></pub-date><pub-date pub-type="epub"><day>13</day><month>12</month><year>2024</year></pub-date><volume>13</volume><elocation-id>e58206</elocation-id><history><date date-type="received"><day>9</day><month>3</month><year>2024</year></date><date date-type="rev-request"><day>14</day><month>5</month><year>2024</year></date><date date-type="rev-recd"><day>13</day><month>8</month><year>2024</year></date><date date-type="accepted"><day>13</day><month>9</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9;Alyssa Bernanke, Rebecca Hasley, Niki Sabetfakhri, Harriet de Wit, Bridget M Smith, Lei Wang, Lisa A Brenner, Colleen Hanlon, Noah S Philip, Olusola Ajilore, Amy Herrold, Alexandra Aaronson. Originally published in JMIR Research Protocols (https://www.researchprotocols.org), 13.12.2024.</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (<ext-link xlink:href="https://creativecommons.org/licenses/by/4.0/" ext-link-type="uri">https://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR Research Protocols, is properly cited. The complete bibliographic information, a link to the original publication on <ext-link xlink:href="https://www.researchprotocols.org" ext-link-type="uri">https://www.researchprotocols.org</ext-link>, as well as this copyright and license information must be included.</license-p></license></permissions><self-uri xlink:href="https://www.researchprotocols.org/2024/1/e58206"/><abstract><sec sec-type="background"><title>Background</title><p>Suicide remains a leading cause of death among veterans in the United States, and mild traumatic brain injury (mTBI) increases the risk of suicidal ideation (SI) and suicide attempts (SAs). mTBI worsens impulsivity and contributes to poor social and occupational functioning, which further increases the risk of SI and SAs. Repetitive transcranial magnetic stimulation is a neuromodulatory treatment approach that induces neuroplasticity, potentially repairing neurodamage. Intermittent theta burst stimulation (iTBS) is a second-generation form of transcranial magnetic stimulation that is safe, shorter in duration, displays a minimal side effect profile and is a promising treatment approach for impulsivity in mTBI. Our novel proposed treatment protocol uses frontal pole iTBS to target the ventromedial prefrontal cortex, which may reduce impulsivity by strengthening functional connectivity between the limbic system and frontal cortex, allowing for improved top-down control of impulsive reactions, including SI and SAs.</p></sec><sec sec-type="objective"><title>Objective</title><p>The objectives of this study are to (1) develop an iTBS intervention for veterans with mTBI, impulsivity, and SI; (2) assess the feasibility and tolerability of the intervention; and (3) gather preliminary clinical outcome data on SI, impulsivity, and functions that will guide future studies.</p></sec><sec sec-type="methods"><title>Methods</title><p>This is a pilot, double-blinded, randomized controlled trial. In developing this protocol, we referenced the SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials) guidelines. We will enroll 56 participants (28 active iTBS and 28 sham iTBS). The iTBS intervention will be performed daily, 5 days a week, for 2 weeks. We will collect 10 validated, psychometric, quantitative outcome measures before, during, and after the intervention. Measures included will assess functioning, impulsivity, suicidality, posttraumatic stress disorder, and depressive symptoms. We will collect qualitative data through semistructured interviews to elicit feedback on the participants&#x02019; experiences and symptoms. We will perform quantitative and qualitative analyses to (1) assess the feasibility, tolerability, and acceptability of the treatment; (2) gather advanced neuroimaging data to assess neural changes elicited by treatment; and (3) assess improvements in outcome measures of impulsivity and suicidality in veterans with mTBI.</p></sec><sec sec-type="results"><title>Results</title><p>This study protocol was approved by the Edward Hines, Jr. VA Hospital Institutional Review Board (Hines IRB number 14-003). This novel treatment is a 5-year research project (April 1, 2023, to March 31, 2028) funded by the Veterans Administration Rehabilitation Research and Development service (CDA2 award IK2 RX002938). Study results will be disseminated at or before the project&#x02019;s end date in March 2028.</p></sec><sec sec-type="conclusions"><title>Conclusions</title><p>We will provide preliminary evidence of the safety, feasibility, and acceptability of a novel frontal pole iTBS treatment for mTBI, impulsivity, SI and SAs, and functional deficits.</p></sec><sec sec-type="Trial Registration"><title>Trial Registration</title><p>ClinicalTrials.gov NCT05647044; https://clinicaltrials.gov/study/NCT05647044</p></sec><sec sec-type="registered-report"><title>International Registered Report Identifier (IRRID)</title><p>PRR1-10.2196/58206</p></sec></abstract><kwd-group><kwd>mild traumatic brain injury</kwd><kwd>transcranial magnetic stimulation</kwd><kwd>intermittent theta burst stimulation</kwd><kwd>suicidality</kwd><kwd>suicidal ideation</kwd><kwd>impulsivity</kwd><kwd>neuromodulation</kwd><kwd>social and occupational functioning</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>ext-peer-rev</meta-name><meta-value>The proposal for this study was peer-reviewed by: Career Development Program - Panel II - Rehabilitation Research and Development Parent IRG - Department of Veterans Affairs (VA) Office of Research and Development (USA).</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="introduction"><title>Introduction</title><sec><title>Background</title><p>The prevalence of suicide among veterans who served in the US military is devastatingly high. Veterans die by suicide at almost double the rate of civilians in the United States [<xref rid="ref1" ref-type="bibr">1</xref>]. The prevalence of suicide among veterans with traumatic brain injury (TBI) is even higher. Veterans with TBI are 1.5 times more likely to die by suicide than veterans without TBI, even when controlling for comorbid psychiatric conditions [<xref rid="ref1" ref-type="bibr">1</xref>,<xref rid="ref2" ref-type="bibr">2</xref>]. These statistics are particularly concerning given that there have been &#x0003e;400,000 new TBI diagnoses among US service members since the beginning of operations Enduring Freedom, Iraqi Freedom, and New Dawn, of which &#x0003e;80% are mild traumatic brain injury (mTBI) [<xref rid="ref3" ref-type="bibr">3</xref>]. Overall, between 16% and 20% of all operations Enduring Freedom, Iraqi Freedom, and New Dawn veterans have a history of mTBI, and among them, up to 22% report suicidal ideation (SI) [<xref rid="ref4" ref-type="bibr">4</xref>].</p><p>TBI consists of any external force applied to the head of any individual, resulting in vascular and axonal damage, edema, and neuronal death [<xref rid="ref5" ref-type="bibr">5</xref>]. TBI is clinically further subcategorized by the severity of the injury as either mild, moderate, or severe. mTBI is defined as a loss of consciousness for &#x0003c;30 minutes, postconcussive altered mental status or amnesia for &#x0003c;24 hours, a Glasgow Coma Score, following injury of 13 to 15 (15 being the maximum score), and lack of abnormalities on standard clinical magnetic resonance imaging (MRI) or computed tomography [<xref rid="ref6" ref-type="bibr">6</xref>]. TBI is an extremely common injury, resulting in an estimated 4.8 million independent emergency room visits throughout the United States annually [<xref rid="ref7" ref-type="bibr">7</xref>-<xref rid="ref9" ref-type="bibr">9</xref>]. TBI results in a significant economic burden: the cost of nonfatal TBI amounts to &#x0003e;US $40 billion per year in the United States [<xref rid="ref10" ref-type="bibr">10</xref>]. Globally, TBI resulted in the loss of 246.7 million disability-adjusted life years between 1990 and 2013 [<xref rid="ref11" ref-type="bibr">11</xref>].</p><p>Given the high suicide rate among US veterans, suicide prevention is a high-priority issue for the US Veterans Administration (VA) [<xref rid="ref12" ref-type="bibr">12</xref>]. The US VA has assembled task forces that have created clinical practice guidelines for the assessment and management of veterans at risk for suicide [<xref rid="ref13" ref-type="bibr">13</xref>]. These guidelines establish substantial risk factors to help providers identify which veterans are at the highest risk. The guidelines specifically cite having a history of TBI, functional deficits, past SI, and a history of impulsivity as independent risk factors for developing SI [<xref rid="ref13" ref-type="bibr">13</xref>]. TBI predisposes individuals to functional deficits [<xref rid="ref14" ref-type="bibr">14</xref>,<xref rid="ref15" ref-type="bibr">15</xref>] and impulsivity [<xref rid="ref16" ref-type="bibr">16</xref>], and those with impulsivity likely struggle with functional deficits [<xref rid="ref17" ref-type="bibr">17</xref>]. Given these findings, we hypothesize that these conditions may be interrelated and could serve as meaningful behavioral targets in the treatment of SI.</p><p>Transcranial magnetic stimulation (TMS) therapy was first described by Barker et al [<xref rid="ref18" ref-type="bibr">18</xref>]. Seminal studies by George et al [<xref rid="ref19" ref-type="bibr">19</xref>] demonstrated the efficacy of TMS in the treatment of depression in large, multisite sham-controlled trials. TMS was subsequently approved by the US Food and Drug Administration (FDA) in 2008 for the treatment of major depressive disorder [<xref rid="ref20" ref-type="bibr">20</xref>]. TMS was first hypothesized as a treatment for TBI by Pape et al [<xref rid="ref21" ref-type="bibr">21</xref>]. It was later shown to be effective in treating several TBI sequelae, including depression [<xref rid="ref22" ref-type="bibr">22</xref>]. TMS also has demonstrated efficacy in the treatment of posttraumatic stress disorder (PTSD), chronic pain, cognitive deficits, and headaches in individuals with mTBI [<xref rid="ref23" ref-type="bibr">23</xref>-<xref rid="ref27" ref-type="bibr">27</xref>]. A second-generation form of TMS, intermittent theta burst stimulation (iTBS), was first shown to treat depression in 2009 in a study by Holzer and Padberg [<xref rid="ref28" ref-type="bibr">28</xref>]. In a large, noninferiority study comparing iTBS and TMS, patients with treatment-resistant depression show similar safety and adverse event (AE) profiles and exhibit improvements in their depressive symptoms to both interventions [<xref rid="ref29" ref-type="bibr">29</xref>].</p><p>This study aims to create a novel iTBS intervention to reduce impulsivity and SI among veterans with mTBI while improving overall social and occupational functioning. This study will be conducted at the Edward Hines, Jr. VA Hospital in Hines, Illinois. We are interested in stimulating the ventromedial prefrontal cortex (VMPFC) with iTBS because the VMPFC appears to exhibit less functional connectivity with the limbic system in individuals with mTBI [<xref rid="ref30" ref-type="bibr">30</xref>]. This diminished connectivity is suspected to be responsible for impulsivity and SI in individuals with mTBI [<xref rid="ref30" ref-type="bibr">30</xref>-<xref rid="ref32" ref-type="bibr">32</xref>]. To the best of our knowledge, no established treatment approach has used VMPFC iTBS to improve social and occupational functioning, SI, and negative urgency impulsivity among individuals with mTBI and comorbid mental illness. A list of the common terms used in the study and their definitions are provided in <xref rid="box1" ref-type="boxed-text">Textbox 1</xref>.</p><boxed-text id="box1" position="float"><caption><title>Terms and definitions used in the study.</title></caption><list list-type="bullet"><list-item><p>Mild traumatic brain injury: a type of brain injury resulting from mechanical forces defined by loss of consciousness for &#x0003c;30 minutes, Glasgow Coma Score of 13-15, post-concussive altered mental status or amnesia &#x0003c;24 hours, and normal findings on neuroimaging</p></list-item><list-item><p>Negative urgency impulsivity: a form of impulsivity in which an individual exhibits poor behavioral control or aggression in the setting of a negative event or affect</p></list-item><list-item><p>Neuromodulation: a category of brain treatments that modulate or alter neuronal activity through direct electrical or chemical stimulation</p></list-item><list-item><p>Transcranial magnetic stimulation: a non-invasive brain treatment that applies a magnetic field directly to the scalp, activating neuronal activity and neuroplasticity to specific cortical regions of the brain</p></list-item><list-item><p>Intermittent theta burst stimulation: a novel second-generation form of transcranial magnetic stimulation that utilizes bursts of magnetic energy known as theta bursts</p></list-item></list></boxed-text></sec><sec><title>Rationale</title><sec><title>SI Epidemiology and Current Treatment</title><p>SI is a severe and prevalent condition among veterans and civilians alike and can prove lethal. The Centers for Disease Control and Prevention estimates that from 2015 to 2019, 4.3% of the general adult US population had SI, and 5% to 10% of these individuals advanced to making a suicide attempt (SA) [<xref rid="ref33" ref-type="bibr">33</xref>]. Consequently, focusing treatment on individuals with SI before they advance to making an SA gives providers an opportunity at suicide prevention.</p><p>Current evidence-based treatment options for SI include pharmacotherapy and psychotherapy. Pharmacotherapeutic treatment (primarily antidepressants) can take 6 to 8 weeks or more to become effective [<xref rid="ref34" ref-type="bibr">34</xref>]. A recent meta-analysis suggested that only two-thirds of the published studies demonstrated a reduction in SI with any pharmacotherapy compared to placebo [<xref rid="ref35" ref-type="bibr">35</xref>]. Furthermore, many patients will require multiple medication trials and may take months to experience any symptomatic improvement [<xref rid="ref36" ref-type="bibr">36</xref>]. Given the latency of these treatment options, individuals with SI require more suicide prevention interventions that are designed to exhibit better and faster resolutions toward promoting resilience.</p></sec><sec><title>mTBI and Suicide: The Role of Impulsivity</title><p>Impulsivity is associated with TBI of all severities [<xref rid="ref16" ref-type="bibr">16</xref>,<xref rid="ref37" ref-type="bibr">37</xref>,<xref rid="ref38" ref-type="bibr">38</xref>]. For this study, we will focus on veterans with mTBI. Veterans with mTBI make up the majority (&#x0003e;80%) of the veteran population with TBI in the United States [<xref rid="ref3" ref-type="bibr">3</xref>]. A form of behavioral impulsivity, negative urgency impulsivity, is particularly prevalent in this population [<xref rid="ref38" ref-type="bibr">38</xref>]. Negative urgency impulsivity refers to poor behavioral control in the setting of negative events or affect [<xref rid="ref39" ref-type="bibr">39</xref>]. It is associated with excessive agitation, irritability, low moods, and a greater tendency for aggression toward oneself or others immediately following a negative event [<xref rid="ref40" ref-type="bibr">40</xref>]. Unsurprisingly, negative urgency impulsivity increases the likelihood of SI [<xref rid="ref41" ref-type="bibr">41</xref>] and is associated with significant risk factors for suicide, such as social and occupational functional deficits [<xref rid="ref42" ref-type="bibr">42</xref>]. Our laboratory&#x02019;s previous work built upon these findings and completed a chart review study that found negative urgency impulsivity most strongly mediated the relationship between a history of TBI and SI and SAs [<xref rid="ref43" ref-type="bibr">43</xref>].</p><p>Post-TBI negative urgency impulsivity is presumed to be secondary to disinhibition of the limbic system from TBI-related damage to the prefrontal cortex, specifically the VMPFC, medial orbitofrontal cortex, or both [<xref rid="ref16" ref-type="bibr">16</xref>]. The VMPFC, which serves as an inhibitory control center for the limbic system, is particularly vulnerable to damage in all severities of TBI as this region abuts the cranial floor and frontal cranial bone, making it susceptible to coup and contrecoup forces from nearly all directions [<xref rid="ref31" ref-type="bibr">31</xref>,<xref rid="ref44" ref-type="bibr">44</xref>,<xref rid="ref45" ref-type="bibr">45</xref>]. Uninhibited limbic effect can manifest as poor frustration tolerance, fear, and aggression [<xref rid="ref46" ref-type="bibr">46</xref>]. These characteristics of negative urgency impulsivity can reduce the quality of life and worsen community and social functioning, predisposing individuals to SI and SAs (<xref rid="figure1" ref-type="fig">Figure 1</xref>) [<xref rid="ref46" ref-type="bibr">46</xref>].</p><p>To the best of our knowledge, no neuroimaging evidence implicates specific brain regions in mTBI-related impulsivity and SI. The presented study will help address this knowledge gap using within-participant neuroimaging data to identify brain regions predisposed to these conditions.</p><fig position="float" id="figure1"><label>Figure 1</label><caption><p>Relationship between impulsivity, functionality outcomes, and suicidal ideation.</p></caption><graphic xlink:href="resprot_v13i1e58206_fig1" position="float"/></fig></sec><sec><title>mTBI and Suicide: The Role of Functional Deficits</title><p>TBI itself predisposes individuals to social and occupational functional deficits [<xref rid="ref47" ref-type="bibr">47</xref>]. A meta-analysis of psychosocial factors found that difficulties in social and occupational functioning were strongly tied to increased levels of SI, social isolation, and low socioeconomic status and are directly associated with increased incidences of SI and completed suicides (<xref rid="figure1" ref-type="fig">Figure 1</xref>) [<xref rid="ref48" ref-type="bibr">48</xref>]. Among individuals with TBI, those who were unemployed in the past year were at the highest risk for SI when compared to individuals who had been employed [<xref rid="ref17" ref-type="bibr">17</xref>]. Given that TBI and impulsivity are both (1) independent risk factors for developing SI and (2) associated with impaired social and community functioning, it appears that TBI, SI, impulsivity, and functional deficits are intertwined and should be considered in tandem. However, the evidence is scarce to directly support biological treatments for SI, impulsivity, and functional deficits following mTBI. This study aims to address this knowledge gap by providing further evidence to support the development of a novel neuromodulatory treatment to improve functioning for those with impulsivity, SI, and mTBI symptoms.</p></sec><sec><title>TMS in Neuropsychiatry</title><p>TMS is a noninvasive neuromodulatory technique that involves placing an insulated electric coil on the scalp [<xref rid="ref49" ref-type="bibr">49</xref>]. The electrical current flowing through the coil produces alternating magnetic fields. These fields pass through the skull, inducing electric currents in the brain tissue beneath the coil [<xref rid="ref50" ref-type="bibr">50</xref>]. In large, multisite, double-blinded, sham-controlled trials, TMS applied [<xref rid="ref51" ref-type="bibr">51</xref>,<xref rid="ref52" ref-type="bibr">52</xref>] to the left dorsolateral prefrontal cortex (DLPFC) was shown to effectively treat depression. TMS was subsequently approved by the FDA to treat treatment-resistant depression in 2008 [<xref rid="ref53" ref-type="bibr">53</xref>-<xref rid="ref55" ref-type="bibr">55</xref>]. In 2020, a nationwide clinical TMS program was implemented in the US VA after completing a multisite clinical trial. Thus, the VA health care system is well-positioned to offer novel TMS treatment approaches for veterans in need.</p><p>iTBS is a second-generation FDA-approved form of TMS designed to mimic endogenous brain rhythms with the added benefit of markedly reduced treatment time [<xref rid="ref28" ref-type="bibr">28</xref>,<xref rid="ref56" ref-type="bibr">56</xref>]. In iTBS, 50 Hz triplets are applied at a theta rhythm (5 Hz), which is thought to facilitate long-term potentiation in less time and with fewer pulses than standard TMS, which generally is administered at 5 to 10 Hz [<xref rid="ref57" ref-type="bibr">57</xref>]. Using this approach, iTBS can be administered in 3 to 10 minutes, compared to the standard 37.5-minute protocol for first-generation TMS [<xref rid="ref58" ref-type="bibr">58</xref>]. One of the most prevalent and widely known iTBS treatment protocols is based on a study by Li et al [<xref rid="ref58" ref-type="bibr">58</xref>] and delivers 1800 pulses of iTBS per day for 10 days. This amount of stimulation appears to be well tolerated and shows a good effect on depressive symptoms, even in a treatment-refractory group [<xref rid="ref58" ref-type="bibr">58</xref>]. Studies demonstrate that this number of pulses results in an optimal &#x0201c;window&#x0201d; of cortical excitability, and additional pulses may have an inhibitory effect [<xref rid="ref59" ref-type="bibr">59</xref>-<xref rid="ref61" ref-type="bibr">61</xref>]. The result of significant symptomatic improvement in a short period is particularly interesting and relevant in treating SI, where a shorter latency to treatment response is of the essence and could potentially be lifesaving.</p></sec><sec><title>TMS as a Treatment for TBI Sequelae</title><p>TMS has an established safety record as a treatment for individuals with mTBI [<xref rid="ref23" ref-type="bibr">23</xref>]. There is accumulating evidence supporting the safety and efficacy of TMS for sequelae of mTBI and related neuropsychiatric conditions, including depression, cognitive deficits, and chronic pain or headaches [<xref rid="ref23" ref-type="bibr">23</xref>-<xref rid="ref26" ref-type="bibr">26</xref>]. TMS also improves PTSD symptoms among those with co-occurring mTBI [<xref rid="ref22" ref-type="bibr">22</xref>,<xref rid="ref27" ref-type="bibr">27</xref>]. Further, multiple studies and meta-analyses demonstrate that TMS, administered to a variety of brain locations, including the DLPFC, does not induce more significant numbers of AEs among individuals with mTBI than among individuals without mTBI [<xref rid="ref23" ref-type="bibr">23</xref>,<xref rid="ref25" ref-type="bibr">25</xref>,<xref rid="ref62" ref-type="bibr">62</xref>,<xref rid="ref63" ref-type="bibr">63</xref>]. Specifically, in a national US VA TMS study of 770 veterans receiving TMS, nearly half had mTBI, and TMS was demonstrated to be equally safe in veterans with and without mTBI [<xref rid="ref64" ref-type="bibr">64</xref>].</p><p>An overall estimate of 70% of individuals with mTBI struggle with at least one psychiatric comorbidity [<xref rid="ref65" ref-type="bibr">65</xref>]. Thus, it is essential to consider TBI and comorbid mental illness simultaneously, as they frequently co-occur. Comorbid conditions include substance use disorders, PTSD, and depression [<xref rid="ref66" ref-type="bibr">66</xref>-<xref rid="ref68" ref-type="bibr">68</xref>]. Moreover, neuroimaging studies of individuals diagnosed with PTSD and substance use disorder (2 conditions that are also associated with impulsive behavior and SI) demonstrate diminished volume and hypoactivity in the VMPFC [<xref rid="ref69" ref-type="bibr">69</xref>,<xref rid="ref70" ref-type="bibr">70</xref>]. Therefore, it is likely that when mental illness diagnoses such as PTSD and substance use disorders co-occur with mTBI, they have an additive effect on brain functioning in the VMPFC, further worsening negative urgency impulsivity [<xref rid="ref69" ref-type="bibr">69</xref>,<xref rid="ref70" ref-type="bibr">70</xref>].</p></sec><sec><title>TMS as Treatment for Suicidality</title><p>Encouraging meta-analyses suggest that TMS may also effectively treat suicidality [<xref rid="ref71" ref-type="bibr">71</xref>,<xref rid="ref72" ref-type="bibr">72</xref>]. For example, a randomized controlled trial (RCT) reported a 44% decrease in individuals experiencing &#x0201c;thoughts of suicide&#x0201d; after high-dose left-sided DLPFC TMS treatment [<xref rid="ref73" ref-type="bibr">73</xref>]. In addition, a study of pooled sham-controlled trials reported that bilateral TMS is associated with a decline in SI [<xref rid="ref74" ref-type="bibr">74</xref>].</p><p>However, drawing overall conclusions from the existing literature on TMS for suicidality remains challenging because of the heterogeneity of the data. Studies are often limited by small sample sizes, inconsistencies in how suicidality is measured across studies, and contradictory findings [<xref rid="ref75" ref-type="bibr">75</xref>,<xref rid="ref76" ref-type="bibr">76</xref>]. Interestingly, an analysis suggests that changes in SI may be statistically independent of depression outcomes, underscoring the importance of studying SI separately from depression in contrast to many previous studies [<xref rid="ref77" ref-type="bibr">77</xref>].</p><p>Post-TBI negative urgency impulsivity is presumed to arise from limbic system disinhibition because of damage to the VMPFC [<xref rid="ref16" ref-type="bibr">16</xref>]. In mTBI, thinning of the right VMPFC is evident when compared to healthy controls [<xref rid="ref78" ref-type="bibr">78</xref>]. Individuals exhibiting this volume loss report increased aggression, anxiety, and depression following injury [<xref rid="ref79" ref-type="bibr">79</xref>]. Uninhibited limbic effect can manifest as poor frustration tolerance and aggression, characteristics of negative urgency impulsivity [<xref rid="ref80" ref-type="bibr">80</xref>]. Interestingly, individuals without a history of mTBI who attempted suicide or have a history of SI also show diminished VMPFC volume and reduced connectivity between the prefrontal cortex and the limbic system, further supporting it as a potential therapeutic target [<xref rid="ref31" ref-type="bibr">31</xref>,<xref rid="ref81" ref-type="bibr">81</xref>]. Our study will collect MRI data to support our hypothesis that iTBS increases neuroconnectivity between the VMPFC and limbic system.</p><p>Frontal pole stimulation is a recent TMS and iTBS site of interest for reducing impulsive behaviors, including substance abuse [<xref rid="ref82" ref-type="bibr">82</xref>] and compulsions in obsessive compulsive disorder [<xref rid="ref83" ref-type="bibr">83</xref>]. iTBS can be applied to the frontal pole to target the VMPFC, and iTBS to the frontal pole is tolerable, with no more subjective pain than TMS [<xref rid="ref63" ref-type="bibr">63</xref>]. This approach allows for more direct stimulation of the VMPFC and modulation of the limbic system [<xref rid="ref63" ref-type="bibr">63</xref>,<xref rid="ref82" ref-type="bibr">82</xref>].</p><p>This study proposes inducing neuroplasticity to the VMPFC by stimulating the frontal pole to treat SI and impulsivity in veterans with mTBI. We selected the frontal pole and associated right VMPFC as a treatment target as volumetric data demonstrates thinning of the right medial orbitofrontal cortex and VMPFC when compared to healthy controls [<xref rid="ref78" ref-type="bibr">78</xref>]. Individuals exhibiting this volume loss also report increased aggression, anxiety, and depression following injury [<xref rid="ref79" ref-type="bibr">79</xref>]. The role of the VMPFC in negative urgency impulsivity is also supported by evidence that individuals with penetrating TBI to the VMPFC are significantly more likely to become aggressive than those with penetrating TBI elsewhere [<xref rid="ref44" ref-type="bibr">44</xref>]. By inducing modulation and neuroplasticity to the VMPFC and limbic system, iTBS at the frontal pole offers a promising means of mitigating impulsive behaviors and decreasing SI by increasing connectivity and undoing limbic damage caused by mTBI. However, more research is essential to ensure safety, tolerability, and efficacy of this treatment approach.</p></sec></sec><sec><title>Objectives</title><p>This pilot study aimed to (1) determine the safety, feasibility, tolerability, and efficacy of frontal pole iTBS for veterans with mTBI, negative urgency impulsivity, and SI; (2) collect advanced neuroimaging data from veterans with mTBI, impulsivity, and suicidality to further our understanding of what neural changes are occurring when treatment is effective; and (3) gather preliminary clinical outcome data on impulsivity, SI, and social and occupational functioning of veterans receiving iTBS. The results of these objectives will help to guide future studies on neuromodulation as a treatment for impulsivity and SI among patients with mTBI.</p></sec><sec><title>Hypotheses</title><p>Our central hypotheses are that frontal pole iTBS will be safe, feasible, and tolerable among veterans with mTBI based on existing literature that suggests frontal pole iTBS is as safe and tolerable as iTBS performed elsewhere [<xref rid="ref23" ref-type="bibr">23</xref>,<xref rid="ref25" ref-type="bibr">25</xref>,<xref rid="ref62" ref-type="bibr">62</xref>]. Similarly, iTBS, when administered to individuals with mTBI is as safe and tolerable as in individuals without mTBI [<xref rid="ref63" ref-type="bibr">63</xref>]. Given that we are using an established iTBS protocol within the established TMS safety guidelines [<xref rid="ref84" ref-type="bibr">84</xref>], we do not anticipate significant AEs.</p><p>We further hypothesize that social and occupational functioning, negative urgency impulsivity, and SI will be improved for individuals who receive active-iTBS compared with those who receive sham-iTBS. Even if only a single domain improves, we consider this a positive finding.</p><p>In addition, we hypothesize that resting-state functional connectivity between the VMPFC and the limbic system (especially the amygdala and anterior cingulate cortex) will be strengthened for the active-iTBS group compared with the sham-iTBS group. We also expect that veterans with increased connectivity between these regions of interest (ROIs) will likely show the most functional improvements.</p><p>Pending the results of this pilot trial, larger-scale RCTs may be warranted to establish the efficacy of frontal pole iTBS for social and occupational functional deficits, negative urgency impulsivity, and SI.</p></sec></sec><sec sec-type="methods"><title>Methods</title><sec><title>Study Design</title><p>The proposed study is a pilot, prospective, randomized, double-blinded, sham-controlled study to develop a frontal pole iTBS intervention. We will examine the safety, feasibility, tolerability, and efficacy of 10 sessions of iTBS over 2 weeks. Preliminary impulsivity, SI, and social and occupational functioning data will be collected before and after receiving active or sham treatment. In developing this protocol, we referenced the SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials) guidelines [<xref rid="ref85" ref-type="bibr">85</xref>]. We used the CONSORT (Consolidated Standards of Reporting Trials) checklist when writing our report [<xref rid="ref86" ref-type="bibr">86</xref>]. Refer to <xref rid="app1" ref-type="supplementary-material">Multimedia Appendix 1</xref> for the CONSORT flow diagram.</p></sec><sec><title>Ethical Considerations</title><p>The study protocol was reviewed and approved by the Edward Hines, Jr. VA Hospital Institutional Review Board (Hines IRB number 1716074) and the University of Illinois, Chicago Institutional Review Board. The study is registered on ClinicalTrials.gov (NCT05647044). This study is designed in accordance with the ethical standards of the US VA Office of Research and Development, based on those from the Declaration of Helsinki, the Belmont Report, US Common Rule and Regulations from the Council for International Organizations of Medical Sciences. The study will be overseen by the institutional review boards of the both Edward Hines, Jr. VA Hospital and the University of Illinois, Chicago. This research study is designed on a 5-year research plan.</p><p>A Health Insurance Portability and Accountability Act (HIPAA) authorization waiver will be obtained to enable electronic medical records review of potential participants before obtaining consent. The HIPAA waiver allows research staff to access information about the patient&#x02019;s medical history and demographics, as well as history of drug or alcohol abuse to determine study eligibility. If a potential participant declines to participate in the study, no further contact will be made.</p><p>If the potential participant consents to the study, they will then begin the informed consent process. Informed consent will be obtained in English by trained research staff. Research participants will have access to research staff and the principal investigator to assist with any questions or concerns until understanding is achieved. A consent note is made in the participant&#x02019;s medical record either electronically or on paper. The original consent is then placed in the medical record, a copy is given to the participant, a copy is filed with the Edward Hines, Jr. VA Hospital Institutional Review Board and the original informed consent is placed in the participant&#x02019;s research binder and maintained in a locked file cabinet at Hines VA Hospital. Once the informed consent process is completed, a note will be documented in the electronic medical record system and the participant will be flagged as a research participant.</p><p>Any identifiable information about the participant, including their signed consent form, is stored in a different location than study data, on encrypted VA servers in files that are only accessible to approved study team members. The collected, deidentified research data are also stored on encrypted VA servers elsewhere, in password-protected folders, only accessible to approved study team personnel. Any participant information obtained in the study will be treated as confidential and safeguarded in accordance with the Privacy Act of 1974. Information published or presented about the results of the study will be done such that no individual identifying information is shared.</p><p>Participants will be compensated up to US $350 for their participation, prorated for their time.</p></sec><sec><title>Participants</title><p>We will enroll 56 veterans aged between 22 and 65 years with a history of mTBI and impulsivity. They must also report that they have experienced SI within the last 3 months. mTBI will be defined according to the VA and Department of Defense guidelines [<xref rid="ref87" ref-type="bibr">87</xref>] and use aspects of the mTBI symptom attribution and classification algorithm [<xref rid="ref88" ref-type="bibr">88</xref>] when determining eligibility. mTBI must have occurred at least 1 year before enrollment to ensure that the injury has stabilized. Though it is not mandatory, veterans may also have diagnoses of depression, PTSD, or bipolar spectrum illness (without a history of psychosis). Recent SI (within the past 3 months) will be defined as a score of &#x02265;1 on the Columbia Suicide Severity Rating Scale [<xref rid="ref89" ref-type="bibr">89</xref>]. Impulsivity will be defined as having any mentions of impulsive behavior in the medical chart and any positive results on the Urgency, Premeditation (lack of), Perseveration (lack of), Sensation Seeking, Positive Urgency Impulsive Behavior Scale&#x02013;Negative Urgency subscale (UPPS-P) [<xref rid="ref41" ref-type="bibr">41</xref>]. For safety, we will exclude persons with contraindications to TMS or MRI because of increased risk of AEs. We will also exclude participants whose SI is active, with intent and plan, as they require emergency psychiatric intervention. We will not exclude individuals based on sex, gender identity, ethnicity, or race. To enhance generalizability, we will include veterans regardless of previous combat or deployment experience. As cannabis and alcohol use is prevalent among veterans, intermittent or low amounts of cannabis or alcohol consumption will not be considered exclusionary if the use does not meet the criteria for a moderate substance use disorder. Detailed information on inclusion and exclusion criteria is listed below (<xref rid="box2" ref-type="boxed-text">Textbox 2</xref>).</p><boxed-text id="box2" position="float"><caption><title>Participant inclusion and exclusion criteria.</title></caption><p>
<bold>Inclusion criteria</bold>
</p><list list-type="bullet"><list-item><p>Aged between 22 and 65 years</p></list-item><list-item><p>Can read and speak English</p></list-item><list-item><p>Mild traumatic brain injury (mTBI) criteria: Symptom Attribution and Classification Algorithm [<xref rid="ref88" ref-type="bibr">88</xref>] criteria for mTBI (without the requirement of clinical neuropsychological impairment).</p></list-item><list-item><p>Columbia Suicide Severity Rating Scale score of &#x02265;1 within 3 months</p></list-item><list-item><p>History of impulsivity documented in the chart and exhibited on the Urgency, Premeditation (lack of), Perseveration (lack of), Sensation Seeking, Positive Urgency Impulsive Behavior Scale&#x02014;Negative Urgency subscale (Urgency score &#x0003e;20) [<xref rid="ref41" ref-type="bibr">41</xref>]</p></list-item></list><p>
<bold>Exclusion criteria</bold>
</p><list list-type="bullet"><list-item><p>Contraindications to intermittent theta burst stimulation or transcranial magnetic stimulation (eg, epilepsy)</p></list-item><list-item><p>Contraindications to magnetic resonance imaging (eg, claustrophobia, ferromagnetic metal implants)</p></list-item><list-item><p>Active substance use disorder per DSM-5 (Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition) criteria</p></list-item><list-item><p>Active suicidal ideation with intent and plan (these participants will be brought to the emergency department for emergent psychiatric care)</p></list-item><list-item><p>History of moderate to severe traumatic brain injury</p></list-item><list-item><p>History of nontraumatic neurological injury (eg, stroke, neurosurgery, hemorrhage)</p></list-item><list-item><p>History of or current psychosis not due to an external cause (eg, due to illicit drug use)</p></list-item><list-item><p>Pregnant or breastfeeding</p></list-item><list-item><p>Within 12 weeks of a major surgery</p></list-item><list-item><p>Active, unstable health condition (ie, decompensated heart failure, recent severe heart attack)</p></list-item><list-item><p>Within 1 year of mTBI</p></list-item></list></boxed-text></sec><sec><title>Power Analysis and Sample Size Justification</title><p>To ensure we have adequate power to detect a difference in our primary outcome, the Social and Occupational Functioning Assessment Scale (SOFAS), we conducted a power analysis. Assuming a significance level of 0.05, a mean SOFAS score of 44.6, and a SD of 15, with 50 veterans, we will have 82% power to detect a significant interaction between time and treatment assuming no change over time in the sham-iTBS group and a change of 13 points in the active iTBS group [<xref rid="ref90" ref-type="bibr">90</xref>]. On the basis of similar studies of iTBS protocols for patients with depression and PTSD, receiving treatment of similar duration, attrition rates are expected to be low&#x02014;under 10% [<xref rid="ref58" ref-type="bibr">58</xref>,<xref rid="ref90" ref-type="bibr">90</xref>,<xref rid="ref91" ref-type="bibr">91</xref>]. As such, we plan to enroll participants to ensure we have an adequate sample size considering 10% attrition. Thus, our total sample size will be 56 with 28 in the active iTBS group and 28 in the sham iTBS group.</p></sec><sec><title>Recruitment</title><p>We will recruit veterans receiving care from the TBI and polytrauma program, primary clinic, women&#x02019;s health clinic, and the Mental Health Service Line at Edward Hines, Jr. VA Hospital in Hines, Illinois, United States. Personnel at all mentioned clinics will be educated on the study and encouraged to give institutional review board (IRB)&#x02013;approved flyers containing contact information to veterans who may be a good fit for the study. We will be added as cosigners in the electronic medical records of Hines VA patients who may be deemed a good fit for this study. We will also mail informational letters to veterans who have completed past TBI studies and permit us to contact them about future studies through a TBI Data Repository (Hines IRB number14-003), which currently includes &#x0003e;300 veterans. Research candidates at the Hines VA will also be identified using administrative electronic health record data available through the VA Informatics and Computing Infrastructure. The VA Informatics and Computing Infrastructure database will search for TBI within the past 10 years (FY2013-FY2023) according to appropriate <italic>International Classification of Diseases</italic> (ninth and tenth editions), clinical modification, codes reflecting study inclusion criteria. All potentially eligible veterans will receive an informational letter and phone call to gauge interest and perform initial eligibility screens.</p></sec><sec><title>Data Collection and Measures</title><sec><title>MRI Data Acquisition, Neuronavigation, and Motor Thresholding</title><p>All participants will undergo an MRI of their brain before and after iTBS administration. Before iTBS, a high-resolution, 3D, T1-weighted, multigradient-echo sagittal anatomical scan (voxel size=0.8 mm isotropic resolution) will be collected at the University of Illinois, Chicago Center for Magnetic Resonance Research to allow for iTBS treatment site neuronavigation for each participant. Participants will also complete a resting-state functional MRI (fMRI) and diffusion tensor imaging before and after iTBS administration to examine treatment-induced connectivity changes. Participants will be asked to complete a standardized MRI safety screening form before starting the study to ensure the MRI safety procedures are followed (<xref rid="app2" ref-type="supplementary-material">Multimedia Appendix 2</xref>).</p><p>Each participant&#x02019;s T1 MRI will be loaded into a TMS Neural Navigator TS system (version 3.3.22, Localite), consisting of a camera and computer system that allows a TMS provider to superimpose an individual&#x02019;s MRI onto where they are in space, allowing for very precise placement of the TMS coil. Electrodes will be placed on the thumb over the abductor pollicis brevis (ABP) muscle and connected to an electromyograph (MagVenture) to measure motor-evoked potentials (MEPs). To determine each participant&#x02019;s motor threshold (MT) for iTBS (to determine at which intensity the iTBS stimulation should be delivered), a MagProX100 with MagOption stimulator and Magpro Cool Coil B65 A/P (MagVenture) will be used. Single pulse TMS will be administered to the left motor cortex at the hand knob. The location of this part of the motor cortex will be estimated using the participant&#x02019;s MRI and then confirmed using TMS to identify the ABP muscle neural coordinates. The resting MT is the lowest stimulus intensity necessary to produce MEPs of the peak-to-peak amplitude of &#x02265;50 &#x000b5;V in 5 of 10 trials. MEPs of the ABP will be recorded using surface electrodes on the right thumb. The right frontal pole will be identified and mapped using the TMS Neural Navigator (Localite) system. The anatomical location is easily identifiable using anatomical landmarks and correlates with electrode frontal polar cortex (FP; FP2) on a 10 to 20 electroencephalogram, a region overlapping with the right VMPFC [<xref rid="ref22" ref-type="bibr">22</xref>,<xref rid="ref63" ref-type="bibr">63</xref>,<xref rid="ref82" ref-type="bibr">82</xref>]. Refer to <xref rid="app3" ref-type="supplementary-material">Multimedia Appendix 3</xref> for the equipment list.</p></sec><sec><title>Data Collection</title><p>Data collection is expected to take approximately 18 to 20 hours per participant over the intervention period of 2 weeks. Assessments will be collected at 4 time points in the study: screening, baseline, midpoint, and end point (<xref rid="table1" ref-type="table">Table 1</xref>).</p><table-wrap position="float" id="table1"><label>Table 1</label><caption><p>Assessment timeline and purpose.</p></caption><table frame="hsides" rules="groups" width="1000" cellpadding="5" cellspacing="0" border="1"><col width="30" span="1"/><col width="200" span="1"/><col width="190" span="1"/><col width="190" span="1"/><col width="200" span="1"/><col width="190" span="1"/><thead><tr valign="top"><td colspan="2" rowspan="1">Assessment name</td><td rowspan="1" colspan="1">Assessment purpose</td><td rowspan="1" colspan="1">Items</td><td rowspan="1" colspan="1">Scoring</td><td rowspan="1" colspan="1">Validity and reliability</td></tr></thead><tbody><tr valign="top"><td colspan="6" rowspan="1">
<bold>Phone screening assessments</bold>
</td></tr><tr valign="top"><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">Ohio State TBI<sup>a</sup> Identification Method [<xref rid="ref92" ref-type="bibr">92</xref>] (rater administered)</td><td rowspan="1" colspan="1">mTBI<sup>b</sup> eligibility determination</td><td rowspan="1" colspan="1">Structured interview</td><td rowspan="1" colspan="1">Determination of the likelihood TBI sustained based on the participant&#x02019;s detail recollection</td><td rowspan="1" colspan="1">Interrater reliability &#x0003e;90% (very high) [<xref rid="ref92" ref-type="bibr">92</xref>]</td></tr><tr valign="top"><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">Columbia Suicide Severity Rating Scale [<xref rid="ref89" ref-type="bibr">89</xref>] (rater administered)</td><td rowspan="1" colspan="1">History of suicidality, eligibility determination&#x02014;secondary outcome</td><td rowspan="1" colspan="1">Five items measuring the presence of SI<sup>c</sup>, intensity of SI, presence of suicidal behaviors, lethality of behaviors</td><td rowspan="1" colspan="1">Ideation: 0-5; intensity: 2-25; suicidal behaviors: yes or no; lethality: 0-2, higher scores=more severe</td><td rowspan="1" colspan="1">Internal validity a=0.95 and test-retest reliability r<sub><italic>tt</italic></sub><italic>=</italic>0.90-1.0 (very high) [<xref rid="ref93" ref-type="bibr">93</xref>,<xref rid="ref94" ref-type="bibr">94</xref>]</td></tr><tr valign="top"><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">Urgency, Premeditation (lack of), Perseveration (lack of), Sensation Seeking, Positive Urgency Impulsive Behavior Scale&#x02014;Negative Urgency subscale [<xref rid="ref41" ref-type="bibr">41</xref>,<xref rid="ref95" ref-type="bibr">95</xref>] (rater administered)</td><td rowspan="1" colspan="1">Negative urgency impulsivity, eligibility determination&#x02014;secondary outcome</td><td rowspan="1" colspan="1">Fifty-nine items measuring 4 traits&#x02013;urgency, lack of premeditation, lack of perseveration, and sensation seeking [<xref rid="ref96" ref-type="bibr">96</xref>]</td><td rowspan="1" colspan="1">4-point Likert scale questions, scored by each trait, some reverse-coded. Higher score=more severe [<xref rid="ref97" ref-type="bibr">97</xref>]</td><td rowspan="1" colspan="1">Cronbach &#x003b1;=0.91 (very high) [<xref rid="ref41" ref-type="bibr">41</xref>,<xref rid="ref97" ref-type="bibr">97</xref>]</td></tr><tr valign="top"><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">Demographics (rater administered)</td><td rowspan="1" colspan="1">Sample characterization</td><td rowspan="1" colspan="1">&#x02014;<sup>d</sup></td><td rowspan="1" colspan="1">&#x02014;</td><td rowspan="1" colspan="1">&#x02014;</td></tr><tr valign="top"><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">UIC<sup>e</sup> CMRR<sup>f</sup> MRI<sup>g</sup> Safety Form (Multimedia Appendix 2; rater administered)</td><td rowspan="1" colspan="1">MRI safety, compatibility, and eligibility determination</td><td rowspan="1" colspan="1">&#x02014;</td><td rowspan="1" colspan="1">&#x02014;</td><td rowspan="1" colspan="1">&#x02014;</td></tr><tr valign="top"><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">TMS<sup>h</sup> Safety Form (Multimedia Appendix 4; rater administered)</td><td rowspan="1" colspan="1">TMS safety compatibility, eligibility determination</td><td rowspan="1" colspan="1">&#x02014;</td><td rowspan="1" colspan="1">&#x02014;</td><td rowspan="1" colspan="1">&#x02014;</td></tr><tr valign="top"><td colspan="6" rowspan="1">
<bold>In-person screening assessments</bold>
</td></tr><tr valign="top"><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">Structured diagnostic interview [<xref rid="ref88" ref-type="bibr">88</xref>] (rater administered)</td><td rowspan="1" colspan="1">mTBI symptoms, eligibility determination</td><td rowspan="1" colspan="1">Structured interview</td><td rowspan="1" colspan="1">Likelihood symptoms owing to TBI sustained</td><td rowspan="1" colspan="1">&#x02014;</td></tr><tr valign="top"><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">Neurobehavioral Symptom Inventory [<xref rid="ref98" ref-type="bibr">98</xref>] (rater administered)</td><td rowspan="1" colspan="1">mTBI symptoms, eligibility determination</td><td rowspan="1" colspan="1">Twenty-two items asking about the severity of postconcussive symptoms</td><td rowspan="1" colspan="1">Severity: 0=never to 4=very severe, symptom always present; higher score=more severe symptoms</td><td rowspan="1" colspan="1">Cronbach &#x003b1;=0.81-0.96 (very high) [<xref rid="ref98" ref-type="bibr">98</xref>]</td></tr><tr valign="top"><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">Clinically Administered PTSD<sup>i</sup> Scale for DSM-5<sup>j</sup> [<xref rid="ref99" ref-type="bibr">99</xref>] (rater administered)</td><td rowspan="1" colspan="1">PTSD diagnosis</td><td rowspan="1" colspan="1">30-item questionnaire corresponding to DSM-5 PTSD criteria</td><td rowspan="1" colspan="1">Severity: 0=absent to 4=extreme, total symptom severity 0-80, higher score=more severe symptoms</td><td rowspan="1" colspan="1">Interrater reliability <italic>K</italic>=0.78-1.0 (high) discriminant validity: rs=0.02&#x02212;0.54 (moderate) [<xref rid="ref100" ref-type="bibr">100</xref>]</td></tr><tr valign="top"><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">Alcohol Use Disorder Identification Test [<xref rid="ref101" ref-type="bibr">101</xref>] (participant self-administered)</td><td rowspan="1" colspan="1">Active alcohol use disorder, eligibility determination</td><td rowspan="1" colspan="1">10-item questionnaire about the frequency and amount of alcohol used</td><td rowspan="1" colspan="1">Questions 1-8 (0-4 points), 9-10 (0,2,4 points, range of 0-40 points, higher score=more severe symptoms)</td><td rowspan="1" colspan="1">AUROC<sup>k</sup>=0.891 (high) [<xref rid="ref101" ref-type="bibr">101</xref>]</td></tr><tr valign="top"><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">Drug Use Disorders Identification Test [<xref rid="ref102" ref-type="bibr">102</xref>] (participant self-administered)</td><td rowspan="1" colspan="1">Active substance abuse disorder, eligibility determination</td><td rowspan="1" colspan="1">11-item questionnaire about the frequency and number of drugs of abuse used</td><td rowspan="1" colspan="1">Questions 1-9 (0-4 points), 10-11 (0,2,4 points, total score 0-44, higher score=more severe symptoms)</td><td rowspan="1" colspan="1">Cronbach &#x003b1;=0.93 (very high), convergent validity <italic>r</italic>=0.76 (high) [<xref rid="ref102" ref-type="bibr">102</xref>,<xref rid="ref103" ref-type="bibr">103</xref>]</td></tr><tr valign="top"><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">Structured Clinical Interview for DSM-5, Research Version [<xref rid="ref104" ref-type="bibr">104</xref>] (rater administered)</td><td rowspan="1" colspan="1">Active mental illness diagnosis</td><td rowspan="1" colspan="1">Structured interview</td><td rowspan="1" colspan="1">&#x02014;</td><td rowspan="1" colspan="1"><italic>K</italic>&#x0003e;0.4 (above average) sensitivity of identifying diagnosis &#x0003e;0.8 (good) [<xref rid="ref105" ref-type="bibr">105</xref>]</td></tr><tr valign="top"><td colspan="6" rowspan="1">
<bold>Baseline, midpoint, and follow-up assessments</bold>
</td></tr><tr valign="top"><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">Social and Occupational Functioning Assessment Scale [<xref rid="ref106" ref-type="bibr">106</xref>] (rater administered)</td><td rowspan="1" colspan="1">Functioning in the community&#x02013;primary outcome</td><td rowspan="1" colspan="1">Single item 100-point scale assessing social activities, relationships, self-care, aggressive behavior</td><td rowspan="1" colspan="1">0-100 (0=not functioning, 100=superior functioning)</td><td rowspan="1" colspan="1">Weighted <italic>K</italic>=0.95 (very high) [<xref rid="ref107" ref-type="bibr">107</xref>]</td></tr><tr valign="top"><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">Columbia Suicide Severity Rating Scale (rater administered)</td><td rowspan="1" colspan="1">As described in &#x0201c;phone screening assessments&#x0201d;</td><td rowspan="1" colspan="1">As described in &#x0201c;phone screening assessments&#x0201d;</td><td rowspan="1" colspan="1">As described in &#x0201c;phone screening assessments&#x0201d;</td><td rowspan="1" colspan="1">As described in &#x0201c;phone screening assessments&#x0201d;</td></tr><tr valign="top"><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">Urgency, Premeditation (lack of), Perseveration (lack of), Sensation Seeking, Positive Urgency Impulsive Behavior Scale&#x02014;Negative Urgency subscale (participant self-administered)</td><td rowspan="1" colspan="1">As described in &#x0201c;phone screening assessments&#x0201d;</td><td rowspan="1" colspan="1">As described in &#x0201c;phone screening assessments&#x0201d;</td><td rowspan="1" colspan="1">As described in &#x0201c;phone screening assessments&#x0201d;</td><td rowspan="1" colspan="1">As described in &#x0201c;phone screening assessments&#x0201d;</td></tr><tr valign="top"><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">Buss-Perry Aggressiveness Scale [<xref rid="ref108" ref-type="bibr">108</xref>] (participant self-administered)</td><td rowspan="1" colspan="1">Aggression symptoms</td><td rowspan="1" colspan="1">29-item scale of true or false statements about aggressive and stable behaviors, including measures of physical aggression, verbal aggression, anger, and hostility</td><td rowspan="1" colspan="1">Scale of 1-5, 1 being &#x0201c;extremely uncharacteristic,&#x0201d; to 5 being &#x0201c;extremely characteristic.&#x0201d; Some reverse coded (stability statements), higher score=more aggressiveness</td><td rowspan="1" colspan="1">Test-retest reliability r<sub><italic>tt</italic></sub>=0.80 (high), Cronbach &#x003b1;=0.68-0.8 for each subscale (moderate-high) [<xref rid="ref108" ref-type="bibr">108</xref>]</td></tr><tr valign="top"><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">Patient Health Questionnaire-9 [<xref rid="ref109" ref-type="bibr">109</xref>] (participant self-administered)</td><td rowspan="1" colspan="1">Depression symptoms</td><td rowspan="1" colspan="1">9-item scale of DSM-5 depressive disorder symptoms (ie, low mood, sleep disturbance, SI)</td><td rowspan="1" colspan="1">Scale of 0-3, 0=&#x0201c;not at all,&#x0201d; 3=&#x0201c;always.&#x0201d; Higher score=more severe depression</td><td rowspan="1" colspan="1">Cronbach &#x003b1;=0.9 (very high) [<xref rid="ref110" ref-type="bibr">110</xref>]</td></tr><tr valign="top"><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">Veteran&#x02019;s RAND [<xref rid="ref111" ref-type="bibr">111</xref>] (participant self-administered)</td><td rowspan="1" colspan="1">Perceived community functioning</td><td rowspan="1" colspan="1">36 items across 8 subscales of health including physical health, limitations owing to health, energy, social health, etc</td><td rowspan="1" colspan="1">0-100, higher score=more favorable health state</td><td rowspan="1" colspan="1">Cronbach &#x003b1;=0.78-0.93 depending on the domain (high-very high) [<xref rid="ref112" ref-type="bibr">112</xref>]</td></tr><tr valign="top"><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">Beck Suicide Scale [<xref rid="ref113" ref-type="bibr">113</xref>] (participant self-administered)</td><td rowspan="1" colspan="1">Suicidal ideation measurement</td><td rowspan="1" colspan="1">21 items about recent thoughts of death, recent suicidal behaviors</td><td rowspan="1" colspan="1">Scale of 0-2, higher number=more severe SI</td><td rowspan="1" colspan="1">Cronbach &#x003b1;=0.89 (very high), strong predictive validity [<xref rid="ref114" ref-type="bibr">114</xref>]</td></tr><tr valign="top"><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">PTSD Checklist for DSM-5 [<xref rid="ref115" ref-type="bibr">115</xref>] (participant self-administered)</td><td rowspan="1" colspan="1">PTSD symptoms</td><td rowspan="1" colspan="1">20 items corresponding to DSM-5 criteria for PTSD symptoms (eg, hypervigilance, flashbacks)</td><td rowspan="1" colspan="1">Scale of 0-4, 0=not at all, 4=extremely, score &#x0003e;33=probable PTSD diagnosis</td><td rowspan="1" colspan="1">Cronbach &#x003b1;=0.94 (very high) and test-retest reliability (r<sub><italic>tt</italic></sub><italic>=</italic>0.82) (high) [<xref rid="ref116" ref-type="bibr">116</xref>]</td></tr><tr valign="top"><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">Inventory of Depressive Symptomatology, Self-Report [<xref rid="ref117" ref-type="bibr">117</xref>] (participant self-administered)</td><td rowspan="1" colspan="1">Depression symptoms</td><td rowspan="1" colspan="1">30 items assessing DSM-5 depressive symptoms</td><td rowspan="1" colspan="1">Scale of 0-3, 0=not present, 3=severe symptoms, higher score=more severe symptoms</td><td rowspan="1" colspan="1">Cronbach &#x003b1;=0.94 (very high) and test-retest reliability r<sub><italic>tt</italic></sub><italic>=</italic>0.82 (high) [<xref rid="ref118" ref-type="bibr">118</xref>]</td></tr><tr valign="top"><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">Difficulties in Emotion Regulation Scale [<xref rid="ref119" ref-type="bibr">119</xref>] (participant self-administered)</td><td rowspan="1" colspan="1">Perceived struggles with emotion modulation</td><td rowspan="1" colspan="1">36-item scale, 6 subscales of emotion regulation</td><td rowspan="1" colspan="1">Scale of 1-5, 1=almost never, 5=almost always. Higher score=more difficulty with regulation</td><td rowspan="1" colspan="1">Cronbach &#x003b1;=0.90 (very high) [<xref rid="ref120" ref-type="bibr">120</xref>]</td></tr><tr valign="top"><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">Delayed Discounting Task [<xref rid="ref121" ref-type="bibr">121</xref>] (administered on computer)</td><td rowspan="1" colspan="1">Impulsivity inhibition measure</td><td rowspan="1" colspan="1">Behavioral assessment of impulsivity, 27 items where participant chooses smaller immediate rewards vs larger delayed reward</td><td rowspan="1" colspan="1">Tendency to choose smaller immediate rewards consistent with more impulsivity</td><td rowspan="1" colspan="1">Test-retest reliability r<sub><italic>tt</italic></sub><italic>=</italic>0.89 (very high) [<xref rid="ref122" ref-type="bibr">122</xref>]</td></tr><tr valign="top"><td rowspan="1" colspan="1">
<break/>
</td><td rowspan="1" colspan="1">Stroop Color &#x00026; Word Test [<xref rid="ref123" ref-type="bibr">123</xref>] (rater administered)</td><td rowspan="1" colspan="1">Impulsivity inhibition measure</td><td rowspan="1" colspan="1">Behavioral assessment of processing speed and inhibition of cognitive interference</td><td rowspan="1" colspan="1">Measure the number of correct answers versus incorrect answers</td><td rowspan="1" colspan="1">Reliability estimates range from a=0.83 to a=0.91 and test-retest reliability ranges from r<sub><italic>tt</italic></sub><italic>=</italic>0.79 to r<sub><italic>tt</italic></sub><italic>=</italic>0.97 (all high-very high) [<xref rid="ref124" ref-type="bibr">124</xref>]</td></tr></tbody></table><table-wrap-foot><fn id="table1fn1"><p><sup>a</sup>TBI: traumatic brain injury.</p></fn><fn id="table1fn2"><p><sup>b</sup>mTBI: mild traumatic brain injury.</p></fn><fn id="table1fn3"><p><sup>c</sup>SI: suicidal ideation.</p></fn><fn id="table1fn4"><p><sup>d</sup>Not applicable.</p></fn><fn id="table1fn5"><p><sup>e</sup>UIC: University of Illinois, Chicago.</p></fn><fn id="table1fn6"><p><sup>f</sup>CMRR: Center for Magnetic Resonance Research.</p></fn><fn id="table1fn7"><p><sup>g</sup>MRI: magnetic resonance imaging.</p></fn><fn id="table1fn8"><p><sup>h</sup>TMS: transcranial magnetic stimulation.</p></fn><fn id="table1fn9"><p><sup>i</sup>PTSD: posttraumatic stress disorder.</p></fn><fn id="table1fn10"><p>jDSM-5: Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition.</p></fn><fn id="table1fn11"><p><sup>k</sup>AUROC: area under the receiver operating characteristic curve.</p></fn></table-wrap-foot></table-wrap><p>Eligibility measures and information collected during the preenrollment phone screen administered by authorized clinical researchers include The Ohio State University TBI Identification Method [<xref rid="ref92" ref-type="bibr">92</xref>], the Columbia Suicide Severity Rating Scale [<xref rid="ref89" ref-type="bibr">89</xref>], the UPPS-P [<xref rid="ref41" ref-type="bibr">41</xref>], self-reported age, the ability to read and speak English, the Center for Magnetic Resonance Research safety form (<xref rid="app2" ref-type="supplementary-material">Multimedia Appendix 2</xref>), and TMS safety form (<xref rid="app4" ref-type="supplementary-material">Multimedia Appendix 4</xref>). If deemed eligible, participants will be asked to complete an in-person screening.</p><p>The in-person screening will consist of completing additional assessments to ensure eligibility and baseline characteristics. They include the structured diagnostic interview from the symptom attribution and classification algorithm, created by individuals involved in this study to determine likelihood and severity of prior TBIs [<xref rid="ref88" ref-type="bibr">88</xref>], the Neurobehavioral Symptom Inventory, to determine TBI-related symptom presence [<xref rid="ref98" ref-type="bibr">98</xref>], the Clinician-Administered PTSD Scale for DSM-5 to determine preexisting diagnosis of PTSD [<xref rid="ref99" ref-type="bibr">99</xref>], the Alcohol Use Disorder Identification Test-Consumption Questions to determine if an alcohol use disorder is present [<xref rid="ref101" ref-type="bibr">101</xref>], the Drug Use Disorders Identification Test to determine if a drug use disorder is present [<xref rid="ref102" ref-type="bibr">102</xref>], and the Structured Clinical Interview for DSM-5&#x02013;Research Version to determine the presence of other psychiatric disorders [<xref rid="ref104" ref-type="bibr">104</xref>].</p><p>Once the listed diagnostic and screening measures are completed and participants meet eligibility criteria, participants will be asked to complete self-reported measures at their baseline, midpoint, and end point visits (<xref rid="table1" ref-type="table">Table 1</xref>).</p><p>Feasibility completion rates will be described according to the reasons participants did not complete the 2-week intervention and the rates of missed sessions. Study completion is defined as completing all 10 sessions. Safety measures will follow procedures used in prior TMS studies [<xref rid="ref125" ref-type="bibr">125</xref>] and will be scored using the <italic>Medical Dictionary for Regulatory Activities</italic>. Side effects, AEs, and the TMS data safety sheet will assess change severity throughout the intervention. Tolerability will be measured through the number of patients who complete the treatment course and via self-report.</p></sec><sec><title>Safety and AE Monitoring</title><p>Participants will participate in safety monitoring using the Data Safety Monitoring Scale. This scale will measure rate changes from baseline vitals (temperature, blood pressure, heart rate, oxygen saturation levels), fatigue, tinnitus (ringing in the ears), sleep, dizziness, nausea, vomiting, confusion, seizure, syncope (fainting), headache, neck pain, skin integrity of the scalp, and substance use.</p><p>Participants will be asked about AEs at each iTBS session, which will be logged to ensure safety throughout the intervention. These will be coded using the current version of the Medical Dictionary for Regulatory Activities, following procedures used in previous TMS studies [<xref rid="ref82" ref-type="bibr">82</xref>]. The TMS safety sheet (<xref rid="app4" ref-type="supplementary-material">Multimedia Appendix 4</xref>) will be collected and scored regarding severity and change from baseline. Data on every side effect and AE will be collected, rated on a score of 0 to 5 to assess severity, and reported.</p><p>All iTBS sessions will be videotaped to monitor for safety and allow for review in case of an AE. Acknowledgment for pictures and videos will be completed as part of our informed consent procedure.</p><p>AEs can be nonserious and serious. A serious AE is when the changes are life-threatening and may be disabling, require hospitalization, or require intervention to prevent impairment. We will measure deleterious changes in (1) neurological status and cognitive symptoms, (2) somatic and vestibular symptoms, (3) and depression. AE will be tracked using the AE log.</p><p>All unanticipated AEs related to this research study will be reported to the IRB, the study sponsor, and the research director within 5 business days. Serious AEs will be reported to these entities within 24 hours. If any unanticipated problem occurs, such as deviation from this protocol that involves risks or has the potential to recur, the investigator will report this information to the IRB. All AE information will be reported within 2 to 5 business days of the investigator or staff becoming aware of the event.</p><p>The study will take place at the Edward Hines, Jr. VA Hospital in Hines, Illinois, a full-service, tertiary-care hospital. Our laboratory is located within the rapid response area, meaning a team of specialized nurses and doctors can be called at any time to emergently assess a patient, should the need arise. Participants will be clinically monitored for seizure by trained research staff. In the event of a seizure, the research team member will call the on-site rapid response team (RRT) to provide emergent medical care to the participant. Cardiopulmonary resuscitation&#x02013;trained research staff will assess the participant&#x02019;s airway, breathing, and circulation until the RRT team arrives. RRT will then take over the participant&#x02019;s care, including administering seizure-abating medications and airway protection, and transport the participant to the emergency department. Any seizure will result in stopping the intervention and withdrawal from the study.</p></sec></sec><sec><title>Experimental Intervention</title><p>Each participant will be randomized to receive active or sham treatment throughout the protocol, with 50% (28/56) receiving active treatment and 50% (28/56) of participants receiving placebo. We will use a T1 MRI to localize the FP stimulation site. This region is correlated with electrode FP2 on a 10 to 20 electroencephalogram, a region overlapping with the right VMPFC [<xref rid="ref22" ref-type="bibr">22</xref>,<xref rid="ref82" ref-type="bibr">82</xref>]. To ensure precise and repeatable coil positioning over the frontal pole FP2 site, the Localite (neuronavigation) system and an MRI instrument marker will be used at every iTBS session.</p><p>Our 9-minute iTBS protocol will be delivered using the MagVenture Mag-Pro X100 with the MagOption stimulator, including active and placebo coils (C-B60 Butterfly coils). The consensus in the literature is that iTBS can safely deliver 1800 pulses at 110% of the MT to the frontal pole [<xref rid="ref82" ref-type="bibr">82</xref>,<xref rid="ref83" ref-type="bibr">83</xref>]. iTBS parameters include 3 pulses of stimulation at 50 Hz, repeated every 200 miliseconds. The interpulse interval is 20 miliseconds. A 2-second train of TBS is repeated every 10 seconds for a total of 570 seconds, equaling a total of 1800 pulses delivered over 9 minutes. To ensure that the participants can tolerate the treatment, stimulation intensity will begin at 60% to 70% of the MT intensity and will slowly increase as the patient tolerates to 110% of the patient&#x02019;s MT intensity over the first few treatment sessions [<xref rid="ref42" ref-type="bibr">42</xref>].</p></sec><sec><title>Study Procedures</title><p>A partial HIPAA waiver and waiver of informed consent for screening purposes will provide regulatory approval to screen potential candidates to determine study eligibility. Once identified as a potential research candidate, candidates will be contacted for an initial phone screening to determine eligibility criteria. Demographics, mental illness diagnosis, current medication use, and history of impulsive behaviors (eg, history of fights, violence, anger, and irritability) will be cross-verified in the patient&#x02019;s electronic medical record. A thorough chart review will be completed to cross-reference current medications with study eligibility criteria to identify antiepileptics or medications that could lower the seizure threshold. If review findings indicate possible contraindications to TMS or MRI related to a metal implant, then the model and manufacturer of the implant will be obtained to determine whether it is safe to expose the implant to a strong magnet. Manufacturer recommendations regarding safety will be followed. If potential participants meet all eligibility criteria, they will be invited for their first research visit, an in-person screening (visit 1). There will be 14 visits for this research study (<xref rid="figure2" ref-type="fig">Figure 2</xref>).</p><fig position="float" id="figure2"><label>Figure 2</label><caption><p>Study visit diagram. iTBS: intermittent theta burst stimulation; MRI: magnetic resonance imaging.</p></caption><graphic xlink:href="resprot_v13i1e58206_fig2" position="float"/></fig><p>After meeting with the research staff and signing the informed consent, participants will complete several baseline diagnostic and screening measures (<xref rid="table1" ref-type="table">Table 1</xref>). These measures will be used to track changes in symptoms of impulsivity, suicidality, depression, anger, aggression, and social and occupational functioning throughout the study. If the participant is a woman, sexually active, and not on any form of physician-prescribed birth control, they will be asked to take a urine pregnancy test at this visit. Veterans who have completed baseline measures and have met eligibility criteria will be asked to complete a pretreatment resting-state fMRI at the University of Illinois, Chicago, an institution partnering with us for this study (visit 2). After the pretreatment MRI, participants will be invited back to the Hines VA to complete their MT and brain mapping using the TMS Neural Navigator (Localite) system (visit 3).</p><p>Participants will be randomized to either active or sham treatment. Blinding procedures for active and sham iTBS will be delivered with the MagProX100 with MagOption stimulator and Magpro Cool Coil B65 A/P (MagVenture), which can be switched to active or sham. The coil is identical visually for the sham and active conditions. Veterans and researchers will wear headphones connected to the noise generator during treatment to hear active iTBS for both conditions, thereby maintaining the blind. The sham coil and scalp electrodes will be placed in the same location for all participants and will mimic the sensation produced by the active coil but will not alter brain physiology. Thus, the sham stimulation looks, sounds, and feels like active stimulation. A single unblinded study team member will determine which participants are randomly placed in the active or sham groups.</p><p>After the MRI and MT have been completed, participants will be randomized, and the intervention will begin (visits 4-13). Intervention sessions will occur once daily for 10 business days, with each session lasting 30 minutes to 1 hour. Research staff will complete a TMS safety rating scale before and after every iTBS session to assess for changes from baseline for vital signs, sleep duration, fatigue level, recent seizures, and tinnitus. Pain and tolerability measures will be completed at the end of every session to assess daily pain and session tolerability. After iTBS session 5 (visit 8), each participant will be asked to complete the self-report rating scales and neurocognitive testing they completed at baseline.</p><p>All veterans who have completed the iTBS treatment course of 10 sessions will be asked to return to the University of Illinois, Chicago&#x02019;s Center for Magnetic Resonance Research to obtain a second resting-state fMRI for their final research visit. Posttreatment MRI data collection is expected to be completed 72 hours after the iTBS course. This time spacing between stimulation and imaging has been done in similar studies [<xref rid="ref78" ref-type="bibr">78</xref>] and is thought to be a long enough gap post-iTBS completion not to represent the immediate effects of the most recent stimulation.</p></sec><sec><title>Analytic Plan</title><p>A statistical significance level corresponding to &#x003b1;=.05 will be used to test hypotheses.</p><p>Descriptive statistics of feasibility, safety, and tolerability measures will be computed for all participants and compared between active- and sham-iTBS groups. We will calculate the categorical variables&#x02019; frequencies and compare them using chi-square analyses for the descriptive statistics [<xref rid="ref126" ref-type="bibr">126</xref>]. For the continuous variables (ie, daily pain ratings), we will compute mean, median, range, and SDs and compare using 2-tailed <italic>t</italic> tests.</p><p>For functional outcome measures, we will estimate a mixed model ANOVA to measure differences within-participants (how the SOFAS changes over time), between-participants (how the SOFAS differs between active and sham iTBS), and whether there is a significant interaction between time and treatment [<xref rid="ref127" ref-type="bibr">127</xref>]. We will assume equal variance between test and control groups [<xref rid="ref128" ref-type="bibr">128</xref>]. If the variance is unequal, we may transition to a generalized linear mixed (GLM) effects model [<xref rid="ref129" ref-type="bibr">129</xref>].</p><p>For our neuroimaging analysis, to evaluate the VMPFC to the amygdala and anterior cingulate relationships and how they change before and after treatment, we will define ROIs for the amygdala and anterior cingulate with clear anatomical boundaries identified using Freesurfer [<xref rid="ref130" ref-type="bibr">130</xref>]. Average time-series data will be extracted, and GLM will be used to quantify the relationship between the seeds and targets. The GLM results will yield individual <italic>r</italic> values (ie, correlations), which will be normalized into <italic>Z</italic> scores using Fisher R-to-Z transformation [<xref rid="ref131" ref-type="bibr">131</xref>]. The individual maps of <italic>Z</italic> scores will be the primary measure of connectivity between the seed and target ROIs. We will then implement an ROI-to-ROI analysis within the connectivity toolbox to evaluate resting-state functional connectivity between the amygdala, anterior cingulate, and VMPFC [<xref rid="ref132" ref-type="bibr">132</xref>]. We will assume a normal distribution and use Fisher&#x02019;s <italic>Z</italic> test to compare active-iTBS and sham-iTBS groups, both before and after treatment [<xref rid="ref133" ref-type="bibr">133</xref>]. We will adjust for a priori covariates, including age, sex, and baseline psychiatric diagnoses. All analyses will be corrected for multiple comparisons using false-discovery rate correction. We will use linear mixed models to test how connectivity changes correspond to functional and mental health outcome changes, with functional and behavioral measures included as the dependent variables [<xref rid="ref134" ref-type="bibr">134</xref>].</p><p>To inform future research studies, we will estimate regression models that include additional covariates such as demographics, psychotropic medication use, comorbid psychiatric diagnoses, and scores on the Inventory of Depressive Symptomatology, Self-Report and the PTSD Checklist for DSM-5, in addition to testing our hypotheses for the primary and secondary outcomes.</p></sec></sec><sec sec-type="results"><title>Results</title><p>This study was funded in April 2023 and began enrolling participants in July 2024. As of July 2024, there are 2 participants enrolled in the study. Data will be analyzed and study results will be disseminated on or before the project&#x02019;s end date in March 2028.</p></sec><sec sec-type="discussion"><title>Discussion</title><sec><title>Principal Findings</title><p>This novel protocol represents the first pilot RCT for frontal pole iTBS for mTBI, negative urgency impulsivity, and suicidality. We hypothesize that iTBS administered to the frontal pole in US veterans with mTBI, impulsivity, and suicidality will be safe and well tolerated as studies show that both TMS and iTBS appear safe and effective when administered to other anatomical sites in individuals with mTBI [<xref rid="ref23" ref-type="bibr">23</xref>-<xref rid="ref26" ref-type="bibr">26</xref>]. Furthermore, studies demonstrated frontal pole iTBS is tolerable with good safety outcomes in individuals without mTBI [<xref rid="ref63" ref-type="bibr">63</xref>].</p><p>We hypothesize that we can improve social and occupational functioning, impulsivity, and SI among US veterans with mTBI. Other studies have specifically found meaningful change in both the UPPS-P and SOFAS over a 2-week neuromodulation intervention period among individuals with major depression [<xref rid="ref90" ref-type="bibr">90</xref>,<xref rid="ref135" ref-type="bibr">135</xref>]. Several repetitive TMS (the precursor to iTBS) trials among individuals with SI and major depression have shown reductions in suicidality [<xref rid="ref71" ref-type="bibr">71</xref>-<xref rid="ref74" ref-type="bibr">74</xref>]. We anticipate these results will generalize to individuals with mTBI when treated with iTBS [<xref rid="ref72" ref-type="bibr">72</xref>,<xref rid="ref136" ref-type="bibr">136</xref>].</p><p>Finally, we hypothesize that we will be able to identify changes in neural connectivity among individuals who respond to our iTBS protocol by comparing pretreatment fMRIs with posttreatment fMRIs. Several studies on both iTBS and TMS, administered to the DLPFC, of a variety of treatment durations, showed increased connectivity between the frontal cortex and areas of the limbic system [<xref rid="ref137" ref-type="bibr">137</xref>]. We expect to see similar results with iTBS administered to the VMPFC.</p><p>We will add to the existing literature in several ways. First, there are no widely established treatments for poorer functional outcomes, suicidality, or impulsivity that occur in the context of mTBI. If we can develop an effective intervention that targets all of these likely interrelated conditions, we will be adding important findings to the literature base and we could also improve the quality of life and treat SI among people with mTBI. By further establishing the frontal pole as a tolerable and effective iTBS stimulation site, we could also encourage other researchers to explore this site for potential therapeutic benefit for a variety of conditions. Finally, by identifying fMRI connectivity changes before and after iTBS treatment, we will add to the literature base regarding how neuromodulation works mechanistically, which is still unclear. Moreover, if we can identify specific fMRI connectivity changes correlating to symptomatic changes, it may help us identify future neuromodulatory treatment sites of interest, to continue to further explore this very promising treatment modality.</p></sec><sec><title>Strengths of the Study</title><p>The proposed study has several key strengths. First, the study uses an established FDA-approved device readily available in both VA and civilian health care systems throughout the United States. Compared with traditional pharmacological and behavioral approaches, iTBS has a reduced latency to treatment response, which could be lifesaving among individuals with SI. Our approach also differs from previous studies that primarily focused on improving SI via the treatment of depressive symptoms. We provide a novel framework for understanding and ultimately treating SI, which could be helpful for individuals who have yet to respond to past evidence-based treatments for this condition. Finally, by targeting the VMPFC and including neuroimaging from before and after treatment, this study has the potential to identify a novel target for iTBS, increase insight into the underlying neurological mechanisms of SI, and identify which individuals are more likely to respond to a neuromodulatory intervention.</p></sec><sec><title>Limitations of the Study</title><p>There are several limitations to consider. The small sample size reduces the study power, which may limit the detection of statistically significant outcome differences. However, this sample size reflects the pilot nature of the study and funding mechanism. Variability in the baseline characteristics of the patient population (ie, co-occurring psychiatric and somatic conditions, coadministration of other medications, etc) that are being studied in detail in this project may impact our findings. Covariates will be explored; however, given the small sample size, only select covariates can be added to the final models. The relatively short follow-up time of 72 hours after the final iTBS treatment will not provide insight into the long-term effects of our intervention. Future studies would benefit from additional follow-up outcomes assessments and imaging several months after the treatment to assess the intervention&#x02019;s durability. Although prior studies used a dose of 110% MT and a time frame of 10 sessions, we are still determining if these parameters are optimal. A future dosing study would help optimize the treatment parameters. This study does not select targets based on resting-state data; however, in collecting these data in tandem using neuronavigation, we can potentially target more specific sites in the future.</p></sec><sec><title>Conclusions</title><p>The proposed study integrates past findings from impulsivity, TBI, neuroanatomical, neuroimaging, neurorehabilitation, and neurostimulation research to create a novel, but highly informed treatment strategy. In this study, we hope to induce neuroplasticity in the connections between the VMPFC and limbic system, through neuromodulation at the frontal pole. In inducing neuroplasticity with iTBS, in an effort to repair damaged neural connections, we hope to mitigate the development of impulsive behaviors, improve social and community functioning, and decrease SI, as we believe all 3 of these conditions would benefit from strengthening the VMPFC-limbic system network. Data obtained by using validated scales will inform future studies.</p><p>Moreover, the collection of pretreatment neuroimaging may help us understand what neural signatures predispose individuals to respond favorably to frontal pole iTBS, so we might be able to predict who is most likely to benefit from treatment, following comparable work in predicting response to neurostimulation in individuals with major depression [<xref rid="ref138" ref-type="bibr">138</xref>]. Thus, findings from the proposed project are expected to have the capacity to (1) help identify which individuals are more likely to respond to a neurostimulation intervention for impulsivity and suicidality related to mTBI and (2) better understand what neural changes we are eliciting. Advancing knowledge in both areas will inform future studies and enable a more rapid determination of which treatments will be most effective for a given individual and determining where connectivity changes are occurring may allow us to further optimize treatment effects.</p></sec></sec></body><back><ack><p>This study is funded by the Veterans Affairs Rehabilitation Research and Development Career Development level 2 grant (grant IK2RX004298), which began on April 1, 2023. The authors of this project gratefully acknowledge the Edward Hines, Jr. VA Hospital, with special thanks to the Mental Health Service Line and Research Service Line for supporting the research team. They also thank the Department of Psychiatry and the Center for Magnetic Resonance Research at the University of Illinois, Chicago. The contents of this paper do not represent the views of the US Department of Veterans Affairs or the US government.</p></ack><fn-group><fn fn-type="con"><p>Authors' Contributions: AB and AA led the writing of this manuscript. AA conceived the project and obtained funding to support the project. All other authors contributed to the study design and reviewed the manuscript.</p></fn><fn fn-type="COI-statement"><p>Conflicts of Interest: CH has served as a consultant for Magstim and is currently employed by BrainsWay.</p></fn></fn-group><app-group><supplementary-material id="app1" position="float" content-type="local-data"><label>Multimedia Appendix 1</label><p>CONSORT (Consolidated Standards of Reporting Trials) flow diagram&#x02014;anticipated.</p><media xlink:href="resprot_v13i1e58206_app1.doc" xlink:title="DOC File , 40 KB" id="d100e1758" position="anchor"/></supplementary-material><supplementary-material id="app2" position="float" content-type="local-data"><label>Multimedia Appendix 2</label><p>University of Illinois&#x02013;Chicago Center for Magentic Resonance Research magnetic resonance imaging safety form.</p><media xlink:href="resprot_v13i1e58206_app2.docx" xlink:title="DOCX File , 27 KB" id="d100e1762" position="anchor"/></supplementary-material><supplementary-material id="app3" position="float" content-type="local-data"><label>Multimedia Appendix 3</label><p>Equipment list.</p><media xlink:href="resprot_v13i1e58206_app3.docx" xlink:title="DOCX File , 13 KB" id="d100e1766" position="anchor"/></supplementary-material><supplementary-material id="app4" position="float" content-type="local-data"><label>Multimedia Appendix 4</label><p>Transcranial magnetic stimulation (TMS) safety form.</p><media xlink:href="resprot_v13i1e58206_app4.docx" xlink:title="DOCX File , 14 KB" id="d100e1770" position="anchor"/></supplementary-material></app-group><glossary><title>Abbreviations</title><def-list><def-item><term id="abb1">ABP</term><def><p>abductor pollicis brevis</p></def></def-item><def-item><term id="abb2">AE</term><def><p>adverse event</p></def></def-item><def-item><term id="abb3">CONSORT</term><def><p>Consolidated Standards of Reporting Trials</p></def></def-item><def-item><term id="abb4">DLPFC</term><def><p>dorsolateral prefrontal cortex</p></def></def-item><def-item><term id="abb5">FDA</term><def><p>Food and Drug Administration</p></def></def-item><def-item><term id="abb6">fMRI</term><def><p>functional magnetic resonance imaging</p></def></def-item><def-item><term id="abb7">FP</term><def><p>frontal polar cortex</p></def></def-item><def-item><term id="abb8">GLM</term><def><p>generalized linear mixed</p></def></def-item><def-item><term id="abb9">HIPAA</term><def><p>Health Insurance Portability and Accountability Act</p></def></def-item><def-item><term id="abb10">IRB</term><def><p>institutional review board</p></def></def-item><def-item><term id="abb11">iTBS</term><def><p>intermittent theta burst stimulation</p></def></def-item><def-item><term id="abb12">MEP</term><def><p>motor-evoked potential</p></def></def-item><def-item><term id="abb13">MRI</term><def><p>magnetic resonance imaging</p></def></def-item><def-item><term id="abb14">MT</term><def><p>motor threshold</p></def></def-item><def-item><term id="abb15">mTBI</term><def><p>mild traumatic brain injury</p></def></def-item><def-item><term id="abb16">PTSD</term><def><p>posttraumatic stress disorder</p></def></def-item><def-item><term id="abb17">ROI</term><def><p>region of interest</p></def></def-item><def-item><term id="abb18">RRT</term><def><p>rapid response team</p></def></def-item><def-item><term id="abb19">SA</term><def><p>suicide attempt</p></def></def-item><def-item><term id="abb20">SI</term><def><p>suicidal ideation</p></def></def-item><def-item><term id="abb21">SOFAS</term><def><p>Social and Occupational Functioning Assessment Scale</p></def></def-item><def-item><term id="abb22">SPIRIT</term><def><p>Standard Protocol Items: Recommendations for Interventional Trials</p></def></def-item><def-item><term id="abb23">TBI</term><def><p>traumatic brain injury</p></def></def-item><def-item><term id="abb24">TMS</term><def><p>transcranial magnetic stimulation</p></def></def-item><def-item><term id="abb25">UPPS-P</term><def><p>Urgency, Premeditation (lack of), Perseveration (lack of), Sensation Seeking, Positive Urgency Impulsive Behavior Scale&#x02013;Negative Urgency subscale VA: US Veterans Administration</p></def></def-item><def-item><term id="abb26">VMPFC</term><def><p>ventromedial prefrontal cortex</p></def></def-item></def-list></glossary><notes><sec sec-type="data-availability"><title>Data Availability</title><p>The datasets generated during and analyzed during this study are not publicly available due to legal restrictions the US Department of Veterans Affairs places on access to veteran data, including both identifying data and sensitive patient information, but are available from the corresponding author on reasonable request with the completion of an approved data use agreement. For more information, please visit the VA website [<xref rid="ref139" ref-type="bibr">139</xref>].</p></sec></notes><ref-list><ref id="ref1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramchand</surname><given-names>R</given-names></name></person-group><article-title>Suicide among veterans: veterans' issues in focus</article-title><source>Rand Health Q</source><year>2022</year><month>06</month><volume>9</volume><issue>3</issue><fpage>21</fpage><comment>
<ext-link xlink:href="https://europepmc.org/abstract/MED/35837519" ext-link-type="uri"/>
</comment><pub-id pub-id-type="medline">35837519</pub-id><!--<pub-id pub-id-type="pmcid">PMC9242579</pub-id>--></element-citation></ref><ref id="ref2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hostetter</surname><given-names>TA</given-names></name><name><surname>Hoffmire</surname><given-names>CA</given-names></name><name><surname>Forster</surname><given-names>JE</given-names></name><name><surname>Adams</surname><given-names>RS</given-names></name><name><surname>Stearns-Yoder</surname><given-names>KA</given-names></name><name><surname>Brenner</surname><given-names>LA</given-names></name></person-group><article-title>Suicide and traumatic brain injury among individuals seeking Veterans Health Administration services between fiscal years 2006 and 2015</article-title><source>J Head Trauma Rehabil</source><year>2019</year><volume>34</volume><issue>5</issue><fpage>E1</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1097/HTR.0000000000000489</pub-id><pub-id pub-id-type="medline">31369450</pub-id></element-citation></ref><ref id="ref3"><label>3</label><element-citation publication-type="webpage"><article-title>DOD TBI worldwide numbers</article-title><source>Health.mil</source><date-in-citation content-type="access-date">2024-04-29</date-in-citation><comment>
<ext-link xlink:href="https://health.mil/Military-Health-Topics/Centers-of-Excellence/Traumatic-Brain-Injury-Center-of-Excellence/DOD-TBI-Worldwide-Numbers" ext-link-type="uri">https://health.mil/Military-Health-Topics/Centers-of-Excellence/Traumatic-Brain-Injury-Center-of-Excellence/DOD-TBI-Worldwide-Numbers</ext-link>
</comment></element-citation></ref><ref id="ref4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bryan</surname><given-names>CJ</given-names></name><name><surname>Clemans</surname><given-names>TA</given-names></name></person-group><article-title>Repetitive traumatic brain injury, psychological symptoms, and suicide risk in a clinical sample of deployed military personnel</article-title><source>JAMA Psychiatry</source><year>2013</year><month>07</month><day>01</day><volume>70</volume><issue>7</issue><fpage>686</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1001/jamapsychiatry.2013.1093</pub-id><pub-id pub-id-type="medline">23676987</pub-id><pub-id pub-id-type="pii">1688032</pub-id><pub-id pub-id-type="pmid">23676987</pub-id>
</element-citation></ref><ref id="ref5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zetterberg</surname><given-names>H</given-names></name><name><surname>Smith</surname><given-names>DH</given-names></name><name><surname>Blennow</surname><given-names>K</given-names></name></person-group><article-title>Biomarkers of mild traumatic brain injury in cerebrospinal fluid and blood</article-title><source>Nat Rev Neurol</source><year>2013</year><month>05</month><day>12</day><volume>9</volume><issue>4</issue><fpage>201</fpage><lpage>10</lpage><comment>
<ext-link xlink:href="https://europepmc.org/abstract/MED/23399646" ext-link-type="uri"/>
</comment><pub-id pub-id-type="doi">10.1038/nrneurol.2013.9</pub-id><pub-id pub-id-type="medline">23399646</pub-id><pub-id pub-id-type="pii">nrneurol.2013.9</pub-id><!--<pub-id pub-id-type="pmcid">PMC4513656</pub-id>--><pub-id pub-id-type="pmid">23399646</pub-id>
</element-citation></ref><ref id="ref6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salat</surname><given-names>DH</given-names></name><name><surname>Robinson</surname><given-names>ME</given-names></name><name><surname>Miller</surname><given-names>DR</given-names></name><name><surname>Clark</surname><given-names>DC</given-names></name><name><surname>McGlinchey</surname><given-names>RE</given-names></name></person-group><article-title>Neuroimaging of deployment-associated traumatic brain injury (TBI) with a focus on mild TBI (mTBI) since 2009</article-title><source>Brain Inj</source><year>2017</year><month>10</month><day>05</day><volume>31</volume><issue>9</issue><fpage>1204</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1080/02699052.2017.1327672</pub-id><pub-id pub-id-type="medline">28981347</pub-id><!--<pub-id pub-id-type="pmcid">PMC9206728</pub-id>--><pub-id pub-id-type="pmid">28981347</pub-id>
</element-citation></ref><ref id="ref7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Korley</surname><given-names>FK</given-names></name><name><surname>Kelen</surname><given-names>GD</given-names></name><name><surname>Jones</surname><given-names>CM</given-names></name><name><surname>Diaz-Arrastia</surname><given-names>R</given-names></name></person-group><article-title>Emergency department evaluation of traumatic brain injury in the United States, 2009-2010</article-title><source>J Head Trauma Rehabil</source><year>2016</year><volume>31</volume><issue>6</issue><fpage>379</fpage><lpage>87</lpage><comment>
<ext-link xlink:href="https://europepmc.org/abstract/MED/26360006" ext-link-type="uri"/>
</comment><pub-id pub-id-type="doi">10.1097/HTR.0000000000000187</pub-id><pub-id pub-id-type="medline">26360006</pub-id><!--<pub-id pub-id-type="pmcid">PMC4786477</pub-id>--><pub-id pub-id-type="pmid">26360006</pub-id>
</element-citation></ref><ref id="ref8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campbell-Sills</surname><given-names>L</given-names></name><name><surname>Jain</surname><given-names>S</given-names></name><name><surname>Sun</surname><given-names>X</given-names></name><name><surname>Fisher</surname><given-names>LB</given-names></name><name><surname>Agtarap</surname><given-names>SD</given-names></name><name><surname>Dikmen</surname><given-names>S</given-names></name><name><surname>Nelson</surname><given-names>LD</given-names></name><name><surname>Temkin</surname><given-names>N</given-names></name><name><surname>McCrea</surname><given-names>M</given-names></name><name><surname>Yuh</surname><given-names>E</given-names></name><name><surname>Giacino</surname><given-names>JT</given-names></name><name><surname>Manley</surname><given-names>GT</given-names></name><collab>TRACK-TBI Investigators</collab></person-group><article-title>Risk factors for suicidal ideation following mild traumatic brain injury: a TRACK-TBI study</article-title><source>J Head Trauma Rehabil</source><year>2021</year><volume>36</volume><issue>1</issue><fpage>E30</fpage><lpage>9</lpage><comment>
<ext-link xlink:href="https://europepmc.org/abstract/MED/32769835" ext-link-type="uri"/>
</comment><pub-id pub-id-type="doi">10.1097/HTR.0000000000000602</pub-id><pub-id pub-id-type="medline">32769835</pub-id><pub-id pub-id-type="pii">00001199-202101000-00011</pub-id><!--<pub-id pub-id-type="pmcid">PMC10134479</pub-id>--><pub-id pub-id-type="pmid">32769835</pub-id>
</element-citation></ref><ref id="ref9"><label>9</label><element-citation publication-type="webpage"><person-group person-group-type="author"><name><surname>Reid</surname><given-names>LD</given-names></name><name><surname>Fingar</surname><given-names>KR</given-names></name></person-group><article-title>Inpatient stays and emergency department visits involving traumatic brain injury, 2017</article-title><source>Healthcare Cost and Utilization Project (HCUP) &#x00026; Agency for Healthcare Research and Quality (AHRQ)</source><date-in-citation content-type="access-date">2024-04-29</date-in-citation><comment>
<ext-link xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK556732/pdf/Bookshelf_NBK556732.pdf" ext-link-type="uri">https://www.ncbi.nlm.nih.gov/books/NBK556732/pdf/Bookshelf_NBK556732.pdf</ext-link>
</comment></element-citation></ref><ref id="ref10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>GF</given-names></name><name><surname>DePadilla</surname><given-names>L</given-names></name><name><surname>Xu</surname><given-names>L</given-names></name></person-group><article-title>Costs of nonfatal traumatic brain injury in the United States, 2016</article-title><source>Med Care</source><year>2021</year><month>05</month><day>01</day><volume>59</volume><issue>5</issue><fpage>451</fpage><lpage>5</lpage><comment>
<ext-link xlink:href="https://europepmc.org/abstract/MED/33528230" ext-link-type="uri"/>
</comment><pub-id pub-id-type="doi">10.1097/MLR.0000000000001511</pub-id><pub-id pub-id-type="medline">33528230</pub-id><pub-id pub-id-type="pii">00005650-202105000-00012</pub-id><!--<pub-id pub-id-type="pmcid">PMC8026675</pub-id>--><pub-id pub-id-type="pmid">33528230</pub-id>
</element-citation></ref><ref id="ref11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rauen</surname><given-names>K</given-names></name><name><surname>Reichelt</surname><given-names>L</given-names></name><name><surname>Probst</surname><given-names>P</given-names></name><name><surname>Sch&#x000e4;pers</surname><given-names>B</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>F</given-names></name><name><surname>Jahn</surname><given-names>K</given-names></name><name><surname>Plesnila</surname><given-names>N</given-names></name></person-group><article-title>Quality of life up to 10 years after traumatic brain injury: a cross-sectional analysis</article-title><source>Health Qual Life Outcomes</source><year>2020</year><month>07</month><day>04</day><volume>18</volume><issue>1</issue><fpage>166</fpage><comment>
<ext-link xlink:href="https://hqlo.biomedcentral.com/articles/10.1186/s12955-020-01391-3" ext-link-type="uri"/>
</comment><pub-id pub-id-type="doi">10.1186/s12955-020-01391-3</pub-id><pub-id pub-id-type="medline">32498679</pub-id><pub-id pub-id-type="pii">10.1186/s12955-020-01391-3</pub-id><!--<pub-id pub-id-type="pmcid">PMC7271485</pub-id>--><pub-id pub-id-type="pmid">32498679</pub-id>
</element-citation></ref><ref id="ref12"><label>12</label><element-citation publication-type="webpage"><article-title>National strategy for preventing veteran suicide</article-title><source>Veterans Health Administration</source><year>2018</year><date-in-citation content-type="access-date">2024-11-04</date-in-citation><comment>
<ext-link xlink:href="https://www.mentalhealth.va.gov/suicide_prevention/docs/Office-of-Mental-Health-and-Suicide-Prevention-National-Strategy-for-Preventing-Veterans-Suicide.pdf" ext-link-type="uri">https://www.mentalhealth.va.gov/suicide_prevention/docs/Office-of-Mental-Health-and-Suicide-Prevention-National-Strategy-for-Preventing-Veterans-Suicide.pdf</ext-link>
</comment></element-citation></ref><ref id="ref13"><label>13</label><element-citation publication-type="webpage"><article-title>VA/DOD clinical practice guidelines: assessment and management of patients at risk for suicide</article-title><source>US Department of Veterans Affairs</source><date-in-citation content-type="access-date">2024-04-29</date-in-citation><comment>
<ext-link xlink:href="https://www.healthquality.va.gov/guidelines/mh/srb/" ext-link-type="uri">https://www.healthquality.va.gov/guidelines/mh/srb/</ext-link>
</comment></element-citation></ref><ref id="ref14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Homaifar</surname><given-names>BY</given-names></name><name><surname>Brenner</surname><given-names>LA</given-names></name><name><surname>Forster</surname><given-names>JE</given-names></name><name><surname>Nagamoto</surname><given-names>H</given-names></name></person-group><article-title>Traumatic brain injury, executive functioning, and suicidal behavior: a brief report</article-title><source>Rehabil Psychol</source><year>2012</year><volume>57</volume><issue>4</issue><fpage>337</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1037/a0030480</pub-id><pub-id pub-id-type="pmid">23181582</pub-id>
</element-citation></ref><ref id="ref15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gaines</surname><given-names>KD</given-names></name><name><surname>Soper</surname><given-names>HV</given-names></name><name><surname>Berenji</surname><given-names>GR</given-names></name></person-group><article-title>Executive functioning of combat mild traumatic brain injury</article-title><source>Appl Neuropsychol Adult</source><year>2016</year><month>10</month><day>23</day><volume>23</volume><issue>2</issue><fpage>115</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1080/23279095.2015.1012762</pub-id><pub-id pub-id-type="medline">26496530</pub-id><pub-id pub-id-type="pmid">26496530</pub-id>
</element-citation></ref><ref id="ref16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cyders</surname><given-names>MA</given-names></name><name><surname>Dzemidzic</surname><given-names>M</given-names></name><name><surname>Eiler</surname><given-names>WJ</given-names></name><name><surname>Coskunpinar</surname><given-names>A</given-names></name><name><surname>Karyadi</surname><given-names>KA</given-names></name><name><surname>Kareken</surname><given-names>DA</given-names></name></person-group><article-title>Negative urgency mediates the relationship between amygdala and orbitofrontal cortex activation to negative emotional stimuli and general risk-taking</article-title><source>Cereb Cortex</source><year>2015</year><month>12</month><day>05</day><volume>25</volume><issue>11</issue><fpage>4094</fpage><lpage>102</lpage><comment>
<ext-link xlink:href="https://europepmc.org/abstract/MED/24904065" ext-link-type="uri"/>
</comment><pub-id pub-id-type="doi">10.1093/cercor/bhu123</pub-id><pub-id pub-id-type="medline">24904065</pub-id><pub-id pub-id-type="pii">bhu123</pub-id><!--<pub-id pub-id-type="pmcid">PMC4626829</pub-id>--><pub-id pub-id-type="pmid">24904065</pub-id>
</element-citation></ref><ref id="ref17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Awan</surname><given-names>N</given-names></name><name><surname>DiSanto</surname><given-names>D</given-names></name><name><surname>Juengst</surname><given-names>SB</given-names></name><name><surname>Kumar</surname><given-names>RG</given-names></name><name><surname>Bertisch</surname><given-names>H</given-names></name><name><surname>Niemeier</surname><given-names>J</given-names></name><name><surname>Fann</surname><given-names>JR</given-names></name><name><surname>Kesinger</surname><given-names>MR</given-names></name><name><surname>Sperry</surname><given-names>J</given-names></name><name><surname>Wagner</surname><given-names>AK</given-names></name></person-group><article-title>Evaluating the cross-sectional and longitudinal relationships predicting suicidal ideation following traumatic brain injury</article-title><source>J Head Trauma Rehabil</source><year>2021</year><volume>36</volume><issue>1</issue><fpage>E18</fpage><lpage>29</lpage><comment>
<ext-link xlink:href="https://europepmc.org/abstract/MED/32769828" ext-link-type="uri"/>
</comment><pub-id pub-id-type="doi">10.1097/HTR.0000000000000588</pub-id><pub-id pub-id-type="medline">32769828</pub-id><pub-id pub-id-type="pii">00001199-202101000-00010</pub-id><!--<pub-id pub-id-type="pmcid">PMC10280901</pub-id>--><pub-id pub-id-type="pmid">32769828</pub-id>
</element-citation></ref><ref id="ref18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barker</surname><given-names>AT</given-names></name><name><surname>Jalinous</surname><given-names>R</given-names></name><name><surname>Freeston</surname><given-names>IL</given-names></name></person-group><article-title>Non-invasive magnetic stimulation of human motor cortex</article-title><source>Lancet</source><year>1985</year><month>05</month><day>11</day><volume>1</volume><issue>8437</issue><fpage>1106</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1016/s0140-6736(85)92413-4</pub-id><pub-id pub-id-type="medline">2860322</pub-id><pub-id pub-id-type="pii">S0140-6736(85)92413-4</pub-id><pub-id pub-id-type="pmid">2860322</pub-id>
</element-citation></ref><ref id="ref19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>George</surname><given-names>MS</given-names></name><name><surname>Nahas</surname><given-names>Z</given-names></name><name><surname>Kozel</surname><given-names>FA</given-names></name><name><surname>Goldman</surname><given-names>J</given-names></name><name><surname>Molloy</surname><given-names>M</given-names></name><name><surname>Oliver</surname><given-names>N</given-names></name></person-group><article-title>Improvement of depression following transcranial magnetic stimulation</article-title><source>Curr Psychiatry Rep</source><year>1999</year><month>12</month><volume>1</volume><issue>2</issue><fpage>114</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1007/s11920-999-0020-2</pub-id><pub-id pub-id-type="medline">11122913</pub-id><pub-id pub-id-type="pmid">11122913</pub-id>
</element-citation></ref><ref id="ref20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horvath</surname><given-names>JC</given-names></name><name><surname>Mathews</surname><given-names>J</given-names></name><name><surname>Demitrack</surname><given-names>MA</given-names></name><name><surname>Pascual-Leone</surname><given-names>A</given-names></name></person-group><article-title>The NeuroStar TMS device: conducting the FDA approved protocol for treatment of depression</article-title><source>J Vis Exp</source><year>2010</year><month>12</month><day>12</day><issue>45</issue><fpage>2345</fpage><comment>
<ext-link xlink:href="https://europepmc.org/abstract/MED/21189465" ext-link-type="uri"/>
</comment><pub-id pub-id-type="doi">10.3791/2345</pub-id><pub-id pub-id-type="medline">21189465</pub-id><pub-id pub-id-type="pii">2345</pub-id><!--<pub-id pub-id-type="pmcid">PMC3159591</pub-id>--><pub-id pub-id-type="pmid">21189465</pub-id>
</element-citation></ref><ref id="ref21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pape</surname><given-names>TL</given-names></name><name><surname>Rosenow</surname><given-names>J</given-names></name><name><surname>Lewis</surname><given-names>G</given-names></name></person-group><article-title>Transcranial magnetic stimulation: a possible treatment for TBI</article-title><source>J Head Trauma Rehabil</source><year>2006</year><volume>21</volume><issue>5</issue><fpage>437</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1097/00001199-200609000-00063</pub-id><pub-id pub-id-type="medline">16983227</pub-id><pub-id pub-id-type="pii">00001199-200609000-00063</pub-id><pub-id pub-id-type="pmid">16983227</pub-id>
</element-citation></ref><ref id="ref22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Philip</surname><given-names>NS</given-names></name><name><surname>Ramanathan</surname><given-names>D</given-names></name><name><surname>Gamboa</surname><given-names>B</given-names></name><name><surname>Brennan</surname><given-names>MC</given-names></name><name><surname>Kozel</surname><given-names>FA</given-names></name><name><surname>Lazzeroni</surname><given-names>L</given-names></name><name><surname>Madore</surname><given-names>MR</given-names></name></person-group><article-title>Repetitive transcranial magnetic stimulation for depression and posttraumatic stress disorder in veterans with mild traumatic brain injury</article-title><source>Neuromodulation</source><year>2023</year><month>06</month><volume>26</volume><issue>4</issue><fpage>878</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1016/j.neurom.2022.11.015</pub-id><pub-id pub-id-type="pmid">36737300</pub-id>
</element-citation></ref><ref id="ref23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oberman</surname><given-names>LM</given-names></name><name><surname>Exley</surname><given-names>S</given-names></name><name><surname>Philip</surname><given-names>NS</given-names></name><name><surname>Siddiqi</surname><given-names>SH</given-names></name><name><surname>Adamson</surname><given-names>MM</given-names></name><name><surname>Brody</surname><given-names>DL</given-names></name></person-group><article-title>Use of repetitive transcranial magnetic stimulation in the treatment of neuropsychiatric and neurocognitive symptoms associated with concussion in military populations</article-title><source>J Head Trauma Rehabil</source><year>2020</year><volume>35</volume><issue>6</issue><fpage>388</fpage><lpage>400</lpage><comment>
<ext-link xlink:href="https://europepmc.org/abstract/MED/33165152" ext-link-type="uri"/>
</comment><pub-id pub-id-type="doi">10.1097/HTR.0000000000000628</pub-id><pub-id pub-id-type="medline">33165152</pub-id><pub-id pub-id-type="pii">00001199-202011000-00003</pub-id><!--<pub-id pub-id-type="pmcid">PMC7664843</pub-id>--><pub-id pub-id-type="pmid">33165152</pub-id>
</element-citation></ref><ref id="ref24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahorsu</surname><given-names>DK</given-names></name><name><surname>Adjaottor</surname><given-names>ES</given-names></name><name><surname>Lam</surname><given-names>BY</given-names></name></person-group><article-title>Intervention effect of non-invasive brain stimulation on cognitive functions among people with traumatic brain injury: a systematic review and meta-analysis</article-title><source>Brain Sci</source><year>2021</year><month>07</month><day>24</day><volume>11</volume><issue>7</issue><fpage>840</fpage><comment>
<ext-link xlink:href="https://www.mdpi.com/resolver?pii=brainsci11070840" ext-link-type="uri"/>
</comment><pub-id pub-id-type="doi">10.3390/brainsci11070840</pub-id><pub-id pub-id-type="medline">34202739</pub-id><pub-id pub-id-type="pii">brainsci11070840</pub-id><!--<pub-id pub-id-type="pmcid">PMC8301762</pub-id>--><pub-id pub-id-type="pmid">34202739</pub-id>
</element-citation></ref><ref id="ref25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leung</surname><given-names>A</given-names></name><name><surname>Metzger-Smith</surname><given-names>V</given-names></name><name><surname>He</surname><given-names>Y</given-names></name><name><surname>Cordero</surname><given-names>J</given-names></name><name><surname>Ehlert</surname><given-names>B</given-names></name><name><surname>Song</surname><given-names>D</given-names></name><name><surname>Golshan</surname><given-names>S</given-names></name><name><surname>Tsai</surname><given-names>A</given-names></name><name><surname>Vaninetti</surname><given-names>M</given-names></name><name><surname>Rutledge</surname><given-names>T</given-names></name><name><surname>Polston</surname><given-names>G</given-names></name><name><surname>Sheu</surname><given-names>R</given-names></name><name><surname>Lee</surname><given-names>R</given-names></name></person-group><article-title>Left dorsolateral prefrontal cortex rTMS in alleviating MTBI related headaches and depressive symptoms</article-title><source>Brain Stimul</source><year>2018</year><month>05</month><volume>11</volume><issue>3</issue><fpage>e1</fpage><pub-id pub-id-type="doi">10.1016/j.brs.2018.01.009</pub-id></element-citation></ref><ref id="ref26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leung</surname><given-names>A</given-names></name><name><surname>Shukla</surname><given-names>S</given-names></name><name><surname>Fallah</surname><given-names>A</given-names></name><name><surname>Song</surname><given-names>D</given-names></name><name><surname>Lin</surname><given-names>L</given-names></name><name><surname>Golshan</surname><given-names>S</given-names></name><name><surname>Tsai</surname><given-names>A</given-names></name><name><surname>Jak</surname><given-names>A</given-names></name><name><surname>Polston</surname><given-names>G</given-names></name><name><surname>Lee</surname><given-names>R</given-names></name></person-group><article-title>Repetitive transcranial magnetic stimulation in managing mild traumatic brain injury-related headaches</article-title><source>Neuromodulation</source><year>2016</year><month>03</month><volume>19</volume><issue>2</issue><fpage>133</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1111/ner.12364</pub-id><pub-id pub-id-type="medline">26555886</pub-id><pub-id pub-id-type="pii">S1094-7159(21)05857-8</pub-id><pub-id pub-id-type="pmid">26555886</pub-id>
</element-citation></ref><ref id="ref27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herrold</surname><given-names>AA</given-names></name><name><surname>Kletzel</surname><given-names>SL</given-names></name><name><surname>Harton</surname><given-names>BC</given-names></name><name><surname>Chambers</surname><given-names>RA</given-names></name><name><surname>Jordan</surname><given-names>N</given-names></name><name><surname>Pape</surname><given-names>TL</given-names></name></person-group><article-title>Transcranial magnetic stimulation: potential treatment for co-occurring alcohol, traumatic brain injury and posttraumatic stress disorders</article-title><source>Neural Regen Res</source><year>2014</year><month>10</month><day>01</day><volume>9</volume><issue>19</issue><fpage>1712</fpage><lpage>30</lpage><comment>
<ext-link xlink:href="https://europepmc.org/abstract/MED/25422632" ext-link-type="uri"/>
</comment><pub-id pub-id-type="doi">10.4103/1673-5374.143408</pub-id><pub-id pub-id-type="medline">25422632</pub-id><pub-id pub-id-type="pii">NRR-9-1712</pub-id><!--<pub-id pub-id-type="pmcid">PMC4238159</pub-id>--><pub-id pub-id-type="pmid">25422632</pub-id>
</element-citation></ref><ref id="ref28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holzer</surname><given-names>M</given-names></name><name><surname>Padberg</surname><given-names>F</given-names></name></person-group><article-title>Intermittent theta burst stimulation (iTBS) ameliorates therapy-resistant depression: a case series</article-title><source>Brain Stimul</source><year>2010</year><month>07</month><volume>3</volume><issue>3</issue><fpage>181</fpage><lpage>3</lpage><pub-id pub-id-type="doi">10.1016/j.brs.2009.10.004</pub-id><pub-id pub-id-type="medline">20633448</pub-id><pub-id pub-id-type="pii">S1935-861X(09)00108-9</pub-id><pub-id pub-id-type="pmid">20633448</pub-id>
</element-citation></ref><ref id="ref29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blumberger</surname><given-names>DM</given-names></name><name><surname>Vila-Rodriguez</surname><given-names>F</given-names></name><name><surname>Thorpe</surname><given-names>KE</given-names></name><name><surname>Feffer</surname><given-names>K</given-names></name><name><surname>Noda</surname><given-names>Y</given-names></name><name><surname>Giacobbe</surname><given-names>P</given-names></name><name><surname>Knyahnytska</surname><given-names>Y</given-names></name><name><surname>Kennedy</surname><given-names>SH</given-names></name><name><surname>Lam</surname><given-names>RW</given-names></name><name><surname>Daskalakis</surname><given-names>ZJ</given-names></name><name><surname>Downar</surname><given-names>J</given-names></name></person-group><article-title>Effectiveness of theta burst versus high-frequency repetitive transcranial magnetic stimulation in patients with depression (THREE-D): a randomised non-inferiority trial</article-title><source>Lancet</source><year>2018</year><month>05</month><day>28</day><volume>391</volume><issue>10131</issue><fpage>1683</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(18)30295-2</pub-id><pub-id pub-id-type="medline">29726344</pub-id><pub-id pub-id-type="pii">S0140-6736(18)30295-2</pub-id><pub-id pub-id-type="pmid">29726344</pub-id>
</element-citation></ref><ref id="ref30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Ai</surname><given-names>M</given-names></name><name><surname>Gan</surname><given-names>Y</given-names></name><name><surname>He</surname><given-names>J</given-names></name><name><surname>Kuang</surname><given-names>L</given-names></name></person-group><article-title>The association between resting state functional connectivity and the trait of impulsivity and suicidal ideation in young depressed patients with suicide attempts</article-title><source>Front Psychiatry</source><year>2021</year><month>7</month><day>28</day><volume>12</volume><fpage>567976</fpage><comment>
<ext-link xlink:href="https://europepmc.org/abstract/MED/34393836" ext-link-type="uri"/>
</comment><pub-id pub-id-type="doi">10.3389/fpsyt.2021.567976</pub-id><pub-id pub-id-type="medline">34393836</pub-id><!--<pub-id pub-id-type="pmcid">PMC8355430</pub-id>--><pub-id pub-id-type="pmid">34393836</pub-id>
</element-citation></ref><ref id="ref31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ding</surname><given-names>Y</given-names></name><name><surname>Lawrence</surname><given-names>N</given-names></name><name><surname>Oli&#x000e9;</surname><given-names>E</given-names></name><name><surname>Cyprien</surname><given-names>F</given-names></name><name><surname>le Bars</surname><given-names>E</given-names></name><name><surname>Bonaf&#x000e9;</surname><given-names>A</given-names></name><name><surname>Phillips</surname><given-names>ML</given-names></name><name><surname>Courtet</surname><given-names>P</given-names></name><name><surname>Jollant</surname><given-names>F</given-names></name></person-group><article-title>Prefrontal cortex markers of suicidal vulnerability in mood disorders: a model-based structural neuroimaging study with a translational perspective</article-title><source>Transl Psychiatry</source><year>2015</year><month>03</month><day>24</day><volume>5</volume><issue>2</issue><fpage>e516</fpage><comment>
<ext-link xlink:href="https://doi.org/10.1038/tp.2015.1" ext-link-type="uri"/>
</comment><pub-id pub-id-type="doi">10.1038/tp.2015.1</pub-id><pub-id pub-id-type="medline">25710122</pub-id><pub-id pub-id-type="pii">tp20151</pub-id><!--<pub-id pub-id-type="pmcid">PMC4445751</pub-id>--><pub-id pub-id-type="pmid">25710122</pub-id>
</element-citation></ref><ref id="ref32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>M</given-names></name><name><surname>Marquardt</surname><given-names>CA</given-names></name><name><surname>Disner</surname><given-names>SG</given-names></name><name><surname>Burton</surname><given-names>PC</given-names></name><name><surname>Davenport</surname><given-names>ND</given-names></name><name><surname>Lissek</surname><given-names>S</given-names></name><name><surname>Sponheim</surname><given-names>SR</given-names></name></person-group><article-title>Posttraumatic stress symptomatology and abnormal neural responding during emotion regulation under cognitive demands: mediating effects of personality</article-title><source>Personal Neurosci</source><year>2020</year><month>07</month><day>30</day><volume>3</volume><fpage>e9</fpage><comment>
<ext-link xlink:href="https://europepmc.org/abstract/MED/32914044" ext-link-type="uri"/>
</comment><pub-id pub-id-type="doi">10.1017/pen.2020.10</pub-id><pub-id pub-id-type="medline">32914044</pub-id><pub-id pub-id-type="pii">S2513988620000103</pub-id><!--<pub-id pub-id-type="pmcid">PMC7443821</pub-id>--><pub-id pub-id-type="pmid">32914044</pub-id>
</element-citation></ref><ref id="ref33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ivey-Stephenson</surname><given-names>AZ</given-names></name><name><surname>Crosby</surname><given-names>AE</given-names></name><name><surname>Hoenig</surname><given-names>JM</given-names></name><name><surname>Gyawali</surname><given-names>S</given-names></name><name><surname>Park-Lee</surname><given-names>E</given-names></name><name><surname>Hedden</surname><given-names>SL</given-names></name></person-group><article-title>Suicidal thoughts and behaviors among adults aged &#x02265;18 years - United States, 2015-2019</article-title><source>MMWR Surveill Summ</source><year>2022</year><month>01</month><day>07</day><volume>71</volume><issue>1</issue><fpage>1</fpage><lpage>19</lpage><comment>
<ext-link xlink:href="https://europepmc.org/abstract/MED/34990443" ext-link-type="uri"/>
</comment><pub-id pub-id-type="doi">10.15585/mmwr.ss7101a1</pub-id><pub-id pub-id-type="medline">34990443</pub-id><!--<pub-id pub-id-type="pmcid">PMC8736267</pub-id>--></element-citation></ref><ref id="ref34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gaynes</surname><given-names>BN</given-names></name><name><surname>Rush</surname><given-names>AJ</given-names></name><name><surname>Trivedi</surname><given-names>MH</given-names></name><name><surname>Wisniewski</surname><given-names>SR</given-names></name><name><surname>Balasubramani</surname><given-names>GK</given-names></name><name><surname>McGrath</surname><given-names>PJ</given-names></name><name><surname>Thase</surname><given-names>ME</given-names></name><name><surname>Klinkman</surname><given-names>M</given-names></name><name><surname>Nierenberg</surname><given-names>AA</given-names></name><name><surname>Yates</surname><given-names>WR</given-names></name><name><surname>Fava</surname><given-names>M</given-names></name></person-group><article-title>Primary versus specialty care outcomes for depressed outpatients managed with measurement-based care: results from STAR*D</article-title><source>J Gen Intern Med</source><year>2008</year><month>05</month><day>5</day><volume>23</volume><issue>5</issue><fpage>551</fpage><lpage>60</lpage><comment>
<ext-link xlink:href="https://europepmc.org/abstract/MED/18247097" ext-link-type="uri"/>
</comment><pub-id pub-id-type="doi">10.1007/s11606-008-0522-3</pub-id><pub-id pub-id-type="medline">18247097</pub-id><!--<pub-id pub-id-type="pmcid">PMC2324144</pub-id>--><pub-id pub-id-type="pmid">18247097</pub-id>
</element-citation></ref><ref id="ref35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mann</surname><given-names>JJ</given-names></name><name><surname>Michel</surname><given-names>CA</given-names></name><name><surname>Auerbach</surname><given-names>RP</given-names></name></person-group><article-title>Improving suicide prevention through evidence-based strategies: a systematic review</article-title><source>Am J Psychiatry</source><year>2021</year><month>07</month><volume>178</volume><issue>7</issue><fpage>611</fpage><lpage>24</lpage><comment>
<ext-link xlink:href="https://europepmc.org/abstract/MED/33596680" ext-link-type="uri"/>
</comment><pub-id pub-id-type="doi">10.1176/appi.ajp.2020.20060864</pub-id><pub-id pub-id-type="medline">33596680</pub-id><!--<pub-id pub-id-type="pmcid">PMC9092896</pub-id>--><pub-id pub-id-type="pmid">33596680</pub-id>
</element-citation></ref><ref id="ref36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kverno</surname><given-names>KS</given-names></name><name><surname>Mangano</surname><given-names>E</given-names></name></person-group><article-title>Treatment-resistant depression: approaches to treatment</article-title><source>J Psychosoc Nurs Ment Health Serv</source><year>2021</year><month>10</month><volume>59</volume><issue>9</issue><fpage>7</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.3928/02793695-20210816-01</pub-id><pub-id pub-id-type="medline">34459676</pub-id></element-citation></ref><ref id="ref37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jorna</surname><given-names>LS</given-names></name><name><surname>Westerhof-Evers</surname><given-names>HJ</given-names></name><name><surname>Khosdelazad</surname><given-names>S</given-names></name><name><surname>Rakers</surname><given-names>SE</given-names></name><name><surname>van der Naalt</surname><given-names>J</given-names></name><name><surname>Groen</surname><given-names>RJ</given-names></name><name><surname>Buunk</surname><given-names>AM</given-names></name><name><surname>Spikman</surname><given-names>JM</given-names></name></person-group><article-title>Behaviors of concern after acquired brain injury: the role of negative emotion recognition and anger misattribution</article-title><source>J Int Neuropsychol Soc</source><year>2021</year><month>12</month><day>14</day><volume>27</volume><issue>10</issue><fpage>1015</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1017/S135561772000140X</pub-id><pub-id pub-id-type="medline">33441210</pub-id><pub-id pub-id-type="pii">S135561772000140X</pub-id><pub-id pub-id-type="pmid">33441210</pub-id>
</element-citation></ref><ref id="ref38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rochat</surname><given-names>L</given-names></name><name><surname>Beni</surname><given-names>C</given-names></name><name><surname>Annoni</surname><given-names>JM</given-names></name><name><surname>Vuadens</surname><given-names>P</given-names></name><name><surname>Van der Linden</surname><given-names>M</given-names></name></person-group><article-title>How inhibition relates to impulsivity after moderate to severe traumatic brain injury</article-title><source>J Int Neuropsychol Soc</source><year>2013</year><month>10</month><day>02</day><volume>19</volume><issue>8</issue><fpage>890</fpage><lpage>8</lpage><comment>
<ext-link xlink:href="https://hdl.handle.net/2268/242656" ext-link-type="uri"/>
</comment><pub-id pub-id-type="doi">10.1017/S1355617713000672</pub-id><pub-id pub-id-type="medline">23816263</pub-id><pub-id pub-id-type="pii">S1355617713000672</pub-id><pub-id pub-id-type="pmid">23816263</pub-id>
</element-citation></ref><ref id="ref39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cyders</surname><given-names>MA</given-names></name><name><surname>Smith</surname><given-names>GT</given-names></name></person-group><article-title>Emotion-based dispositions to rash action: positive and negative urgency</article-title><source>Psychol Bull</source><year>2008</year><month>12</month><volume>134</volume><issue>6</issue><fpage>807</fpage><lpage>28</lpage><comment>
<ext-link xlink:href="https://europepmc.org/abstract/MED/18954158" ext-link-type="uri"/>
</comment><pub-id pub-id-type="doi">10.1037/a0013341</pub-id><pub-id pub-id-type="medline">18954158</pub-id><pub-id pub-id-type="pii">2008-14745-002</pub-id><!--<pub-id pub-id-type="pmcid">PMC2705930</pub-id>--><pub-id pub-id-type="pmid">18954158</pub-id>
</element-citation></ref><ref id="ref40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wood</surname><given-names>RL</given-names></name></person-group><article-title>Recognising and assessing neurobehavioural disability after traumatic brain injury</article-title><source>NeuroRehabilitation</source><year>2013</year><volume>32</volume><issue>4</issue><fpage>699</fpage><lpage>706</lpage><pub-id pub-id-type="doi">10.3233/NRE-130895</pub-id><pub-id pub-id-type="medline">23867397</pub-id><pub-id pub-id-type="pii">X5U45483540L4806</pub-id><pub-id pub-id-type="pmid">23867397</pub-id>
</element-citation></ref><ref id="ref41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lynam</surname><given-names>DR</given-names></name><name><surname>Miller</surname><given-names>JD</given-names></name><name><surname>Miller</surname><given-names>DJ</given-names></name><name><surname>Bornovalova</surname><given-names>MA</given-names></name><name><surname>Lejuez</surname><given-names>CW</given-names></name></person-group><article-title>Testing the relations between impulsivity-related traits, suicidality, and nonsuicidal self-injury: a test of the incremental validity of the UPPS model</article-title><source>Personal Disord</source><year>2011</year><month>05</month><volume>2</volume><issue>2</issue><fpage>151</fpage><lpage>60</lpage><comment>
<ext-link xlink:href="https://europepmc.org/abstract/MED/21833346" ext-link-type="uri"/>
</comment><pub-id pub-id-type="doi">10.1037/a0019978</pub-id><pub-id pub-id-type="medline">21833346</pub-id><pub-id pub-id-type="pii">2011-04288-001</pub-id><!--<pub-id pub-id-type="pmcid">PMC3152436</pub-id>--><pub-id pub-id-type="pmid">21833346</pub-id>
</element-citation></ref><ref id="ref42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eslinger</surname><given-names>PJ</given-names></name><name><surname>Grattan</surname><given-names>LM</given-names></name><name><surname>Geder</surname><given-names>L</given-names></name></person-group><article-title>Impact of frontal lobe lesions on rehabilitation and recovery from acute brain injury</article-title><source>NeuroRehabilitation</source><year>1995</year><volume>5</volume><issue>2</issue><fpage>161</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.3233/NRE-1995-5206</pub-id><pub-id pub-id-type="medline">24525496</pub-id><pub-id pub-id-type="pii">6560G78X82026J17</pub-id><pub-id pub-id-type="pmid">24525496</pub-id>
</element-citation></ref><ref id="ref43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aaronson</surname><given-names>AL</given-names></name><name><surname>Smith</surname><given-names>B</given-names></name><name><surname>Krese</surname><given-names>K</given-names></name><name><surname>Barnhart</surname><given-names>M</given-names></name><name><surname>Adamson</surname><given-names>M</given-names></name><name><surname>de Wit</surname><given-names>H</given-names></name><name><surname>Philip</surname><given-names>NS</given-names></name><name><surname>Brenner</surname><given-names>LA</given-names></name><name><surname>Bender-Pape</surname><given-names>T</given-names></name><name><surname>Herrold</surname><given-names>AA</given-names></name></person-group><article-title>Impulsivity and psychiatric diagnoses as mediators of suicidal ideation and suicide attempts among veterans with traumatic brain injury</article-title><source>J Neuropsychiatry Clin Neurosci</source><year>2024</year><month>04</month><volume>36</volume><issue>2</issue><fpage>125</fpage><lpage>33</lpage><comment>
<ext-link xlink:href="https://europepmc.org/abstract/MED/38192217" ext-link-type="uri"/>
</comment><pub-id pub-id-type="doi">10.1176/appi.neuropsych.20230044</pub-id><pub-id pub-id-type="medline">38192217</pub-id><!--<pub-id pub-id-type="pmcid">PMC11018458</pub-id>--><pub-id pub-id-type="pmid">38192217</pub-id>
</element-citation></ref><ref id="ref44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grafman</surname><given-names>J</given-names></name><name><surname>Schwab</surname><given-names>K</given-names></name><name><surname>Warden</surname><given-names>D</given-names></name><name><surname>Pridgen</surname><given-names>A</given-names></name><name><surname>Brown</surname><given-names>HR</given-names></name><name><surname>Salazar</surname><given-names>AM</given-names></name></person-group><article-title>Frontal lobe injuries, violence, and aggression: a report of the Vietnam Head Injury Study</article-title><source>Neurology</source><year>1996</year><month>05</month><volume>46</volume><issue>5</issue><fpage>1231</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1212/wnl.46.5.1231</pub-id><pub-id pub-id-type="medline">8628458</pub-id><pub-id pub-id-type="pmid">8628458</pub-id>
</element-citation></ref><ref id="ref45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Draper</surname><given-names>K</given-names></name><name><surname>Ponsford</surname><given-names>J</given-names></name><name><surname>Sch&#x000f6;nberger</surname><given-names>M</given-names></name></person-group><article-title>Psychosocial and emotional outcomes 10 years following traumatic brain injury</article-title><source>J Head Trauma Rehabil</source><year>2007</year><volume>22</volume><issue>5</issue><fpage>278</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1097/01.HTR.0000290972.63753.a7</pub-id><pub-id pub-id-type="medline">17878769</pub-id><pub-id pub-id-type="pii">00001199-200709000-00003</pub-id><pub-id pub-id-type="pmid">17878769</pub-id>
</element-citation></ref><ref id="ref46"><label>46</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Silver</surname><given-names>JM</given-names></name><name><surname>Yudofsky</surname><given-names>SC</given-names></name><name><surname>Anderson</surname><given-names>KE</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Silver</surname><given-names>JM</given-names></name><name><surname>Yudofsky</surname><given-names>SC</given-names></name></person-group><article-title>Aggressive disorders</article-title><source>Textbook of Traumatic Brain Injury. 2nd edition</source><year>2011</year><publisher-loc>Washington, DC</publisher-loc><publisher-name>American Psychiatric Publishing</publisher-name></element-citation></ref><ref id="ref47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramanathan-Elion</surname><given-names>DM</given-names></name><name><surname>Baydoun</surname><given-names>HA</given-names></name><name><surname>Johnstone</surname><given-names>B</given-names></name></person-group><article-title>Psychological predictors of functional outcomes in service members with traumatic brain injury</article-title><source>Brain Inj</source><year>2020</year><month>07</month><day>28</day><volume>34</volume><issue>9</issue><fpage>1183</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1080/02699052.2020.1793387</pub-id><pub-id pub-id-type="medline">32683899</pub-id><pub-id pub-id-type="pmid">32683899</pub-id>
</element-citation></ref><ref id="ref48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Batty</surname><given-names>GD</given-names></name><name><surname>Kivim&#x000e4;ki</surname><given-names>M</given-names></name><name><surname>Bell</surname><given-names>S</given-names></name><name><surname>Gale</surname><given-names>CR</given-names></name><name><surname>Shipley</surname><given-names>M</given-names></name><name><surname>Whitley</surname><given-names>E</given-names></name><name><surname>Gunnell</surname><given-names>D</given-names></name></person-group><article-title>Psychosocial characteristics as potential predictors of suicide in adults: an overview of the evidence with new results from prospective cohort studies</article-title><source>Transl Psychiatry</source><year>2018</year><month>01</month><day>22</day><volume>8</volume><issue>1</issue><fpage>22</fpage><comment>
<ext-link xlink:href="https://doi.org/10.1038/s41398-017-0072-8" ext-link-type="uri"/>
</comment><pub-id pub-id-type="doi">10.1038/s41398-017-0072-8</pub-id><pub-id pub-id-type="medline">29353878</pub-id><pub-id pub-id-type="pii">10.1038/s41398-017-0072-8</pub-id><!--<pub-id pub-id-type="pmcid">PMC5802587</pub-id>--><pub-id pub-id-type="pmid">29353878</pub-id>
</element-citation></ref><ref id="ref49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lefaucheur</surname><given-names>JP</given-names></name><name><surname>Aleman</surname><given-names>A</given-names></name><name><surname>Baeken</surname><given-names>C</given-names></name><name><surname>Benninger</surname><given-names>DH</given-names></name><name><surname>Brunelin</surname><given-names>J</given-names></name><name><surname>Di Lazzaro</surname><given-names>V</given-names></name><name><surname>Filipovi&#x00107;</surname><given-names>SR</given-names></name><name><surname>Grefkes</surname><given-names>C</given-names></name><name><surname>Hasan</surname><given-names>A</given-names></name><name><surname>Hummel</surname><given-names>FC</given-names></name><name><surname>J&#x000e4;&#x000e4;skel&#x000e4;inen</surname><given-names>SK</given-names></name><name><surname>Langguth</surname><given-names>B</given-names></name><name><surname>Leocani</surname><given-names>L</given-names></name><name><surname>Londero</surname><given-names>A</given-names></name><name><surname>Nardone</surname><given-names>R</given-names></name><name><surname>Nguyen</surname><given-names>J</given-names></name><name><surname>Nyffeler</surname><given-names>T</given-names></name><name><surname>Oliveira-Maia</surname><given-names>AJ</given-names></name><name><surname>Oliviero</surname><given-names>A</given-names></name><name><surname>Padberg</surname><given-names>F</given-names></name><name><surname>Palm</surname><given-names>U</given-names></name><name><surname>Paulus</surname><given-names>W</given-names></name><name><surname>Poulet</surname><given-names>E</given-names></name><name><surname>Quartarone</surname><given-names>A</given-names></name><name><surname>Rachid</surname><given-names>F</given-names></name><name><surname>Rektorov&#x000e1;</surname><given-names>I</given-names></name><name><surname>Rossi</surname><given-names>S</given-names></name><name><surname>Sahlsten</surname><given-names>H</given-names></name><name><surname>Schecklmann</surname><given-names>M</given-names></name><name><surname>Szekely</surname><given-names>D</given-names></name><name><surname>Ziemann</surname><given-names>U</given-names></name></person-group><article-title>Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS): an update (2014-2018)</article-title><source>Clin Neurophysiol</source><year>2020</year><month>03</month><volume>131</volume><issue>2</issue><fpage>474</fpage><lpage>528</lpage><comment>
<ext-link xlink:href="https://boris.unibe.ch/id/eprint/138033" ext-link-type="uri"/>
</comment><pub-id pub-id-type="doi">10.1016/j.clinph.2019.11.002</pub-id><pub-id pub-id-type="medline">31901449</pub-id><pub-id pub-id-type="pii">S1388-2457(19)31279-9</pub-id><pub-id pub-id-type="pmid">31901449</pub-id>
</element-citation></ref><ref id="ref50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klomjai</surname><given-names>W</given-names></name><name><surname>Katz</surname><given-names>R</given-names></name><name><surname>Lackmy-Vall&#x000e9;e</surname><given-names>A</given-names></name></person-group><article-title>Basic principles of transcranial magnetic stimulation (TMS) and repetitive TMS (rTMS)</article-title><source>Ann Phys Rehabil Med</source><year>2015</year><month>10</month><volume>58</volume><issue>4</issue><fpage>208</fpage><lpage>13</lpage><comment>
<ext-link xlink:href="https://linkinghub.elsevier.com/retrieve/pii/S1877-0657(15)00079-2" ext-link-type="uri"/>
</comment><pub-id pub-id-type="doi">10.1016/j.rehab.2015.05.005</pub-id><pub-id pub-id-type="medline">26319963</pub-id><pub-id pub-id-type="pii">S1877-0657(15)00079-2</pub-id><pub-id pub-id-type="pmid">26319963</pub-id>
</element-citation></ref><ref id="ref51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>George</surname><given-names>MS</given-names></name><name><surname>Lisanby</surname><given-names>SH</given-names></name><name><surname>Avery</surname><given-names>D</given-names></name><name><surname>McDonald</surname><given-names>WM</given-names></name><name><surname>Durkalski</surname><given-names>V</given-names></name><name><surname>Pavlicova</surname><given-names>M</given-names></name><name><surname>Anderson</surname><given-names>B</given-names></name><name><surname>Nahas</surname><given-names>Z</given-names></name><name><surname>Bulow</surname><given-names>P</given-names></name><name><surname>Zarkowski</surname><given-names>P</given-names></name><name><surname>Holtzheimer 3rd</surname><given-names>PE</given-names></name><name><surname>Schwartz</surname><given-names>T</given-names></name><name><surname>Sackeim</surname><given-names>HA</given-names></name></person-group><article-title>Daily left prefrontal transcranial magnetic stimulation therapy for major depressive disorder: a sham-controlled randomized trial</article-title><source>Arch Gen Psychiatry</source><year>2010</year><month>05</month><day>01</day><volume>67</volume><issue>5</issue><fpage>507</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1001/archgenpsychiatry.2010.46</pub-id><pub-id pub-id-type="medline">20439832</pub-id><pub-id pub-id-type="pii">67/5/507</pub-id><pub-id pub-id-type="pmid">20439832</pub-id>
</element-citation></ref><ref id="ref52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O'Reardon</surname><given-names>JP</given-names></name><name><surname>Solvason</surname><given-names>HB</given-names></name><name><surname>Janicak</surname><given-names>PG</given-names></name><name><surname>Sampson</surname><given-names>S</given-names></name><name><surname>Isenberg</surname><given-names>KE</given-names></name><name><surname>Nahas</surname><given-names>Z</given-names></name><name><surname>McDonald</surname><given-names>WM</given-names></name><name><surname>Avery</surname><given-names>D</given-names></name><name><surname>Fitzgerald</surname><given-names>PB</given-names></name><name><surname>Loo</surname><given-names>C</given-names></name><name><surname>Demitrack</surname><given-names>MA</given-names></name><name><surname>George</surname><given-names>MS</given-names></name><name><surname>Sackeim</surname><given-names>HA</given-names></name></person-group><article-title>Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: a multisite randomized controlled trial</article-title><source>Biol Psychiatry</source><year>2007</year><month>12</month><day>01</day><volume>62</volume><issue>11</issue><fpage>1208</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1016/j.biopsych.2007.01.018</pub-id><pub-id pub-id-type="medline">17573044</pub-id><pub-id pub-id-type="pii">S0006-3223(07)00146-1</pub-id><pub-id pub-id-type="pmid">17573044</pub-id>
</element-citation></ref><ref id="ref53"><label>53</label><element-citation publication-type="webpage"><article-title>Repetitive transcranial magnetic stimulation (rTMS) systems - class II special controls guidance for industry and FDA staff</article-title><source>Food and Drug Administration, USA</source><date-in-citation content-type="access-date">2024-04-29</date-in-citation><comment>
<ext-link xlink:href="https://www.fda.gov/medical-devices/guidance-documents-medical-devices-and-radiation-emitting-products/repetitive-transcranial-magnetic-stimulation-rtms-systems-class-ii-special-controls-guidance" ext-link-type="uri">https://www.fda.gov/medical-devices/guidance-documents-medical-devices-and-radiation-emitting-products/repetitive-transcranial-magnetic-stimulation-rtms-systems-class-ii-special-controls-guidance</ext-link>
</comment></element-citation></ref><ref id="ref54"><label>54</label><element-citation publication-type="webpage"><article-title>FDA permits marketing of transcranial magnetic stimulation for treatment of obsessive-compulsive disorder</article-title><source>Food and Drug Administration, USA</source><year>2018</year><date-in-citation content-type="access-date">2024-04-29</date-in-citation><comment>
<ext-link xlink:href="https://www.fda.gov/news-events/press-announcements/fda-permits-marketing-transcranial-magnetic-stimulation-treatment-obsessive-compulsive-disorder" ext-link-type="uri">https://www.fda.gov/news-events/press-announcements/fda-permits-marketing-transcranial-magnetic-stimulation-treatment-obsessive-compulsive-disorder</ext-link>
</comment></element-citation></ref><ref id="ref55"><label>55</label><element-citation publication-type="webpage"><article-title>Coverage guidance for TMS for OCD</article-title><source>Clinical TMS Society</source><date-in-citation content-type="access-date">2024-04-29</date-in-citation><comment>
<ext-link xlink:href="https://www.clinicaltmssociety.org/sites/default/files/ctmss_recommended_ocd_coverage_policy_0.pdf" ext-link-type="uri">https://www.clinicaltmssociety.org/sites/default/files/ctmss_recommended_ocd_coverage_policy_0.pdf</ext-link>
</comment></element-citation></ref><ref id="ref56"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>YZ</given-names></name><name><surname>Rothwell</surname><given-names>JC</given-names></name></person-group><article-title>The effect of short-duration bursts of high-frequency, low-intensity transcranial magnetic stimulation on the human motor cortex</article-title><source>Clin Neurophysiol</source><year>2004</year><month>05</month><volume>115</volume><issue>5</issue><fpage>1069</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1016/j.clinph.2003.12.026</pub-id><pub-id pub-id-type="medline">15066532</pub-id><pub-id pub-id-type="pii">S1388245704000070</pub-id><pub-id pub-id-type="pmid">15066532</pub-id>
</element-citation></ref><ref id="ref57"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Larson</surname><given-names>J</given-names></name><name><surname>Munk&#x000e1;csy</surname><given-names>E</given-names></name></person-group><article-title>Theta-burst LTP</article-title><source>Brain Res</source><year>2015</year><month>10</month><day>24</day><volume>1621</volume><fpage>38</fpage><lpage>50</lpage><comment>
<ext-link xlink:href="https://europepmc.org/abstract/MED/25452022" ext-link-type="uri"/>
</comment><pub-id pub-id-type="doi">10.1016/j.brainres.2014.10.034</pub-id><pub-id pub-id-type="medline">25452022</pub-id><pub-id pub-id-type="pii">S0006-8993(14)01436-X</pub-id><!--<pub-id pub-id-type="pmcid">PMC4411212</pub-id>--><pub-id pub-id-type="pmid">25452022</pub-id>
</element-citation></ref><ref id="ref58"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>CT</given-names></name><name><surname>Chen</surname><given-names>MH</given-names></name><name><surname>Juan</surname><given-names>CH</given-names></name><name><surname>Huang</surname><given-names>HH</given-names></name><name><surname>Chen</surname><given-names>LF</given-names></name><name><surname>Hsieh</surname><given-names>JC</given-names></name><name><surname>Tu</surname><given-names>PC</given-names></name><name><surname>Bai</surname><given-names>YM</given-names></name><name><surname>Tsai</surname><given-names>SJ</given-names></name><name><surname>Lee</surname><given-names>YC</given-names></name><name><surname>Su</surname><given-names>TP</given-names></name></person-group><article-title>Efficacy of prefrontal theta-burst stimulation in refractory depression: a randomized sham-controlled study</article-title><source>Brain</source><year>2014</year><month>07</month><volume>137</volume><issue>Pt 7</issue><fpage>2088</fpage><lpage>98</lpage><pub-id pub-id-type="doi">10.1093/brain/awu109</pub-id><pub-id pub-id-type="medline">24817188</pub-id><pub-id pub-id-type="pii">awu109</pub-id><pub-id pub-id-type="pmid">24817188</pub-id>
</element-citation></ref><ref id="ref59"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gamboa</surname><given-names>OL</given-names></name><name><surname>Antal</surname><given-names>A</given-names></name><name><surname>Laczo</surname><given-names>B</given-names></name><name><surname>Moliadze</surname><given-names>V</given-names></name><name><surname>Nitsche</surname><given-names>MA</given-names></name><name><surname>Paulus</surname><given-names>W</given-names></name></person-group><article-title>Impact of repetitive theta burst stimulation on motor cortex excitability</article-title><source>Brain Stimul</source><year>2011</year><month>07</month><volume>4</volume><issue>3</issue><fpage>145</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1016/j.brs.2010.09.008</pub-id><pub-id pub-id-type="medline">21777874</pub-id><pub-id pub-id-type="pii">S1935-861X(10)00135-X</pub-id><pub-id pub-id-type="pmid">21777874</pub-id>
</element-citation></ref><ref id="ref60"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gamboa</surname><given-names>OL</given-names></name><name><surname>Antal</surname><given-names>A</given-names></name><name><surname>Moliadze</surname><given-names>V</given-names></name><name><surname>Paulus</surname><given-names>W</given-names></name></person-group><article-title>Simply longer is not better: reversal of theta burst after-effect with prolonged stimulation</article-title><source>Exp Brain Res</source><year>2010</year><month>07</month><day>22</day><volume>204</volume><issue>2</issue><fpage>181</fpage><lpage>7</lpage><comment>
<ext-link xlink:href="https://europepmc.org/abstract/MED/20567808" ext-link-type="uri"/>
</comment><pub-id pub-id-type="doi">10.1007/s00221-010-2293-4</pub-id><pub-id pub-id-type="medline">20567808</pub-id><!--<pub-id pub-id-type="pmcid">PMC2892066</pub-id>--><pub-id pub-id-type="pmid">20567808</pub-id>
</element-citation></ref><ref id="ref61"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nettekoven</surname><given-names>C</given-names></name><name><surname>Volz</surname><given-names>LJ</given-names></name><name><surname>Kutscha</surname><given-names>M</given-names></name><name><surname>Pool</surname><given-names>EM</given-names></name><name><surname>Rehme</surname><given-names>AK</given-names></name><name><surname>Eickhoff</surname><given-names>SB</given-names></name><name><surname>Fink</surname><given-names>GR</given-names></name><name><surname>Grefkes</surname><given-names>C</given-names></name></person-group><article-title>Dose-dependent effects of theta burst rTMS on cortical excitability and resting-state connectivity of the human motor system</article-title><source>J Neurosci</source><year>2014</year><month>05</month><day>14</day><volume>34</volume><issue>20</issue><fpage>6849</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.1523/jneurosci.4993-13.2014</pub-id><pub-id pub-id-type="pmid">24828639</pub-id>
</element-citation></ref><ref id="ref62"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>GS</given-names></name><name><surname>Kwak</surname><given-names>SG</given-names></name><name><surname>Lee</surname><given-names>HD</given-names></name><name><surname>Chang</surname><given-names>MC</given-names></name></person-group><article-title>Effect of high-frequency repetitive transcranial magnetic stimulation on chronic central pain after mild traumatic brain injury: a pilot study</article-title><source>J Rehabil Med</source><year>2018</year><month>03</month><day>28</day><volume>50</volume><issue>3</issue><fpage>246</fpage><lpage>52</lpage><comment>
<ext-link xlink:href="https://doi.org/10.2340/16501977-2321" ext-link-type="uri"/>
</comment><pub-id pub-id-type="doi">10.2340/16501977-2321</pub-id><pub-id pub-id-type="medline">29392332</pub-id><pub-id pub-id-type="pmid">29392332</pub-id>
</element-citation></ref><ref id="ref63"><label>63</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>HR</given-names></name><name><surname>Imperatore</surname><given-names>JP</given-names></name><name><surname>Hanlon</surname><given-names>CA</given-names></name></person-group><article-title>The frontal pole as a target for transcranial magnetic stimulation: a retrospective analysis of feasibility and tolerability</article-title><source>Brain Stimul</source><year>2021</year><month>05</month><volume>14</volume><issue>3</issue><fpage>655</fpage><lpage>7</lpage><comment>
<ext-link xlink:href="https://linkinghub.elsevier.com/retrieve/pii/S1935-861X(21)00077-2" ext-link-type="uri"/>
</comment><pub-id pub-id-type="doi">10.1016/j.brs.2021.04.007</pub-id><pub-id pub-id-type="medline">33826932</pub-id><pub-id pub-id-type="pii">S1935-861X(21)00077-2</pub-id><pub-id pub-id-type="pmid">33826932</pub-id>
</element-citation></ref><ref id="ref64"><label>64</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Madore</surname><given-names>MR</given-names></name><name><surname>Kozel</surname><given-names>FA</given-names></name><name><surname>Williams</surname><given-names>LM</given-names></name><name><surname>Green</surname><given-names>LC</given-names></name><name><surname>George</surname><given-names>MS</given-names></name><name><surname>Holtzheimer</surname><given-names>PE</given-names></name><name><surname>Yesavage</surname><given-names>JA</given-names></name><name><surname>Philip</surname><given-names>NS</given-names></name></person-group><article-title>Prefrontal transcranial magnetic stimulation for depression in US military veterans - a naturalistic cohort study in the Veterans Health Administration</article-title><source>J Affect Disord</source><year>2022</year><month>01</month><day>15</day><volume>297</volume><fpage>671</fpage><lpage>8</lpage><comment>
<ext-link xlink:href="https://linkinghub.elsevier.com/retrieve/pii/S0165-0327(21)01102-2" ext-link-type="uri"/>
</comment><pub-id pub-id-type="doi">10.1016/j.jad.2021.10.025</pub-id><pub-id pub-id-type="medline">34687780</pub-id><pub-id pub-id-type="pii">S0165-0327(21)01102-2</pub-id><!--<pub-id pub-id-type="pmcid">PMC8667345</pub-id>--><pub-id pub-id-type="pmid">34687780</pub-id>
</element-citation></ref><ref id="ref65"><label>65</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ponsford</surname><given-names>J</given-names></name><name><surname>Alway</surname><given-names>Y</given-names></name><name><surname>Gould</surname><given-names>KR</given-names></name></person-group><article-title>Epidemiology and natural history of psychiatric disorders after TBI</article-title><source>J Neuropsychiatry Clin Neurosci</source><year>2018</year><month>10</month><volume>30</volume><issue>4</issue><fpage>262</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1176/appi.neuropsych.18040093</pub-id><pub-id pub-id-type="medline">29939106</pub-id><pub-id pub-id-type="pmid">29939106</pub-id>
</element-citation></ref><ref id="ref66"><label>66</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heltemes</surname><given-names>KJ</given-names></name><name><surname>Dougherty</surname><given-names>AL</given-names></name><name><surname>MacGregor</surname><given-names>AJ</given-names></name><name><surname>Galarneau</surname><given-names>MR</given-names></name></person-group><article-title>Alcohol abuse disorders among U.S. service members with mild traumatic brain injury</article-title><source>Mil Med</source><year>2011</year><month>03</month><volume>176</volume><issue>2</issue><fpage>147</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.7205/milmed-d-10-00191</pub-id><pub-id pub-id-type="medline">21366075</pub-id><pub-id pub-id-type="pmid">21366075</pub-id>
</element-citation></ref><ref id="ref67"><label>67</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoge</surname><given-names>CW</given-names></name><name><surname>McGurk</surname><given-names>D</given-names></name><name><surname>Thomas</surname><given-names>JL</given-names></name><name><surname>Cox</surname><given-names>AL</given-names></name><name><surname>Engel</surname><given-names>CC</given-names></name><name><surname>Castro</surname><given-names>CA</given-names></name></person-group><article-title>Mild traumatic brain injury in U.S. soldiers returning from Iraq</article-title><source>N Engl J Med</source><year>2008</year><month>01</month><day>31</day><volume>358</volume><issue>5</issue><fpage>453</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1056/nejmoa072972</pub-id><pub-id pub-id-type="pmid">18234750</pub-id>
</element-citation></ref><ref id="ref68"><label>68</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hibbard</surname><given-names>MR</given-names></name><name><surname>Uysal</surname><given-names>S</given-names></name><name><surname>Kepler</surname><given-names>K</given-names></name><name><surname>Bogdany</surname><given-names>J</given-names></name><name><surname>Silver</surname><given-names>J</given-names></name></person-group><article-title>Axis I psychopathology in individuals with traumatic brain injury</article-title><source>J Head Trauma Rehabil</source><year>1998</year><month>08</month><volume>13</volume><issue>4</issue><fpage>24</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.1097/00001199-199808000-00003</pub-id><pub-id pub-id-type="medline">9651237</pub-id><pub-id pub-id-type="pmid">9651237</pub-id>
</element-citation></ref><ref id="ref69"><label>69</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morey</surname><given-names>RA</given-names></name><name><surname>Haswell</surname><given-names>CC</given-names></name><name><surname>Hooper</surname><given-names>SR</given-names></name><name><surname>De Bellis</surname><given-names>MD</given-names></name></person-group><article-title>Amygdala, hippocampus, and ventral medial prefrontal cortex volumes differ in maltreated youth with and without chronic posttraumatic stress disorder</article-title><source>Neuropsychopharmacology</source><year>2016</year><month>03</month><day>14</day><volume>41</volume><issue>3</issue><fpage>791</fpage><lpage>801</lpage><comment>
<ext-link xlink:href="https://europepmc.org/abstract/MED/26171720" ext-link-type="uri"/>
</comment><pub-id pub-id-type="doi">10.1038/npp.2015.205</pub-id><pub-id pub-id-type="medline">26171720</pub-id><pub-id pub-id-type="pii">npp2015205</pub-id><!--<pub-id pub-id-type="pmcid">PMC4707825</pub-id>--><pub-id pub-id-type="pmid">26171720</pub-id>
</element-citation></ref><ref id="ref70"><label>70</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilcox</surname><given-names>CE</given-names></name><name><surname>Pommy</surname><given-names>JM</given-names></name><name><surname>Adinoff</surname><given-names>B</given-names></name></person-group><article-title>Neural circuitry of impaired emotion regulation in substance use disorders</article-title><source>Am J Psychiatry</source><year>2016</year><month>05</month><day>01</day><volume>173</volume><issue>4</issue><fpage>344</fpage><lpage>61</lpage><comment>
<ext-link xlink:href="https://europepmc.org/abstract/MED/26771738" ext-link-type="uri"/>
</comment><pub-id pub-id-type="doi">10.1176/appi.ajp.2015.15060710</pub-id><pub-id pub-id-type="medline">26771738</pub-id><!--<pub-id pub-id-type="pmcid">PMC4979988</pub-id>--><pub-id pub-id-type="pmid">26771738</pub-id>
</element-citation></ref><ref id="ref71"><label>71</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kucuker</surname><given-names>MU</given-names></name><name><surname>Almorsy</surname><given-names>AG</given-names></name><name><surname>Sonmez</surname><given-names>AI</given-names></name><name><surname>Ligezka</surname><given-names>AN</given-names></name><name><surname>Doruk Camsari</surname><given-names>D</given-names></name><name><surname>Lewis</surname><given-names>CP</given-names></name><name><surname>Croarkin</surname><given-names>PE</given-names></name></person-group><article-title>A systematic review of neuromodulation treatment effects on suicidality</article-title><source>Front Hum Neurosci</source><year>2021</year><month>6</month><day>25</day><volume>15</volume><fpage>660926</fpage><comment>
<ext-link xlink:href="https://europepmc.org/abstract/MED/34248523" ext-link-type="uri"/>
</comment><pub-id pub-id-type="doi">10.3389/fnhum.2021.660926</pub-id><pub-id pub-id-type="medline">34248523</pub-id><!--<pub-id pub-id-type="pmcid">PMC8267816</pub-id>--><pub-id pub-id-type="pmid">34248523</pub-id>
</element-citation></ref><ref id="ref72"><label>72</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Magnin</surname><given-names>C</given-names></name><name><surname>Brunelin</surname><given-names>J</given-names></name><name><surname>Leaune</surname><given-names>E</given-names></name><name><surname>Fang</surname><given-names>Y</given-names></name><name><surname>Poulet</surname><given-names>E</given-names></name></person-group><article-title>Can seizure therapies and noninvasive brain stimulations prevent suicidality? A systematic review</article-title><source>Brain Behav</source><year>2021</year><month>05</month><volume>11</volume><issue>5</issue><fpage>e02144</fpage><comment>
<ext-link xlink:href="https://europepmc.org/abstract/MED/33838000" ext-link-type="uri"/>
</comment><pub-id pub-id-type="doi">10.1002/brb3.2144</pub-id><pub-id pub-id-type="medline">33838000</pub-id><!--<pub-id pub-id-type="pmcid">PMC8119823</pub-id>--><pub-id pub-id-type="pmid">33838000</pub-id>
</element-citation></ref><ref id="ref73"><label>73</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>George</surname><given-names>MS</given-names></name><name><surname>Raman</surname><given-names>R</given-names></name><name><surname>Benedek</surname><given-names>DM</given-names></name><name><surname>Pelic</surname><given-names>CG</given-names></name><name><surname>Grammer</surname><given-names>GG</given-names></name><name><surname>Stokes</surname><given-names>KT</given-names></name><name><surname>Schmidt</surname><given-names>M</given-names></name><name><surname>Spiegel</surname><given-names>C</given-names></name><name><surname>Dealmeida</surname><given-names>N</given-names></name><name><surname>Beaver</surname><given-names>KL</given-names></name><name><surname>Borckardt</surname><given-names>JJ</given-names></name><name><surname>Sun</surname><given-names>X</given-names></name><name><surname>Jain</surname><given-names>S</given-names></name><name><surname>Stein</surname><given-names>MB</given-names></name></person-group><article-title>A two-site pilot randomized 3 day trial of high dose left prefrontal repetitive transcranial magnetic stimulation (rTMS) for suicidal inpatients</article-title><source>Brain Stimul</source><year>2014</year><month>05</month><volume>7</volume><issue>3</issue><fpage>421</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1016/j.brs.2014.03.006</pub-id><pub-id pub-id-type="medline">24731434</pub-id><pub-id pub-id-type="pii">S1935-861X(14)00121-1</pub-id><pub-id pub-id-type="pmid">24731434</pub-id>
</element-citation></ref><ref id="ref74"><label>74</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weissman</surname><given-names>CR</given-names></name><name><surname>Blumberger</surname><given-names>DM</given-names></name><name><surname>Brown</surname><given-names>PE</given-names></name><name><surname>Isserles</surname><given-names>M</given-names></name><name><surname>Rajji</surname><given-names>TK</given-names></name><name><surname>Downar</surname><given-names>J</given-names></name><name><surname>Mulsant</surname><given-names>BH</given-names></name><name><surname>Fitzgerald</surname><given-names>PB</given-names></name><name><surname>Daskalakis</surname><given-names>ZJ</given-names></name></person-group><article-title>Bilateral repetitive transcranial magnetic stimulation decreases suicidal ideation in depression</article-title><source>J Clin Psychiatry</source><year>2018</year><volume>79</volume><issue>3</issue><fpage>17m11692</fpage><pub-id pub-id-type="doi">10.4088/JCP.17m11692</pub-id><pub-id pub-id-type="medline">29701939</pub-id><pub-id pub-id-type="pii">17m11692</pub-id></element-citation></ref><ref id="ref75"><label>75</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rao</surname><given-names>V</given-names></name><name><surname>Bechtold</surname><given-names>K</given-names></name><name><surname>McCann</surname><given-names>U</given-names></name><name><surname>Roy</surname><given-names>D</given-names></name><name><surname>Peters</surname><given-names>M</given-names></name><name><surname>Vaishnavi</surname><given-names>S</given-names></name><name><surname>Yousem</surname><given-names>D</given-names></name><name><surname>Mori</surname><given-names>S</given-names></name><name><surname>Yan</surname><given-names>H</given-names></name><name><surname>Leoutsakos</surname><given-names>J</given-names></name><name><surname>Tibbs</surname><given-names>M</given-names></name><name><surname>Reti</surname><given-names>I</given-names></name></person-group><article-title>Low-frequency right repetitive transcranial magnetic stimulation for the treatment of depression after traumatic brain injury: a randomized sham-controlled pilot study</article-title><source>J Neuropsychiatry Clin Neurosci</source><year>2019</year><month>10</month><volume>31</volume><issue>4</issue><fpage>306</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1176/appi.neuropsych.17110338</pub-id><pub-id pub-id-type="medline">31018810</pub-id><pub-id pub-id-type="pmid">31018810</pub-id>
</element-citation></ref><ref id="ref76"><label>76</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Croarkin</surname><given-names>PE</given-names></name><name><surname>MacMaster</surname><given-names>FP</given-names></name></person-group><article-title>Transcranial magnetic stimulation for adolescent depression</article-title><source>Child Adolesc Psychiatr Clin N Am</source><year>2019</year><month>01</month><volume>28</volume><issue>1</issue><fpage>33</fpage><lpage>43</lpage><comment>
<ext-link xlink:href="https://europepmc.org/abstract/MED/30389074" ext-link-type="uri"/>
</comment><pub-id pub-id-type="doi">10.1016/j.chc.2018.07.003</pub-id><pub-id pub-id-type="medline">30389074</pub-id><pub-id pub-id-type="pii">S1056-4993(18)30655-2</pub-id><!--<pub-id pub-id-type="pmcid">PMC6221455</pub-id>--><pub-id pub-id-type="pmid">30389074</pub-id>
</element-citation></ref><ref id="ref77"><label>77</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bozzay</surname><given-names>ML</given-names></name><name><surname>Primack</surname><given-names>J</given-names></name><name><surname>Barredo</surname><given-names>J</given-names></name><name><surname>Philip</surname><given-names>NS</given-names></name></person-group><article-title>Transcranial magnetic stimulation to reduce suicidality - a review and naturalistic outcomes</article-title><source>J Psychiatr Res</source><year>2020</year><month>07</month><volume>125</volume><fpage>106</fpage><lpage>12</lpage><comment>
<ext-link xlink:href="https://europepmc.org/abstract/MED/32251917" ext-link-type="uri"/>
</comment><pub-id pub-id-type="doi">10.1016/j.jpsychires.2020.03.016</pub-id><pub-id pub-id-type="medline">32251917</pub-id><pub-id pub-id-type="pii">S0022-3956(19)31344-5</pub-id><!--<pub-id pub-id-type="pmcid">PMC7197489</pub-id>--><pub-id pub-id-type="pmid">32251917</pub-id>
</element-citation></ref><ref id="ref78"><label>78</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname><given-names>JB</given-names></name><name><surname>Wilson</surname><given-names>SH</given-names></name><name><surname>Oakes</surname><given-names>TR</given-names></name><name><surname>Santhanam</surname><given-names>P</given-names></name><name><surname>Weaver</surname><given-names>LK</given-names></name></person-group><article-title>Structural and volumetric brain MRI findings in mild traumatic brain injury</article-title><source>AJNR Am J Neuroradiol</source><year>2020</year><month>01</month><day>02</day><volume>41</volume><issue>1</issue><fpage>92</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.3174/ajnr.a6346</pub-id><pub-id pub-id-type="pmid">31896572</pub-id>
</element-citation></ref><ref id="ref79"><label>79</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Epstein</surname><given-names>DJ</given-names></name><name><surname>Legarreta</surname><given-names>M</given-names></name><name><surname>Bueler</surname><given-names>E</given-names></name><name><surname>King</surname><given-names>J</given-names></name><name><surname>McGlade</surname><given-names>E</given-names></name><name><surname>Yurgelun-Todd</surname><given-names>D</given-names></name></person-group><article-title>Orbitofrontal cortical thinning and aggression in mild traumatic brain injury patients</article-title><source>Brain Behav</source><year>2016</year><month>12</month><day>28</day><volume>6</volume><issue>12</issue><fpage>e00581</fpage><comment>
<ext-link xlink:href="https://europepmc.org/abstract/MED/28032004" ext-link-type="uri"/>
</comment><pub-id pub-id-type="doi">10.1002/brb3.581</pub-id><pub-id pub-id-type="medline">28032004</pub-id><pub-id pub-id-type="pii">BRB3581</pub-id><!--<pub-id pub-id-type="pmcid">PMC5167002</pub-id>--><pub-id pub-id-type="pmid">28032004</pub-id>
</element-citation></ref><ref id="ref80"><label>80</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Silver</surname><given-names>JM</given-names></name><name><surname>McAllister</surname><given-names>TW</given-names></name><name><surname>Yudofsky</surname><given-names>SC</given-names></name></person-group><source>Textbook of Traumatic Brain Injury. 2nd edition</source><year>2011</year><publisher-loc>Washington, DC</publisher-loc><publisher-name>American Psychiatric Publishing</publisher-name></element-citation></ref><ref id="ref81"><label>81</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gosnell</surname><given-names>SN</given-names></name><name><surname>Velasquez</surname><given-names>KM</given-names></name><name><surname>Molfese</surname><given-names>DL</given-names></name><name><surname>Molfese</surname><given-names>PJ</given-names></name><name><surname>Madan</surname><given-names>A</given-names></name><name><surname>Fowler</surname><given-names>JC</given-names></name><name><surname>Christopher Frueh</surname><given-names>B</given-names></name><name><surname>Baldwin</surname><given-names>PR</given-names></name><name><surname>Salas</surname><given-names>R</given-names></name></person-group><article-title>Prefrontal cortex, temporal cortex, and hippocampus volume are affected in suicidal psychiatric patients</article-title><source>Psychiatry Res Neuroimaging</source><year>2016</year><month>10</month><day>30</day><volume>256</volume><fpage>50</fpage><lpage>6</lpage><comment>
<ext-link xlink:href="https://europepmc.org/abstract/MED/27685801" ext-link-type="uri"/>
</comment><pub-id pub-id-type="doi">10.1016/j.pscychresns.2016.09.005</pub-id><pub-id pub-id-type="medline">27685801</pub-id><pub-id pub-id-type="pii">S0925-4927(15)30184-0</pub-id><!--<pub-id pub-id-type="pmcid">PMC9694115</pub-id>--><pub-id pub-id-type="pmid">27685801</pub-id>
</element-citation></ref><ref id="ref82"><label>82</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanlon</surname><given-names>CA</given-names></name><name><surname>Dowdle</surname><given-names>LT</given-names></name><name><surname>Correia</surname><given-names>B</given-names></name><name><surname>Mithoefer</surname><given-names>O</given-names></name><name><surname>Kearney-Ramos</surname><given-names>T</given-names></name><name><surname>Lench</surname><given-names>D</given-names></name><name><surname>Griffin</surname><given-names>M</given-names></name><name><surname>Anton</surname><given-names>RF</given-names></name><name><surname>George</surname><given-names>MS</given-names></name></person-group><article-title>Left frontal pole theta burst stimulation decreases orbitofrontal and insula activity in cocaine users and alcohol users</article-title><source>Drug Alcohol Depend</source><year>2017</year><month>10</month><day>01</day><volume>178</volume><fpage>310</fpage><lpage>7</lpage><comment>
<ext-link xlink:href="https://europepmc.org/abstract/MED/28686990" ext-link-type="uri"/>
</comment><pub-id pub-id-type="doi">10.1016/j.drugalcdep.2017.03.039</pub-id><pub-id pub-id-type="medline">28686990</pub-id><pub-id pub-id-type="pii">S0376-8716(17)30230-2</pub-id><!--<pub-id pub-id-type="pmcid">PMC5896018</pub-id>--><pub-id pub-id-type="pmid">28686990</pub-id>
</element-citation></ref><ref id="ref83"><label>83</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Price</surname><given-names>RB</given-names></name><name><surname>Gillan</surname><given-names>CM</given-names></name><name><surname>Hanlon</surname><given-names>C</given-names></name><name><surname>Ferrarelli</surname><given-names>F</given-names></name><name><surname>Kim</surname><given-names>T</given-names></name><name><surname>Karim</surname><given-names>HT</given-names></name><name><surname>Renard</surname><given-names>M</given-names></name><name><surname>Kaskie</surname><given-names>R</given-names></name><name><surname>Degutis</surname><given-names>M</given-names></name><name><surname>Wears</surname><given-names>A</given-names></name><name><surname>Vienneau</surname><given-names>EP</given-names></name><name><surname>Peterchev</surname><given-names>AV</given-names></name><name><surname>Brown</surname><given-names>V</given-names></name><name><surname>Siegle</surname><given-names>GJ</given-names></name><name><surname>Wallace</surname><given-names>ML</given-names></name><name><surname>Ahmari</surname><given-names>SE</given-names></name></person-group><article-title>Effect of experimental manipulation of the orbitofrontal cortex on short-term markers of compulsive behavior: a theta burst stimulation study</article-title><source>Am J Psychiatry</source><year>2021</year><month>05</month><day>01</day><volume>178</volume><issue>5</issue><fpage>459</fpage><lpage>68</lpage><comment>
<ext-link xlink:href="https://europepmc.org/abstract/MED/33726523" ext-link-type="uri"/>
</comment><pub-id pub-id-type="doi">10.1176/appi.ajp.2020.20060821</pub-id><pub-id pub-id-type="medline">33726523</pub-id><!--<pub-id pub-id-type="pmcid">PMC8119344</pub-id>--><pub-id pub-id-type="pmid">33726523</pub-id>
</element-citation></ref><ref id="ref84"><label>84</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rossi</surname><given-names>S</given-names></name><name><surname>Antal</surname><given-names>A</given-names></name><name><surname>Bestmann</surname><given-names>S</given-names></name><name><surname>Bikson</surname><given-names>M</given-names></name><name><surname>Brewer</surname><given-names>C</given-names></name><name><surname>Brockm&#x000f6;ller</surname><given-names>J</given-names></name><name><surname>Carpenter</surname><given-names>LL</given-names></name><name><surname>Cincotta</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>R</given-names></name><name><surname>Daskalakis</surname><given-names>JD</given-names></name><name><surname>Di Lazzaro</surname><given-names>V</given-names></name><name><surname>Fox</surname><given-names>MD</given-names></name><name><surname>George</surname><given-names>MS</given-names></name><name><surname>Gilbert</surname><given-names>D</given-names></name><name><surname>Kimiskidis</surname><given-names>VK</given-names></name><name><surname>Koch</surname><given-names>G</given-names></name><name><surname>Ilmoniemi</surname><given-names>RJ</given-names></name><name><surname>Lefaucheur</surname><given-names>JP</given-names></name><name><surname>Leocani</surname><given-names>L</given-names></name><name><surname>Lisanby</surname><given-names>SH</given-names></name><name><surname>Miniussi</surname><given-names>C</given-names></name><name><surname>Padberg</surname><given-names>F</given-names></name><name><surname>Pascual-Leone</surname><given-names>A</given-names></name><name><surname>Paulus</surname><given-names>W</given-names></name><name><surname>Peterchev</surname><given-names>AV</given-names></name><name><surname>Quartarone</surname><given-names>A</given-names></name><name><surname>Rotenberg</surname><given-names>A</given-names></name><name><surname>Rothwell</surname><given-names>J</given-names></name><name><surname>Rossini</surname><given-names>PM</given-names></name><name><surname>Santarnecchi</surname><given-names>E</given-names></name><name><surname>Shafi</surname><given-names>MM</given-names></name><name><surname>Siebner</surname><given-names>HR</given-names></name><name><surname>Ugawa</surname><given-names>Y</given-names></name><name><surname>Wassermann</surname><given-names>EM</given-names></name><name><surname>Zangen</surname><given-names>A</given-names></name><name><surname>Ziemann</surname><given-names>U</given-names></name><name><surname>Hallett</surname><given-names>M</given-names></name><collab>basis of this article began with a Consensus Statement from the IFCN Workshop on "Present, Future of TMS: Safety, Ethical Guidelines"</collab></person-group><article-title>Safety and recommendations for TMS use in healthy subjects and patient populations, with updates on training, ethical and regulatory issues: expert guidelines</article-title><source>Clin Neurophysiol</source><year>2021</year><month>01</month><volume>132</volume><issue>1</issue><fpage>269</fpage><lpage>306</lpage><comment>
<ext-link xlink:href="https://linkinghub.elsevier.com/retrieve/pii/S1388-2457(20)30514-9" ext-link-type="uri"/>
</comment><pub-id pub-id-type="doi">10.1016/j.clinph.2020.10.003</pub-id><pub-id pub-id-type="medline">33243615</pub-id><pub-id pub-id-type="pii">S1388-2457(20)30514-9</pub-id><!--<pub-id pub-id-type="pmcid">PMC9094636</pub-id>--><pub-id pub-id-type="pmid">33243615</pub-id>
</element-citation></ref><ref id="ref85"><label>85</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>AW</given-names></name><name><surname>Tetzlaff</surname><given-names>JM</given-names></name><name><surname>Altman</surname><given-names>DG</given-names></name><name><surname>Laupacis</surname><given-names>A</given-names></name><name><surname>G&#x000f8;tzsche</surname><given-names>PC</given-names></name><name><surname>Krle&#x0017e;a-Jeri&#x00107;</surname><given-names>K</given-names></name><name><surname>Hr&#x000f3;bjartsson</surname><given-names>A</given-names></name><name><surname>Mann</surname><given-names>H</given-names></name><name><surname>Dickersin</surname><given-names>K</given-names></name><name><surname>Berlin</surname><given-names>JA</given-names></name><name><surname>Dor&#x000e9;</surname><given-names>CJ</given-names></name><name><surname>Parulekar</surname><given-names>WR</given-names></name><name><surname>Summerskill</surname><given-names>WS</given-names></name><name><surname>Groves</surname><given-names>T</given-names></name><name><surname>Schulz</surname><given-names>KF</given-names></name><name><surname>Sox</surname><given-names>HC</given-names></name><name><surname>Rockhold</surname><given-names>FW</given-names></name><name><surname>Rennie</surname><given-names>D</given-names></name><name><surname>Moher</surname><given-names>D</given-names></name></person-group><article-title>SPIRIT 2013 statement: defining standard protocol items for clinical trials</article-title><source>Ann Intern Med</source><year>2013</year><month>03</month><day>05</day><volume>158</volume><issue>3</issue><fpage>200</fpage><lpage>7</lpage><comment>
<ext-link xlink:href="https://www.acpjournals.org/doi/abs/10.7326/0003-4819-158-3-201302050-00583?url_ver=Z39.88-2003&#x00026;rfr_id=ori:rid:crossref.org&#x00026;rfr_dat=cr_pub0pubmed" ext-link-type="uri"/>
</comment><pub-id pub-id-type="doi">10.7326/0003-4819-158-3-201302050-00583</pub-id><pub-id pub-id-type="medline">23295957</pub-id><pub-id pub-id-type="pii">1556168</pub-id><!--<pub-id pub-id-type="pmcid">PMC5114123</pub-id>--><pub-id pub-id-type="pmid">23295957</pub-id>
</element-citation></ref><ref id="ref86"><label>86</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Altman</surname><given-names>DG</given-names></name><name><surname>Schulz</surname><given-names>KF</given-names></name><name><surname>Moher</surname><given-names>D</given-names></name><collab>CONSORT Group</collab></person-group><article-title>CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials</article-title><source>BMJ</source><year>2010</year><month>03</month><day>23</day><volume>340</volume><fpage>c332</fpage><comment>
<ext-link xlink:href="https://europepmc.org/abstract/MED/20332509" ext-link-type="uri"/>
</comment><pub-id pub-id-type="doi">10.1136/bmj.c332</pub-id><pub-id pub-id-type="medline">20332509</pub-id><pub-id pub-id-type="pii">bmj.c332</pub-id><!--<pub-id pub-id-type="pmcid">PMC2844940</pub-id>--><pub-id pub-id-type="pmid">20332509</pub-id>
</element-citation></ref><ref id="ref87"><label>87</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>Management of Concussion/mTBI Working Group</collab></person-group><article-title>VA/DoD clinical practice guideline for management of concussion/mild traumatic brain injury version 2.0</article-title><source>Department of Veterans Affairs</source><year>2016</year><date-in-citation content-type="access-date">2024-11-04</date-in-citation><comment>
<ext-link xlink:href="https://www.healthquality.va.gov/guidelines/rehab/mtbi/mtbicpgfullcpg50821816.pdf" ext-link-type="uri">https://www.healthquality.va.gov/guidelines/rehab/mtbi/mtbicpgfullcpg50821816.pdf</ext-link>
</comment></element-citation></ref><ref id="ref88"><label>88</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pape</surname><given-names>TL</given-names></name><name><surname>Herrold</surname><given-names>AA</given-names></name><name><surname>Smith</surname><given-names>B</given-names></name><name><surname>Babcock-Parziale</surname><given-names>J</given-names></name><name><surname>Harp</surname><given-names>J</given-names></name><name><surname>Shandera-Ochsner</surname><given-names>A</given-names></name><name><surname>Jenkins</surname><given-names>S</given-names></name><name><surname>Evans</surname><given-names>CT</given-names></name><name><surname>Schleenbaker</surname><given-names>R</given-names></name><name><surname>High</surname><given-names>WM</given-names></name></person-group><article-title>Algorithm for symptom attribution and classification following possible mild traumatic brain injury</article-title><source>J Head Trauma Rehabil</source><year>2016</year><volume>31</volume><issue>6</issue><fpage>E10</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1097/HTR.0000000000000220</pub-id><pub-id pub-id-type="medline">26828712</pub-id></element-citation></ref><ref id="ref89"><label>89</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Posner</surname><given-names>K</given-names></name><name><surname>Brown</surname><given-names>GK</given-names></name><name><surname>Stanley</surname><given-names>B</given-names></name><name><surname>Brent</surname><given-names>DA</given-names></name><name><surname>Yershova</surname><given-names>KV</given-names></name><name><surname>Oquendo</surname><given-names>MA</given-names></name><name><surname>Currier</surname><given-names>GW</given-names></name><name><surname>Melvin</surname><given-names>GA</given-names></name><name><surname>Greenhill</surname><given-names>L</given-names></name><name><surname>Shen</surname><given-names>S</given-names></name><name><surname>Mann</surname><given-names>JJ</given-names></name></person-group><article-title>The Columbia-suicide severity rating scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults</article-title><source>Am J Psychiatry</source><year>2011</year><month>12</month><volume>168</volume><issue>12</issue><fpage>1266</fpage><lpage>77</lpage><comment>
<ext-link xlink:href="https://europepmc.org/abstract/MED/22193671" ext-link-type="uri"/>
</comment><pub-id pub-id-type="doi">10.1176/appi.ajp.2011.10111704</pub-id><pub-id pub-id-type="medline">22193671</pub-id><!--<pub-id pub-id-type="pmcid">PMC3893686</pub-id>--><pub-id pub-id-type="pmid">22193671</pub-id>
</element-citation></ref><ref id="ref90"><label>90</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Philip</surname><given-names>NS</given-names></name><name><surname>Barredo</surname><given-names>J</given-names></name><name><surname>Aiken</surname><given-names>E</given-names></name><name><surname>Larson</surname><given-names>V</given-names></name><name><surname>Jones</surname><given-names>RN</given-names></name><name><surname>Shea</surname><given-names>MT</given-names></name><name><surname>Greenberg</surname><given-names>BD</given-names></name><name><surname>van 't Wout-Frank</surname><given-names>M</given-names></name></person-group><article-title>Theta-burst transcranial magnetic stimulation for posttraumatic stress disorder</article-title><source>Am J Psychiatry</source><year>2019</year><month>11</month><day>01</day><volume>176</volume><issue>11</issue><fpage>939</fpage><lpage>48</lpage><comment>
<ext-link xlink:href="https://europepmc.org/abstract/MED/31230462" ext-link-type="uri"/>
</comment><pub-id pub-id-type="doi">10.1176/appi.ajp.2019.18101160</pub-id><pub-id pub-id-type="medline">31230462</pub-id><!--<pub-id pub-id-type="pmcid">PMC6824981</pub-id>--><pub-id pub-id-type="pmid">31230462</pub-id>
</element-citation></ref><ref id="ref91"><label>91</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duprat</surname><given-names>R</given-names></name><name><surname>Desmyter</surname><given-names>S</given-names></name><name><surname>Rudi</surname><given-names>DR</given-names></name><name><surname>van Heeringen</surname><given-names>K</given-names></name><name><surname>Van den Abbeele</surname><given-names>D</given-names></name><name><surname>Tandt</surname><given-names>H</given-names></name><name><surname>Bakic</surname><given-names>J</given-names></name><name><surname>Pourtois</surname><given-names>G</given-names></name><name><surname>Dedoncker</surname><given-names>J</given-names></name><name><surname>Vervaet</surname><given-names>M</given-names></name><name><surname>Van Autreve</surname><given-names>S</given-names></name><name><surname>Lemmens</surname><given-names>GM</given-names></name><name><surname>Baeken</surname><given-names>C</given-names></name></person-group><article-title>Accelerated intermittent theta burst stimulation treatment in medication-resistant major depression: a fast road to remission?</article-title><source>J Affect Disord</source><year>2016</year><month>08</month><volume>200</volume><fpage>6</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1016/j.jad.2016.04.015</pub-id><pub-id pub-id-type="medline">27107779</pub-id><pub-id pub-id-type="pii">S0165-0327(15)31444-0</pub-id><pub-id pub-id-type="pmid">27107779</pub-id>
</element-citation></ref><ref id="ref92"><label>92</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Corrigan</surname><given-names>JD</given-names></name><name><surname>Bogner</surname><given-names>J</given-names></name></person-group><article-title>Initial reliability and validity of the Ohio State University TBI identification method</article-title><source>J Head Trauma Rehabil</source><year>2007</year><volume>22</volume><issue>6</issue><fpage>318</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.1097/01.HTR.0000300227.67748.77</pub-id><pub-id pub-id-type="medline">18025964</pub-id><pub-id pub-id-type="pii">00001199-200711000-00002</pub-id><pub-id pub-id-type="pmid">18025964</pub-id>
</element-citation></ref><ref id="ref93"><label>93</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Erford</surname><given-names>BT</given-names></name><name><surname>Jackson</surname><given-names>J</given-names></name><name><surname>Bardhoshi</surname><given-names>G</given-names></name><name><surname>Duncan</surname><given-names>K</given-names></name><name><surname>Atalay</surname><given-names>Z</given-names></name></person-group><article-title>Selecting suicide ideation assessment instruments: a meta-analytic review</article-title><source>Meas Eval Couns Dev</source><year>2017</year><month>12</month><day>20</day><volume>51</volume><issue>1</issue><fpage>42</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.1080/07481756.2017.1358062</pub-id></element-citation></ref><ref id="ref94"><label>94</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Madan</surname><given-names>A</given-names></name><name><surname>Frueh</surname><given-names>BC</given-names></name><name><surname>Allen</surname><given-names>JG</given-names></name><name><surname>Ellis</surname><given-names>TE</given-names></name><name><surname>Rufino</surname><given-names>KA</given-names></name><name><surname>Oldham</surname><given-names>JM</given-names></name><name><surname>Fowler</surname><given-names>JC</given-names></name></person-group><article-title>Psychometric reevaluation of the Columbia&#x02013;Suicide Severity Rating scale</article-title><source>J Clin Psychiatry</source><year>2016</year><month>07</month><day>27</day><volume>77</volume><issue>07</issue><fpage>e867</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.4088/jcp.15m10069</pub-id><pub-id pub-id-type="pmid">27464320</pub-id>
</element-citation></ref><ref id="ref95"><label>95</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roxburgh</surname><given-names>AD</given-names></name><name><surname>White</surname><given-names>DJ</given-names></name><name><surname>Cornwell</surname><given-names>BR</given-names></name></person-group><article-title>Negative urgency is related to impaired response inhibition during threatening conditions</article-title><source>Acta Psychol (Amst)</source><year>2022</year><month>08</month><volume>228</volume><fpage>103648</fpage><comment>
<ext-link xlink:href="https://linkinghub.elsevier.com/retrieve/pii/S0001-6918(22)00163-9" ext-link-type="uri"/>
</comment><pub-id pub-id-type="doi">10.1016/j.actpsy.2022.103648</pub-id><pub-id pub-id-type="medline">35777308</pub-id><pub-id pub-id-type="pii">S0001-6918(22)00163-9</pub-id><pub-id pub-id-type="pmid">35777308</pub-id>
</element-citation></ref><ref id="ref96"><label>96</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fern&#x000e1;ndez-Serrano</surname><given-names>MJ</given-names></name><name><surname>Perales</surname><given-names>JC</given-names></name><name><surname>Moreno-L&#x000f3;pez</surname><given-names>L</given-names></name><name><surname>P&#x000e9;rez-Garc&#x000ed;a</surname><given-names>M</given-names></name><name><surname>Verdejo-Garc&#x000ed;a</surname><given-names>A</given-names></name></person-group><article-title>Neuropsychological profiling of impulsivity and compulsivity in cocaine dependent individuals</article-title><source>Psychopharmacology (Berl)</source><year>2012</year><month>01</month><day>16</day><volume>219</volume><issue>2</issue><fpage>673</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1007/s00213-011-2485-z</pub-id><pub-id pub-id-type="medline">21922168</pub-id><pub-id pub-id-type="pmid">21922168</pub-id>
</element-citation></ref><ref id="ref97"><label>97</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whiteside</surname><given-names>SP</given-names></name><name><surname>Lynam</surname><given-names>DR</given-names></name></person-group><article-title>The Five Factor Model and impulsivity: using a structural model of personality to understand impulsivity</article-title><source>Pers Individ Dif</source><year>2001</year><month>3</month><volume>30</volume><issue>4</issue><fpage>669</fpage><lpage>89</lpage><pub-id pub-id-type="doi">10.1016/s0191-8869(00)00064-7</pub-id></element-citation></ref><ref id="ref98"><label>98</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silva</surname><given-names>MA</given-names></name></person-group><article-title>Review of the Neurobehavioral Symptom inventory</article-title><source>Rehabil Psychol</source><year>2021</year><month>05</month><volume>66</volume><issue>2</issue><fpage>170</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1037/rep0000367</pub-id><pub-id pub-id-type="medline">33119379</pub-id><pub-id pub-id-type="pii">2020-81356-001</pub-id><pub-id pub-id-type="pmid">33119379</pub-id>
</element-citation></ref><ref id="ref99"><label>99</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rivest-Beauregard</surname><given-names>M</given-names></name><name><surname>Brunet</surname><given-names>A</given-names></name><name><surname>Gaston</surname><given-names>L</given-names></name><name><surname>Al Joboory</surname><given-names>S</given-names></name><name><surname>Trousselard</surname><given-names>M</given-names></name><name><surname>Simson</surname><given-names>J</given-names></name><name><surname>Amara</surname><given-names>P</given-names></name><name><surname>Sourdril</surname><given-names>N</given-names></name><name><surname>Gandubert</surname><given-names>C</given-names></name><name><surname>Hingray</surname><given-names>C</given-names></name><name><surname>Dallel</surname><given-names>S</given-names></name><name><surname>Guinard</surname><given-names>J</given-names></name><name><surname>Saumier</surname><given-names>D</given-names></name><name><surname>Richa</surname><given-names>S</given-names></name><name><surname>El-Hage</surname><given-names>W</given-names></name></person-group><article-title>The clinician-administered PTSD scale for DSM-5 (CAPS-5) structured interview for PTSD: a French language validation study</article-title><source>Psychol Assess</source><year>2022</year><month>03</month><volume>34</volume><issue>3</issue><fpage>e26</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1037/pas0001099</pub-id><pub-id pub-id-type="medline">35007103</pub-id><pub-id pub-id-type="pii">2022-18512-001</pub-id><pub-id pub-id-type="pmid">35007103</pub-id>
</element-citation></ref><ref id="ref100"><label>100</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weathers</surname><given-names>FW</given-names></name><name><surname>Bovin</surname><given-names>MJ</given-names></name><name><surname>Lee</surname><given-names>DJ</given-names></name><name><surname>Sloan</surname><given-names>DM</given-names></name><name><surname>Schnurr</surname><given-names>PP</given-names></name><name><surname>Kaloupek</surname><given-names>DG</given-names></name><name><surname>Keane</surname><given-names>TM</given-names></name><name><surname>Marx</surname><given-names>BP</given-names></name></person-group><article-title>The clinician-administered PTSD scale for DSM-5 (CAPS-5): development and initial psychometric evaluation in military veterans</article-title><source>Psychol Assess</source><year>2018</year><month>03</month><volume>30</volume><issue>3</issue><fpage>383</fpage><lpage>95</lpage><comment>
<ext-link xlink:href="https://europepmc.org/abstract/MED/28493729" ext-link-type="uri"/>
</comment><pub-id pub-id-type="doi">10.1037/pas0000486</pub-id><pub-id pub-id-type="medline">28493729</pub-id><pub-id pub-id-type="pii">2017-20898-001</pub-id><!--<pub-id pub-id-type="pmcid">PMC5805662</pub-id>--><pub-id pub-id-type="pmid">28493729</pub-id>
</element-citation></ref><ref id="ref101"><label>101</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bush</surname><given-names>K</given-names></name><name><surname>Kivlahan</surname><given-names>DR</given-names></name><name><surname>McDonell</surname><given-names>MB</given-names></name><name><surname>Fihn</surname><given-names>SD</given-names></name><name><surname>Bradley</surname><given-names>KA</given-names></name></person-group><article-title>The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol use disorders identification test</article-title><source>Arch Intern Med</source><year>1998</year><month>09</month><day>14</day><volume>158</volume><issue>16</issue><fpage>1789</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1001/archinte.158.16.1789</pub-id><pub-id pub-id-type="medline">9738608</pub-id><pub-id pub-id-type="pmid">9738608</pub-id>
</element-citation></ref><ref id="ref102"><label>102</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berman</surname><given-names>AH</given-names></name><name><surname>Bergman</surname><given-names>H</given-names></name><name><surname>Palmstierna</surname><given-names>T</given-names></name><name><surname>Schlyter</surname><given-names>F</given-names></name></person-group><article-title>Evaluation of the Drug Use Disorders Identification Test (DUDIT) in criminal justice and detoxification settings and in a Swedish population sample</article-title><source>Eur Addict Res</source><year>2005</year><month>12</month><day>10</day><volume>11</volume><issue>1</issue><fpage>22</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1159/000081413</pub-id><pub-id pub-id-type="medline">15608468</pub-id><pub-id pub-id-type="pii">81413</pub-id><pub-id pub-id-type="pmid">15608468</pub-id>
</element-citation></ref><ref id="ref103"><label>103</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cuneyt Evren</surname><given-names>EO</given-names></name><name><surname>Ovali</surname><given-names>E</given-names></name><name><surname>Karabulut</surname><given-names>V</given-names></name><name><surname>Cetingok</surname><given-names>S</given-names></name></person-group><article-title>Psychometric properties of the Drug Use Disorders Identification Test (DUDIT) in heroin dependent adults and adolescents with drug use disorder</article-title><source>Klinik Psikofarmakol Bulteni</source><year>2016</year><month>11</month><day>08</day><volume>24</volume><issue>1</issue><fpage>39</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.5455/bcp.20130310124522</pub-id></element-citation></ref><ref id="ref104"><label>104</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>First</surname><given-names>MB</given-names></name><name><surname>Williams</surname><given-names>JB</given-names></name><name><surname>Karg</surname><given-names>RS</given-names></name><name><surname>Spitzer</surname><given-names>RL</given-names></name></person-group><source>User's Guide for the Structured Clinical Interview for DSM-5&#x000ae; Disorders&#x02014;Clinician Version (SCID-5-CV)</source><year>2016</year><publisher-loc>Washington, DC</publisher-loc><publisher-name>American Psychiatric Association Publishing</publisher-name></element-citation></ref><ref id="ref105"><label>105</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shabani</surname><given-names>A</given-names></name><name><surname>Masoumian</surname><given-names>S</given-names></name><name><surname>Zamirinejad</surname><given-names>S</given-names></name><name><surname>Hejri</surname><given-names>M</given-names></name><name><surname>Pirmorad</surname><given-names>T</given-names></name><name><surname>Yaghmaeezadeh</surname><given-names>H</given-names></name></person-group><article-title>Psychometric properties of structured clinical interview for DSM-5 disorders-clinician version (SCID-5-CV)</article-title><source>Brain Behav</source><year>2021</year><month>05</month><volume>11</volume><issue>5</issue><fpage>e01894</fpage><comment>
<ext-link xlink:href="https://europepmc.org/abstract/MED/33729681" ext-link-type="uri"/>
</comment><pub-id pub-id-type="doi">10.1002/brb3.1894</pub-id><pub-id pub-id-type="medline">33729681</pub-id><!--<pub-id pub-id-type="pmcid">PMC8119811</pub-id>--><pub-id pub-id-type="pmid">33729681</pub-id>
</element-citation></ref><ref id="ref106"><label>106</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldman</surname><given-names>HH</given-names></name><name><surname>Skodol</surname><given-names>AE</given-names></name><name><surname>Lave</surname><given-names>TR</given-names></name></person-group><article-title>Revising axis V for DSM-IV: a review of measures of social functioning</article-title><source>Am J Psychiatry</source><year>1992</year><month>09</month><volume>149</volume><issue>9</issue><fpage>1148</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1176/ajp.149.9.1148</pub-id><pub-id pub-id-type="medline">1386964</pub-id><pub-id pub-id-type="pmid">1386964</pub-id>
</element-citation></ref><ref id="ref107"><label>107</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morosini</surname><given-names>PL</given-names></name><name><surname>Magliano</surname><given-names>L</given-names></name><name><surname>Brambilla</surname><given-names>L</given-names></name><name><surname>Ugolini</surname><given-names>S</given-names></name><name><surname>Pioli</surname><given-names>R</given-names></name></person-group><article-title>Development, reliability and acceptability of a new version of the DSM&#x02010;IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social funtioning</article-title><source>Acta Psychiatr Scand</source><year>2001</year><month>12</month><day>24</day><volume>101</volume><issue>4</issue><fpage>323</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1034/j.1600-0447.2000.101004323.x</pub-id></element-citation></ref><ref id="ref108"><label>108</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buss</surname><given-names>AH</given-names></name><name><surname>Perry</surname><given-names>M</given-names></name></person-group><article-title>The aggression questionnaire</article-title><source>J Pers Soc Psychol</source><year>1992</year><month>09</month><volume>63</volume><issue>3</issue><fpage>452</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1037//0022-3514.63.3.452</pub-id><pub-id pub-id-type="medline">1403624</pub-id><pub-id pub-id-type="pmid">1403624</pub-id>
</element-citation></ref><ref id="ref109"><label>109</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kroenke</surname><given-names>K</given-names></name><name><surname>Spitzer</surname><given-names>RL</given-names></name><name><surname>Williams</surname><given-names>JB</given-names></name></person-group><article-title>The PHQ-9: validity of a brief depression severity measure</article-title><source>J Gen Intern Med</source><year>2001</year><month>09</month><volume>16</volume><issue>9</issue><fpage>606</fpage><lpage>13</lpage><comment>
<ext-link xlink:href="https://europepmc.org/abstract/MED/11556941" ext-link-type="uri"/>
</comment><pub-id pub-id-type="doi">10.1046/j.1525-1497.2001.016009606.x</pub-id><pub-id pub-id-type="medline">11556941</pub-id><pub-id pub-id-type="pii">jgi01114</pub-id><!--<pub-id pub-id-type="pmcid">PMC1495268</pub-id>--><pub-id pub-id-type="pmid">11556941</pub-id>
</element-citation></ref><ref id="ref110"><label>110</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hansson</surname><given-names>M</given-names></name><name><surname>Chotai</surname><given-names>J</given-names></name><name><surname>Nordst&#x000f6;m</surname><given-names>A</given-names></name><name><surname>Bodlund</surname><given-names>O</given-names></name></person-group><article-title>Comparison of two self-rating scales to detect depression: HADS and PHQ-9</article-title><source>Br J Gen Pract</source><year>2009</year><month>09</month><day>01</day><volume>59</volume><issue>566</issue><fpage>e283</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.3399/bjgp09x454070</pub-id><pub-id pub-id-type="pmid">19761655</pub-id>
</element-citation></ref><ref id="ref111"><label>111</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brazier</surname><given-names>J</given-names></name><name><surname>Roberts</surname><given-names>J</given-names></name><name><surname>Deverill</surname><given-names>M</given-names></name></person-group><article-title>The estimation of a preference-based measure of health from the SF-36</article-title><source>J Health Econ</source><year>2002</year><month>03</month><volume>21</volume><issue>2</issue><fpage>271</fpage><lpage>92</lpage><comment>
<ext-link xlink:href="https://eprints.whiterose.ac.uk/474/" ext-link-type="uri"/>
</comment><pub-id pub-id-type="doi">10.1016/s0167-6296(01)00130-8</pub-id><pub-id pub-id-type="medline">11939242</pub-id><pub-id pub-id-type="pii">S0167-6296(01)00130-8</pub-id><pub-id pub-id-type="pmid">11939242</pub-id>
</element-citation></ref><ref id="ref112"><label>112</label><element-citation publication-type="webpage"><article-title>36-item short form survey (SF-36) scoring instructions</article-title><source>RAND Corporation</source><date-in-citation content-type="access-date">2024-07-16</date-in-citation><comment>
<ext-link xlink:href="https://www.rand.org/health-care/surveys_tools/mos/36-item-short-form/scoring.html" ext-link-type="uri">https://www.rand.org/health-care/surveys_tools/mos/36-item-short-form/scoring.html</ext-link>
</comment></element-citation></ref><ref id="ref113"><label>113</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beck</surname><given-names>AT</given-names></name><name><surname>Kovacs</surname><given-names>M</given-names></name><name><surname>Weissman</surname><given-names>A</given-names></name></person-group><article-title>Assessment of suicidal intention: the Scale for Suicide Ideation</article-title><source>J Consult Clin Psychol</source><year>1979</year><month>04</month><volume>47</volume><issue>2</issue><fpage>343</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1037//0022-006x.47.2.343</pub-id><pub-id pub-id-type="medline">469082</pub-id><pub-id pub-id-type="pmid">469082</pub-id>
</element-citation></ref><ref id="ref114"><label>114</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beck</surname><given-names>AT</given-names></name><name><surname>Brown</surname><given-names>GK</given-names></name><name><surname>Steer</surname><given-names>RA</given-names></name></person-group><article-title>Psychometric characteristics of the scale for suicide ideation with psychiatric outpatients</article-title><source>Behav Res Ther</source><year>1997</year><month>12</month><volume>35</volume><issue>11</issue><fpage>1039</fpage><lpage>46</lpage><comment>
<ext-link xlink:href="https://linkinghub.elsevier.com/retrieve/pii/S0005-7967(97)00073-9" ext-link-type="uri"/>
</comment><pub-id pub-id-type="doi">10.1016/s0005-7967(97)00073-9</pub-id><pub-id pub-id-type="medline">9431735</pub-id><pub-id pub-id-type="pii">S0005-7967(97)00073-9</pub-id><pub-id pub-id-type="pmid">9431735</pub-id>
</element-citation></ref><ref id="ref115"><label>115</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bovin</surname><given-names>MJ</given-names></name><name><surname>Marx</surname><given-names>BP</given-names></name><name><surname>Weathers</surname><given-names>FW</given-names></name><name><surname>Gallagher</surname><given-names>MW</given-names></name><name><surname>Rodriguez</surname><given-names>P</given-names></name><name><surname>Schnurr</surname><given-names>PP</given-names></name><name><surname>Keane</surname><given-names>TM</given-names></name></person-group><article-title>Psychometric properties of the PTSD checklist for diagnostic and statistical manual of mental disorders-fifth edition (PCL-5) in veterans</article-title><source>Psychol Assess</source><year>2016</year><month>12</month><volume>28</volume><issue>11</issue><fpage>1379</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1037/pas0000254</pub-id><pub-id pub-id-type="medline">26653052</pub-id><pub-id pub-id-type="pii">2015-55809-001</pub-id><pub-id pub-id-type="pmid">26653052</pub-id>
</element-citation></ref><ref id="ref116"><label>116</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blevins</surname><given-names>CA</given-names></name><name><surname>Weathers</surname><given-names>FW</given-names></name><name><surname>Davis</surname><given-names>MT</given-names></name><name><surname>Witte</surname><given-names>TK</given-names></name><name><surname>Domino</surname><given-names>JL</given-names></name></person-group><article-title>The posttraumatic stress disorder checklist for DSM-5 (PCL-5): development and initial psychometric evaluation</article-title><source>J Trauma Stress</source><year>2015</year><month>12</month><day>25</day><volume>28</volume><issue>6</issue><fpage>489</fpage><lpage>98</lpage><pub-id pub-id-type="doi">10.1002/jts.22059</pub-id><pub-id pub-id-type="medline">26606250</pub-id><pub-id pub-id-type="pmid">26606250</pub-id>
</element-citation></ref><ref id="ref117"><label>117</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trivedi</surname><given-names>MH</given-names></name><name><surname>Rush</surname><given-names>AJ</given-names></name><name><surname>Ibrahim</surname><given-names>HM</given-names></name><name><surname>Carmody</surname><given-names>TJ</given-names></name><name><surname>Biggs</surname><given-names>MM</given-names></name><name><surname>Suppes</surname><given-names>T</given-names></name><name><surname>Crismon</surname><given-names>ML</given-names></name><name><surname>Shores-Wilson</surname><given-names>K</given-names></name><name><surname>Toprac</surname><given-names>MG</given-names></name><name><surname>Dennehy</surname><given-names>EB</given-names></name><name><surname>Witte</surname><given-names>B</given-names></name><name><surname>Kashner</surname><given-names>TM</given-names></name></person-group><article-title>The Inventory of Depressive Symptomatology, Clinician Rating (IDS-C) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: a psychometric evaluation</article-title><source>Psychol Med</source><year>2004</year><month>01</month><day>14</day><volume>34</volume><issue>1</issue><fpage>73</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1017/s0033291703001107</pub-id><pub-id pub-id-type="medline">14971628</pub-id><pub-id pub-id-type="pmid">14971628</pub-id>
</element-citation></ref><ref id="ref118"><label>118</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Corruble</surname><given-names>E</given-names></name><name><surname>Legrand</surname><given-names>JM</given-names></name><name><surname>Duret</surname><given-names>C</given-names></name><name><surname>Charles</surname><given-names>G</given-names></name><name><surname>Guelfi</surname><given-names>JD</given-names></name></person-group><article-title>IDS-C and IDS-sr: psychometric properties in depressed in-patients</article-title><source>J Affect Disord</source><year>1999</year><month>12</month><volume>56</volume><issue>2-3</issue><fpage>95</fpage><lpage>101</lpage><pub-id pub-id-type="doi">10.1016/s0165-0327(99)00055-5</pub-id><pub-id pub-id-type="medline">10701466</pub-id><pub-id pub-id-type="pii">S0165-0327(99)00055-5</pub-id><pub-id pub-id-type="pmid">10701466</pub-id>
</element-citation></ref><ref id="ref119"><label>119</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hallion</surname><given-names>LS</given-names></name><name><surname>Steinman</surname><given-names>SA</given-names></name><name><surname>Tolin</surname><given-names>DF</given-names></name><name><surname>Diefenbach</surname><given-names>GJ</given-names></name></person-group><article-title>Psychometric properties of the Difficulties in Emotion Regulation Scale (DERS) and its short forms in adults with emotional disorders</article-title><source>Front Psychol</source><year>2018</year><month>4</month><day>19</day><volume>9</volume><fpage>539</fpage><comment>
<ext-link xlink:href="https://europepmc.org/abstract/MED/29725312" ext-link-type="uri"/>
</comment><pub-id pub-id-type="doi">10.3389/fpsyg.2018.00539</pub-id><pub-id pub-id-type="medline">29725312</pub-id><!--<pub-id pub-id-type="pmcid">PMC5917244</pub-id>--><pub-id pub-id-type="pmid">29725312</pub-id>
</element-citation></ref><ref id="ref120"><label>120</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gouveia</surname><given-names>P</given-names></name><name><surname>Ramos</surname><given-names>C</given-names></name><name><surname>Brito</surname><given-names>J</given-names></name><name><surname>Almeida</surname><given-names>TC</given-names></name><name><surname>Cardoso</surname><given-names>J</given-names></name></person-group><article-title>Correction: the Difficulties in Emotion Regulation Scale - short form (DERS-SF): psychometric properties and invariance between genders</article-title><source>Psicol Reflex Crit</source><year>2022</year><month>07</month><day>04</day><volume>35</volume><issue>1</issue><fpage>19</fpage><comment>
<ext-link xlink:href="https://europepmc.org/abstract/MED/35781848" ext-link-type="uri"/>
</comment><pub-id pub-id-type="doi">10.1186/s41155-022-00225-z</pub-id><pub-id pub-id-type="medline">35781848</pub-id><pub-id pub-id-type="pii">10.1186/s41155-022-00225-z</pub-id><!--<pub-id pub-id-type="pmcid">PMC9253204</pub-id>--><pub-id pub-id-type="pmid">35781848</pub-id>
</element-citation></ref><ref id="ref121"><label>121</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Du</surname><given-names>W</given-names></name><name><surname>Green</surname><given-names>L</given-names></name><name><surname>Myerson</surname><given-names>J</given-names></name></person-group><article-title>Cross-cultural comparisons of discounting delayed and probabilistic rewards</article-title><source>Psychol Rec</source><year>2017</year><month>5</month><day>30</day><volume>52</volume><issue>4</issue><fpage>479</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1007/bf03395199</pub-id></element-citation></ref><ref id="ref122"><label>122</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weafer</surname><given-names>J</given-names></name><name><surname>Baggott</surname><given-names>MJ</given-names></name><name><surname>de Wit</surname><given-names>H</given-names></name></person-group><article-title>Test-retest reliability of behavioral measures of impulsive choice, impulsive action, and inattention</article-title><source>Exp Clin Psychopharmacol</source><year>2013</year><month>12</month><volume>21</volume><issue>6</issue><fpage>475</fpage><lpage>81</lpage><comment>
<ext-link xlink:href="https://europepmc.org/abstract/MED/24099351" ext-link-type="uri"/>
</comment><pub-id pub-id-type="doi">10.1037/a0033659</pub-id><pub-id pub-id-type="medline">24099351</pub-id><pub-id pub-id-type="pii">2013-34870-001</pub-id><!--<pub-id pub-id-type="pmcid">PMC4266373</pub-id>--><pub-id pub-id-type="pmid">24099351</pub-id>
</element-citation></ref><ref id="ref123"><label>123</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scarpina</surname><given-names>F</given-names></name><name><surname>Tagini</surname><given-names>S</given-names></name></person-group><article-title>The Stroop Color and Word test</article-title><source>Front Psychol</source><year>2017</year><month>04</month><day>12</day><volume>8</volume><fpage>557</fpage><comment>
<ext-link xlink:href="http://hdl.handle.net/2318/1729697" ext-link-type="uri"/>
</comment><pub-id pub-id-type="doi">10.3389/fpsyg.2017.00557</pub-id><pub-id pub-id-type="medline">28446889</pub-id><!--<pub-id pub-id-type="pmcid">PMC5388755</pub-id>--><pub-id pub-id-type="pmid">28446889</pub-id>
</element-citation></ref><ref id="ref124"><label>124</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leverett</surname><given-names>JP</given-names></name><name><surname>Lassiter</surname><given-names>KS</given-names></name><name><surname>Buchanan</surname><given-names>GM</given-names></name></person-group><article-title>Correlations for the Stroop Color and Word Test with measures of reading and language achievement</article-title><source>Percept Mot Skills</source><year>2002</year><month>04</month><day>01</day><volume>94</volume><issue>2</issue><fpage>459</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.2466/pms.2002.94.2.459</pub-id><pub-id pub-id-type="medline">12027339</pub-id><pub-id pub-id-type="pmid">12027339</pub-id>
</element-citation></ref><ref id="ref125"><label>125</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Philip</surname><given-names>NS</given-names></name><name><surname>Barredo</surname><given-names>J</given-names></name><name><surname>van 't Wout-Frank</surname><given-names>M</given-names></name><name><surname>Tyrka</surname><given-names>AR</given-names></name><name><surname>Price</surname><given-names>LH</given-names></name><name><surname>Carpenter</surname><given-names>LL</given-names></name></person-group><article-title>Network mechanisms of clinical response to transcranial magnetic stimulation in posttraumatic stress disorder and major depressive disorder</article-title><source>Biol Psychiatry</source><year>2018</year><month>02</month><day>01</day><volume>83</volume><issue>3</issue><fpage>263</fpage><lpage>72</lpage><comment>
<ext-link xlink:href="https://europepmc.org/abstract/MED/28886760" ext-link-type="uri"/>
</comment><pub-id pub-id-type="doi">10.1016/j.biopsych.2017.07.021</pub-id><pub-id pub-id-type="medline">28886760</pub-id><pub-id pub-id-type="pii">S0006-3223(17)31850-4</pub-id><!--<pub-id pub-id-type="pmcid">PMC6679924</pub-id>--><pub-id pub-id-type="pmid">28886760</pub-id>
</element-citation></ref><ref id="ref126"><label>126</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Richardson</surname><given-names>EG</given-names></name></person-group><article-title>Editorial: descriptive statistics</article-title><source>Foot Ankle Int</source><year>2007</year><month>12</month><day>01</day><volume>28</volume><issue>12</issue><fpage>1217</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.3113/fai.2007.1217</pub-id><pub-id pub-id-type="pmid">18183681</pub-id>
</element-citation></ref><ref id="ref127"><label>127</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Melo</surname><given-names>MB</given-names></name><name><surname>Daldegan-Bueno</surname><given-names>D</given-names></name><name><surname>Menezes Oliveira</surname><given-names>MG</given-names></name><name><surname>de Souza</surname><given-names>AL</given-names></name></person-group><article-title>Beyond ANOVA and MANOVA for repeated measures: advantages of generalized estimated equations and generalized linear mixed models and its use in neuroscience research</article-title><source>Eur J Neurosci</source><year>2022</year><month>12</month><day>14</day><volume>56</volume><issue>12</issue><fpage>6089</fpage><lpage>98</lpage><pub-id pub-id-type="doi">10.1111/ejn.15858</pub-id><pub-id pub-id-type="medline">36342498</pub-id><pub-id pub-id-type="pmid">36342498</pub-id>
</element-citation></ref><ref id="ref128"><label>128</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>Z</given-names></name><name><surname>Guindani</surname><given-names>M</given-names></name><name><surname>Grieco</surname><given-names>SF</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Holmes</surname><given-names>TC</given-names></name><name><surname>Xu</surname><given-names>X</given-names></name></person-group><article-title>Beyond t test and ANOVA: applications of mixed-effects models for more rigorous statistical analysis in neuroscience research</article-title><source>Neuron</source><year>2022</year><month>01</month><day>05</day><volume>110</volume><issue>1</issue><fpage>21</fpage><lpage>35</lpage><comment>
<ext-link xlink:href="https://linkinghub.elsevier.com/retrieve/pii/S0896-6273(21)00845-X" ext-link-type="uri"/>
</comment><pub-id pub-id-type="doi">10.1016/j.neuron.2021.10.030</pub-id><pub-id pub-id-type="medline">34784504</pub-id><pub-id pub-id-type="pii">S0896-6273(21)00845-X</pub-id><!--<pub-id pub-id-type="pmcid">PMC8763600</pub-id>--><pub-id pub-id-type="pmid">34784504</pub-id>
</element-citation></ref><ref id="ref129"><label>129</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tu</surname><given-names>YK</given-names></name></person-group><article-title>Use of generalized linear mixed models for network meta-analysis</article-title><source>Med Decis Making</source><year>2014</year><month>09</month><day>26</day><volume>34</volume><issue>7</issue><fpage>911</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1177/0272989x14545789</pub-id><pub-id pub-id-type="pmid">25260872</pub-id>
</element-citation></ref><ref id="ref130"><label>130</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Desikan</surname><given-names>RS</given-names></name><name><surname>S&#x000e9;gonne</surname><given-names>F</given-names></name><name><surname>Fischl</surname><given-names>B</given-names></name><name><surname>Quinn</surname><given-names>BT</given-names></name><name><surname>Dickerson</surname><given-names>BC</given-names></name><name><surname>Blacker</surname><given-names>D</given-names></name><name><surname>Buckner</surname><given-names>RL</given-names></name><name><surname>Dale</surname><given-names>AM</given-names></name><name><surname>Maguire</surname><given-names>RP</given-names></name><name><surname>Hyman</surname><given-names>BT</given-names></name><name><surname>Albert</surname><given-names>MS</given-names></name><name><surname>Killiany</surname><given-names>RJ</given-names></name></person-group><article-title>An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest</article-title><source>Neuroimage</source><year>2006</year><month>07</month><day>01</day><volume>31</volume><issue>3</issue><fpage>968</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1016/j.neuroimage.2006.01.021</pub-id><pub-id pub-id-type="medline">16530430</pub-id><pub-id pub-id-type="pii">S1053-8119(06)00043-7</pub-id><pub-id pub-id-type="pmid">16530430</pub-id>
</element-citation></ref><ref id="ref131"><label>131</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Welz</surname><given-names>T</given-names></name><name><surname>Doebler</surname><given-names>P</given-names></name><name><surname>Pauly</surname><given-names>M</given-names></name></person-group><article-title>Fisher transformation based confidence intervals of correlations in fixed- and random-effects meta-analysis</article-title><source>Br J Math Stat Psychol</source><year>2022</year><month>02</month><day>02</day><volume>75</volume><issue>1</issue><fpage>1</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1111/bmsp.12242</pub-id><pub-id pub-id-type="medline">33934346</pub-id><pub-id pub-id-type="pmid">33934346</pub-id>
</element-citation></ref><ref id="ref132"><label>132</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whitfield-Gabrieli</surname><given-names>S</given-names></name><name><surname>Nieto-Castanon</surname><given-names>A</given-names></name></person-group><article-title>Conn: a functional connectivity toolbox for correlated and anticorrelated brain networks</article-title><source>Brain Connect</source><year>2012</year><month>06</month><volume>2</volume><issue>3</issue><fpage>125</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1089/brain.2012.0073</pub-id><pub-id pub-id-type="medline">22642651</pub-id><pub-id pub-id-type="pmid">22642651</pub-id>
</element-citation></ref><ref id="ref133"><label>133</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Aert</surname><given-names>RC</given-names></name></person-group><article-title>Meta-analyzing partial correlation coefficients using Fisher's z transformation</article-title><source>Res Synth Methods</source><year>2023</year><month>09</month><day>08</day><volume>14</volume><issue>5</issue><fpage>768</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1002/jrsm.1654</pub-id><pub-id pub-id-type="medline">37421188</pub-id><pub-id pub-id-type="pmid">37421188</pub-id>
</element-citation></ref><ref id="ref134"><label>134</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Opoku</surname><given-names>EA</given-names></name><name><surname>Ahmed</surname><given-names>SE</given-names></name><name><surname>Nathoo</surname><given-names>FS</given-names></name></person-group><article-title>Sparse estimation strategies in linear mixed effect models for high-dimensional data application</article-title><source>Entropy (Basel)</source><year>2021</year><month>10</month><day>15</day><volume>23</volume><issue>10</issue><fpage>1348</fpage><comment>
<ext-link xlink:href="https://www.mdpi.com/resolver?pii=e23101348" ext-link-type="uri"/>
</comment><pub-id pub-id-type="doi">10.3390/e23101348</pub-id><pub-id pub-id-type="medline">34682072</pub-id><pub-id pub-id-type="pii">e23101348</pub-id><!--<pub-id pub-id-type="pmcid">PMC8534815</pub-id>--><pub-id pub-id-type="pmid">34682072</pub-id>
</element-citation></ref><ref id="ref135"><label>135</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Linhartov&#x000e1;</surname><given-names>P</given-names></name><name><surname>Sv&#x0011b;r&#x000e1;k</surname><given-names>T</given-names></name><name><surname>Gajdos</surname><given-names>M</given-names></name><name><surname>Ka&#x00161;p&#x000e1;rek</surname><given-names>T</given-names></name></person-group><article-title>Repetitive transcranial magnetic stimulation in borderline personality disorder: clinical and brain connectivity changes</article-title><source>Brain Stimul</source><year>2021</year><month>11</month><volume>14</volume><issue>6</issue><fpage>1680</fpage><pub-id pub-id-type="doi">10.1016/j.brs.2021.10.292</pub-id></element-citation></ref><ref id="ref136"><label>136</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barredo</surname><given-names>J</given-names></name><name><surname>Berlow</surname><given-names>Y</given-names></name><name><surname>Swearingen</surname><given-names>HR</given-names></name><name><surname>Greenberg</surname><given-names>BD</given-names></name><name><surname>Carpenter</surname><given-names>LL</given-names></name><name><surname>Philip</surname><given-names>NS</given-names></name></person-group><article-title>Multimodal elements of suicidality reduction after transcranial magnetic stimulation</article-title><source>Neuromodulation</source><year>2021</year><month>07</month><volume>24</volume><issue>5</issue><fpage>930</fpage><lpage>7</lpage><comment>
<ext-link xlink:href="https://linkinghub.elsevier.com/retrieve/pii/S1094-7159(21)06203-6" ext-link-type="uri"/>
</comment><pub-id pub-id-type="doi">10.1111/ner.13376</pub-id><pub-id pub-id-type="medline">33650209</pub-id><pub-id pub-id-type="pii">S1094-7159(21)06203-6</pub-id><!--<pub-id pub-id-type="pmcid">PMC8295183</pub-id>--><pub-id pub-id-type="pmid">33650209</pub-id>
</element-citation></ref><ref id="ref137"><label>137</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Batail</surname><given-names>JM</given-names></name><name><surname>Xiao</surname><given-names>X</given-names></name><name><surname>Azeez</surname><given-names>A</given-names></name><name><surname>Tischler</surname><given-names>C</given-names></name><name><surname>Kratter</surname><given-names>IH</given-names></name><name><surname>Bishop</surname><given-names>JH</given-names></name><name><surname>Saggar</surname><given-names>M</given-names></name><name><surname>Williams</surname><given-names>NR</given-names></name></person-group><article-title>Network effects of Stanford Neuromodulation Therapy (SNT) in treatment-resistant major depressive disorder: a randomized, controlled trial</article-title><source>Transl Psychiatry</source><year>2023</year><month>07</month><day>03</day><volume>13</volume><issue>1</issue><fpage>240</fpage><comment>
<ext-link xlink:href="https://doi.org/10.1038/s41398-023-02537-9" ext-link-type="uri"/>
</comment><pub-id pub-id-type="doi">10.1038/s41398-023-02537-9</pub-id><pub-id pub-id-type="medline">37400432</pub-id><pub-id pub-id-type="pii">10.1038/s41398-023-02537-9</pub-id><!--<pub-id pub-id-type="pmcid">PMC10318050</pub-id>--><pub-id pub-id-type="pmid">37400432</pub-id>
</element-citation></ref><ref id="ref138"><label>138</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fox</surname><given-names>MD</given-names></name><name><surname>Buckner</surname><given-names>RL</given-names></name><name><surname>White</surname><given-names>MP</given-names></name><name><surname>Greicius</surname><given-names>MD</given-names></name><name><surname>Pascual-Leone</surname><given-names>A</given-names></name></person-group><article-title>Efficacy of transcranial magnetic stimulation targets for depression is related to intrinsic functional connectivity with the subgenual cingulate</article-title><source>Biol Psychiatry</source><year>2012</year><month>10</month><day>01</day><volume>72</volume><issue>7</issue><fpage>595</fpage><lpage>603</lpage><comment>
<ext-link xlink:href="https://europepmc.org/abstract/MED/22658708" ext-link-type="uri"/>
</comment><pub-id pub-id-type="doi">10.1016/j.biopsych.2012.04.028</pub-id><pub-id pub-id-type="medline">22658708</pub-id><pub-id pub-id-type="pii">S0006-3223(12)00411-8</pub-id><!--<pub-id pub-id-type="pmcid">PMC4120275</pub-id>--><pub-id pub-id-type="pmid">22658708</pub-id>
</element-citation></ref><ref id="ref139"><label>139</label><element-citation publication-type="webpage"><article-title>The researcher's guide to VA Data VA information resource center</article-title><source>US Departments of Veterans Affairs</source><date-in-citation content-type="access-date">2024-04-29</date-in-citation><comment>
<ext-link xlink:href="https://www.virec.research.va.gov/" ext-link-type="uri">https://www.virec.research.va.gov/</ext-link>
</comment></element-citation></ref></ref-list></back></article>